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A B S T R A C T
Background
The anaemia seen in chronic kidney disease (CKD) may be exacerbated by iron deficiency. Iron can be provided through diKerent routes,
with advantages and drawbacks of each route. It remains unclear whether the potential harms and additional costs of intravenous (IV)
compared with oral iron are justified. This is an update of a review first published in 2012.
Objectives
To determine the benefits and harms of IV iron supplementation compared with oral iron for anaemia in adults and children with CKD,
including participants on dialysis, with kidney transplants and CKD not requiring dialysis.
Search methods
We searched the Cochrane Kidney and Transplant Register of Studies up to 7 December 2018 through contact with the Information
Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, and
EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search Portal, and ClinicalTrials.gov.
Selection criteria
We included randomised controlled trials (RCTs) and quasi-RCTs in which IV and oral routes of iron administration were compared in adults
and children with CKD.
Data collection and analysis
Two authors independently assessed study eligibility, risk of bias, and extracted data. Results were reported as risk ratios (RR) with 95%
confidence intervals (CI) for dichotomous outcomes. For continuous outcomes the mean diKerence (MD) was used or standardised mean
diKerence (SMD) if diKerent scales had been used. Statistical analyses were performed using the random-eKects model. Subgroup analysis
and univariate meta-regression were performed to investigate between study diKerences. The certainty of the evidence was assessed using
GRADE.
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Main results
We included 39 studies (3852 participants), 11 of which were added in this update. A low risk of bias was attributed to 20 (51%) studies for
sequence generation, 14 (36%) studies for allocation concealment, 22 (56%) studies for attrition bias and 20 (51%) for selective outcome
reporting. All studies were at a high risk of performance bias. However, all studies were considered at low risk of detection bias because
the primary outcome in all studies was laboratory-based and unlikely to be influenced by lack of blinding.
There is insuKicient evidence to suggest that IV iron compared with oral iron makes any diKerence to death (all causes) (11 studies, 1952
participants: RR 1.12, 95% CI 0.64, 1.94) (absolute eKect: 33 participants per 1000 with IV iron versus 31 per 1000 with oral iron), the number
of participants needing to start dialysis (4 studies, 743 participants: RR 0.81, 95% CI 0.41, 1.61) or the number needing blood transfusions
(5 studies, 774 participants: RR 0.86, 95% CI 0.55, 1.34) (absolute eKect: 87 per 1,000 with IV iron versus 101 per 1,000 with oral iron). These
analyses were assessed as having low certainty evidence. It is uncertain whether IV iron compared with oral iron reduces cardiovascular
death because the certainty of this evidence was very low (3 studies, 206 participants: RR 1.71, 95% CI 0.41 to 7.18). Quality of life was
reported in five studies with four reporting no diKerence between treatment groups and one reporting improvement in participants treated
with IV iron.
IV iron compared with oral iron may increase the numbers of participants, who experience allergic reactions or hypotension (15 studies,
2607 participants: RR 3.56, 95% CI 1.88 to 6.74) (absolute harm: 24 per 1000 with IV iron versus 7 per 1000) but may reduce the number of
participants with all gastrointestinal adverse eKects (14 studies, 1986 participants: RR 0.47, 95% CI 0.33 to 0.66) (absolute benefit: 150 per
1000 with IV iron versus 319 per 1000). These analyses were assessed as having low certainty evidence.
IV iron compared with oral iron may increase the number of participants who achieve target haemoglobin (13 studies, 2206 participants:
RR 1.71, 95% CI 1.43 to 2.04) (absolute benefit: 542 participants per 1,000 with IV iron versus 317 per 1000 with oral iron), increased
haemoglobin (31 studies, 3373 participants: MD 0.72 g/dL, 95% CI 0.39 to 1.05); ferritin (33 studies, 3389 participants: MD 224.84 µg/L, 95%
CI 165.85 to 283.83) and transferrin saturation (27 studies, 3089 participants: MD 7.69%, 95% CI 5.10 to 10.28), and may reduce the dose
required of erythropoietin-stimulating agents (ESAs) (11 studies, 522 participants: SMD -0.72, 95% CI -1.12 to -0.31) while making little or
no diKerence to glomerular filtration rate (8 studies, 1052 participants: 0.83 mL/min, 95% CI -0.79 to 2.44). All analyses were assessed as
having low certainty evidence. There were moderate to high degrees of heterogeneity in these analyses but in meta-regression, definite
reasons for this could not be determined.
Authors' conclusions
The included studies provide low certainty evidence that IV iron compared with oral iron increases haemoglobin, ferritin and transferrin
levels in CKD participants, increases the number of participants who achieve target haemoglobin and reduces ESA requirements. However,
there is insuKicient evidence to determine whether IV iron compared with oral iron influences death (all causes), cardiovascular death and
quality of life though most studies reported only short periods of follow-up. Adverse eKects were reported in only 50% of included studies.
We therefore suggest that further studies that focus on patient-centred outcomes with longer follow-up periods are needed to determine
if the use of IV iron is justified on the basis of reductions in ESA dose and cost, improvements in patient quality of life, and with few serious
adverse eKects.
P L A I N   L A N G U A G E   S U M M A R Y
Iron treatment for adults and children with reduced kidney function
What is the issue?
Anaemia (reduction in the number of circulating red blood cells) oPen occurs in people who have kidney damage, especially those who
need dialysis treatment. Anaemia can cause tiredness, reduce exercise tolerance and increase heart size. A common cause of anaemia is
reduced production of a hormone, erythropoietin. Iron deficiency can make anaemia worse, and reduce the response to medications that
stimulate erythropoietin production. Iron can be taken orally (by mouth) or injected intravenously (via a vein). Intravenous (IV) iron is given
under supervision in hospitals. There is uncertainty about whether IV iron should be used rather than oral iron.
What did we do?
We reviewed 39 studies (3852 participants) which compared IV iron supplements with oral iron in participants with chronic kidney disease.
What did we find?
We found that IV iron may increase blood levels of haemoglobin and iron compared with oral iron. However, IV iron may increase the
number of allergic reactions though it may reduce side eKects such as constipation, diarrhoea, nausea and vomiting seen with oral iron.
We did not find suKicient evidence to determine whether IV iron compared with oral iron improved quality of life, altered overall death
rate or death due to heart disease.
Conclusions
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Although the results suggest that IV iron compared with oral iron may be more eKective in raising iron and haemoglobin levels, we found
insuKicient data to determine if the benefits of IV iron are justified by improved quality of life or mortality despite the small risk of potentially
serious allergic eKects in some patients given IV iron.
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Summary of findings for the main comparison.   Patient-centred outcomes for oral versus IV iron in adults and children with chronic kidney disease
Patient-centred outcomes for oral versus IV iron in adults and children with CKD
Patient or population: adults and children with CKD
Setting: Nephrology departments
Intervention: IV iron
Comparison: oral iron
Anticipated absolute effects* (95% CI)Outcomes
Risk with oral
iron
Risk with IV iron
Relative effect
(95% CI)
No. of partic-
ipants
(studies)
Quality of the
evidence
(GRADE)
Comments
Death (all causes) 30 per 1,000 33 per 1,000
(19 to 58)
RR 1.12
(0.64 to 1.94)
1952 (11) ⊕⊕⊝⊝
LOW 1 2
Only 11/38
studies repre-
sented with
only about
1/3 of pa-
tients.
Cardiovascular death 20 per 1,000 34 per 1,000
(8 to 142)
RR 1.71
(0.41 to 7.18)
206 (3) ⊕⊝⊝⊝
VERY LOW 1 2 4
-
Type of adverse event: allergic re-
actions/hypotension
7 per 1,000 24 per 1,000
(13 to 46)
RR 3.56
(1.88 to 6.74)
2607 (15) ⊕⊕⊝⊝
LOW 1 2
-
Type of adverse event: all gas-
trointestinal adverse effects
319 per 1,000 150 per 1,000
(105 to 211)
RR 0.47
(0.33 to 0.66)
1986 (14) ⊕⊕⊝⊝
LOW 2 3
-
Type of adverse event: infection 80 per 1,000 106 per 1,000
(72 to 157)
RR 1.32
(0.90 to 1.95)
954 (4) ⊕⊕⊝⊝
LOW 1 2
-
Numbers of non-dialysis patients
needing to commence dialysis
46 per 1,000 38 per 1,000
(19 to 75)
RR 0.81
(0.41 to 1.61)
743 (4) ⊕⊕⊝⊝
LOW 1 2
-
Number requiring transfusion 101 per 1,000 87 per 1,000
(56 to 136)
RR 0.86
(0.55 to 1.34)
774 (5) ⊕⊕⊝⊝
LOW 1 2
-
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
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CI: Confidence interval; CKD: chronic kidney disease; IV: intravenous; RR: Risk ratio
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is sub-
stantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1 Downgraded one level for imprecision
2 Downgraded one level for likely publication bias
3 Downgraded one level for high heterogeneity
4 Downgraded one level for publication bias
 
 
Summary of findings 2.   Laboratory and pharmaceutical outcomes for adults and children with chronic kidney disease
Laboratory and pharmaceutical outcomes for adults and children with CKD
Patient or population: adults and children with CKD
Setting: Nephrology departments
Intervention: IV iron
Comparison: oral iron
Anticipated absolute effects* (95% CI)Outcomes
Risk with oral iron Risk with IV iron
Relative ef-
fect
(95% CI)
№ of partici-
pants
(studies)
Quality of the
evidence
(GRADE)
Comments
Number achiev-
ing target Hb or
increase ≥1 g/dL
317 per 1,000 542 per 1,000
(453 to 646)
RR 1.71
(1.43 to 2.04)
2206 (13) ⊕⊕⊝⊝
LOW 1 2
Risk of bias (ROB) downgrad-
ed as little info on random se-
quence generation (RSG) and
allocation concealment. Het-
erogeneity 60%
Hb: final or
change (g/dL)
The mean Hb level was 0.72 g/dL higher with IV iron compared to
oral iron (0.39 to 1.05 higher)
- 3373 (31) ⊕⊕⊝⊝
LOW 1 2
21/31 are at ROB for RSG &/or
allocation concealment. Het-
erogeneity 94%
Ferritin: final or
change (µg/L)
The mean ferritin level was 224.84 µg/L higher with IV iron com-
pared to oral iron (165.85 to 283.83 higher)
- 3389 (33) ⊕⊕⊝⊝
LOW 1 2
8/13 are at ROB for RSG or al-
location concealment. Het-
erogeneity 60%.
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TSAT: final or
change (%)
The mean TSAT was 7.69% higher with IV iron compared to oral
iron (5.1 to 10.28 higher)
- 3089 (27) ⊕⊕⊝⊝
LOW 1 2
11/27 only are at low risk of
bias and heterogeneity is
97%.
HCT (%) The mean HCT was 1.18% higher with IV iron compared to oral
iron (2.17 lower to 4.52 higher)
- 152 (4) ⊕⊝⊝⊝
VERY LOW 1 2
3 4
Only 4 studies in this analy-
sis, all with unknown risk of
selection bias. Heterogeneity
96%.
ESA dose: final or
change
The SMD for ESA dose was 0.72 lower with IV iron compared to
oral iron (0.31 to 1.12 lower)
- 522 (11) ⊕⊕⊝⊝
LOW 1 2
ROB downgraded as little in-
formation on RSG and Allo-
cation concealment. Hetero-
geneity 77%
eGFR: final or
change (mL/min)
the mean eGFR was 0.83 mL/min higher with IV iron compared to
oral iron (0.79 lower to 2.44 higher)
- 1052 (8) ⊕⊕⊝⊝
LOW 1 3
Half of the studies are at ROB
for RSG & allocation conceal-
ment.
*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
 
CI: Confidence interval; CKD: chronic kidney disease; eGFR: estimated glomerular filtration rate; ESA: erythrocyte-stimulating agent; Hb: haemoglobin; HCT: haematocrit;
IV: intravenous; RR: Risk ratio; TSAT: transferrin saturation
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is sub-
stantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1 Downgraded one level for risk of bias
2 Downgraded one level for inconsistency
3 Downgraded one level for imprecision
4 Downgraded one level for likely publication bias
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B A C K G R O U N D
Description of the condition
A reduction in the number of circulating red blood cells is termed
anaemia. The prevalence of anaemia in patients with chronic
kidney disease (CKD) is twice that in the general population. As
kidney function deteriorates, the prevalence of anaemia increases
from 8.4% at CKD stage 1 to 53.4% at CKD stage 5 (StauKer 2014).
The cause of anaemia in CKD is multifactorial though largely driven
by decreased kidney production of erythropoietin. Iron deficiency
can exacerbate the degree of anaemia and reduce the response to
erythropoietin-stimulating agents (ESAs). Anaemia has been found
to contribute to a number of pathological processes. Observational
studies have shown anaemia to be associated with increased
mortality (at an haemoglobin level (Hb) < 11.0 g/dL) (Kovesdy
2006; Levin 2006), increased hospital stay (Li 2004), increased
cardiovascular events (Li 2004; Vlagopoulos 2005; Weiner 2005)
and decreased quality of life (Fukuhara 2007). Limited data have
also shown that an increase in Hb can improve a number of
these indices (Levin 2006; Moreno 2000). However, a systematic
review of studies assessing the eKects of targeting higher Hb
concentrations in patients with CKD by using higher doses of
ESA showed a significantly higher risk of death (all causes) (risk
ratio (RR) 1.17) and arteriovenous access thrombosis (RR 1.34)
in the higher Hb target group compared with the lower Hb
group (Phrommintikul 2007). National (CARI 2008; Moist 2008;
NICE 2015) and international guidelines (KDIGO 2008; Locatelli
2010) recommend target Hb levels of between 10 g/dL to 12 g/dL
for patients with CKD. The most recent guidelines (KDIGO 2012)
suggest that the Hb in adult CKD patients should not exceed 11.5
g/dL.
Iron is an essential mineral to maintain health. It is required in many
intracellular processes including DNA synthesis, mitochondrial
energy generation and enzymatic reactions. It is used in the
production of myoglobin in muscles and Hb, the oxygen carrying
component of the red blood cells. Determining iron deficiency
in CKD can be challenging as it is oPen a functional deficiency
caused by insuKicient iron availability despite adequate body
iron stores. The aetiology of iron deficiency in CKD is complex
but includes reduced dietary intake and blood loss, particularly
from the gastrointestinal tract, due to uraemia induced platelet
dysfunction (Hedges 2007). These losses are compounded in
patients on haemodialysis (HD) by the use of heparin, losses
from clotted dialysis lines and blood sampling, which can lead
to losses of 2 litres to 5 litres of blood per year (Sargent 2004).
Lastly, chronic inflammation and uraemia result in an upregulation
and reduced clearance of hepcidin, inhibiting the release of iron
from macrophages and decreasing gastrointestinal iron absorption
(Lopez 2015).
Description of the intervention
Therapeutic iron can be given orally. Four iron preparations are
commonly used: ferrous sulphate, ferrous sulphate exsiccated,
ferrous gluconate, and ferrous fumarate. It can be given
intramuscularly in the form of iron dextran or it can be given
intravenously. Six main forms of intravenous (IV) iron are currently
available: iron sucrose, ferric gluconate, ferric carboxymaltose, iron
isomaltoside-1000, ferumoxytol, and iron dextran (low-molecular-
weight forms) (Lopez 2015).
Oral iron frequently causes gastrointestinal side eKects including
heartburn, nausea, vomiting, diarrhoea, and constipation (Lopez
2015). These events aKect patient compliance and can limit total
intake. Although serious adverse events related to IV forms of iron
are rare, the eKects can be life threatening and include pulmonary
embolism, anaphylactic reaction, loss of consciousness, circulatory
collapse, hypotension, dyspnoea, pruritus, hypersensitivity and
urticaria (Bailie 2012; Lopez 2015). The cumulative rate for all
adverse events, for all IV iron preparations, is 14.1 adverse events
per million units sold though it appears to be higher in products
such as ferumoxytol compared with iron sucrose (Bailie 2012). IV
iron preparations require administration under supervision and
this need increases the cost of administration and is inconvenient
for patients who are not receiving in-centre HD. IV iron has also
been linked to an increased risk of infection and cardiovascular
disease; iron can act as a growth factor for some bacteria and free
iron has been shown to impair neutrophil and T cell function as well
as increase reactive oxygen species (Fishbane 2014; Ishida 2014).
The majority of the literature to date supports these associations
although the most recent cohort study of nearly 23,000 HD patients
suggested no diKerence in length of stay, death or readmission for
infection in those who received IV iron during admission and those
who did not (Ishida 2015). Furthermore there is increasing evidence
that free iron plays a role in direct injury to kidney tissue, which
could result in more rapid deterioration in kidney function (Shah
2011).
Controversies remain about the most eKective and safe way to
provide iron supplementation in patients with CKD (Fishbane 2007;
Macdougall 2016). Current parameters used to monitor iron status
include serum ferritin levels, serum iron, transferrin saturation
(TSAT), per cent of hypochromic red blood cells, and reticulocyte
Hb content. There is debate about the most valuable measures
to assess iron status, and the setting of optimum levels of these
measures in patients with CKD to increase Hb and optimise ESA
response. Novel markers being developed but not yet in routine
use include hepcidin, soluble transferrin receptor one and non-
transferrin bound iron (Gaweda 2015).
How the intervention might work
Iron deficiency is the most common cause of anaemia in CKD
and of hypo-responsiveness to ESAs (Kwack 2006). ESAs accelerate
erythropoiesis by increasing iron utilisation and depleting iron
stores. Optimal eKicacy of ESAs depends on the availability of iron
to achieve and maintain target Hb levels. Patients with CKD stage
5D require higher targets for ferritin and TSAT levels to achieve
increased Hb levels compared with patients whose kidney function
is normal. Two studies targeting ferritin levels of 400 ng/mL or
30% to 50% TSAT resulted in significant reductions in the ESA
dose required to maintain Hb levels compared with targeting a
ferritin level of 200 ng/mL or TSAT levels of 20% to 30% (Besarab
2000; DeVita 2003). However, such high ferritin and TSAT levels
increase the risk of iron overload and its associated complications.
The Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines
(KDOQI 2007), the Canadian (Madore 2008) and the European
guidelines (Locatelli 2009) recommend serum ferritin of > 200
ng/mL and TSAT > 20% in patients receiving HD. KDIGO 2012
recommend that iron can be given until TSAT > 30% or serum ferritin
> 500 ng/mL. In patients with less severe degrees of CKD, serum
ferritin levels > 100 ng/mL and TSAT > 20% are recommended.
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Why it is important to do this review
The original study published in 2012 found strong evidence for
increased ferritin and TSAT levels and a small increase in Hb with
IV iron compared with oral iron. There was limited evidence that
this came with a reduction in ESA use. Only half of the studies
reported on adverse events. There have been several studies done
over the last six years which have looked at the adverse event rate
of the many preparations of IV iron and also included hard end
points including all cause and cardiovascular death. At present the
majority of HD patients receive IV iron and the use of IV iron in
the peritoneal dialysis (PD) and CKD populations is increasing. We
felt it was important to update this review to ensure that patient
focused adverse events were analysed as well as providing up to
date evidence on the eKicacy and safety of IV iron. In this review,
we aimed to explore all possible causes of heterogeneity of study
results in detail by subgroup analysis and to further investigate the
eKects of IV iron in patients with CKD who were not on dialysis.
O B J E C T I V E S
Our objective was to determine the benefits and harms of IV
iron supplementation compared with oral iron for anaemia in
patients with CKD, treated with HD, PD, not receiving dialysis
and post transplant. The review aimed to examine the eKects of
these interventions on patient centred outcomes including death,
requirements for transfusion, hospitalisation, cardiac function,
quality of life and change in eGFR as well as iron parameters,
achieving target levels of Hb, reducing doses of ESA required, and
to determine adverse eKects of the therapies.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) and quasi-
RCTs (studies in which allocation to treatment was obtained by
alternation, use of alternate medical records, date of birth or other
predictable methods) in which oral and IV routes of administration
of iron were compared in patients with CKD.
Types of participants
Inclusion criteria
We included adult and paediatric patients with CKD (stages 3 to
5D; glomerular filtration rate (GFR) < 60 mL/min/1.73 m2). Studies
in patients receiving HD, PD, or those not requiring dialysis, were
included. Studies of kidney transplant patients were also included.
Exclusion criteria
Studies of iron administration in patients comparing diKerent IV or
oral iron preparations and diKerent doses of the same IV or oral
preparation were excluded. Studies in patients with acute kidney
injury were excluded.
Types of interventions• We examined diKerent IV iron supplements (including iron
sucrose, dextran, ferric gluconate, ferric carboxymaltose,
ferumoxytol) and oral iron preparations (including oral iron
preparations which contain folic acid, vitamin C or both).
• We included studies using diKerent doses and durations of IV
iron compared with oral iron preparations provided that the
control group received oral iron supplements only.
Types of outcome measures
Primary outcomes• Death (all causes)• Cardiovascular death• Quality of life
Secondary outcomes• Hb* Number achieving target Hb level* Time to achieve target Hb* Final or change in Hb at end of study* Increase in Hb > 10 g/L or other target during study• Iron* Number achieving target levels of iron (ferritin, TSAT, per cent
of hypochromic red blood cells)* Final or change in ferritin levels at the end of study* Final or change in TSAT at end of study* Per cent of hypochromic red blood cells• Erythrocyte stimulating agents (ESAs)* Reduction in required dose of ESA* Number needing to increase ESA dose* Number needing to decrease ESA dose or cease ESA• Infection• Change in GFR in non-dialysis patients• Number needing transfusions• Any adverse events of treatment* Adverse eKects of oral iron* Adverse eKects of IV iron supplements including
hypersensitivity reactions* Number of patients needing to cease oral or IV supplements
because of adverse eKects
Other outcomes• Haematocrit (HCT)• Reticulocyte Hb concentration• Numbers of non-dialysis patients needing to commence dialysis• Hospitalisation (other than for iron infusions and dialysis)• Exercise tolerance• LeP ventricular function• Sexual function• Nutritional status• Adherence to therapy• Numbers and costs of hospitalisations/professional supervision
required for IV iron supplements• Iron overload (as defined by the triallists)
Search methods for identification of studies
Electronic searches
We searched the Cochrane Kidney and Transplant Register of
Studies up to 7 December 2018 through contact with the
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Information Specialist using search terms relevant to this review.
The Register contains studies identified from the following sources.
1. Monthly searches of the Cochrane Central Register of Controlled
Trials (CENTRAL)
2. Weekly searches of MEDLINE OVID SP
3. Handsearching of kidney-related journals and the proceedings
of major kidney conferences
4. Searching of the current year of EMBASE OVID SP
5. Weekly current awareness alerts for selected kidney and
transplant journals
6. Searches of the International Clinical Trials Register (ICTRP)
Search Portal and ClinicalTrials.gov.
Studies contained in the Register are identified through searches of
CENTRAL, MEDLINE, and EMBASE based on the scope of Cochrane
Kidney and Transplant. Details of search strategies, as well as a
list of handsearched journals, conference proceedings and current
awareness alerts, are available in the Specialised Register section of
information about Cochrane Kidney and Transplant.
See Appendix 1 for search terms used in strategies for this review.
Searching other resources
1. Reference lists of review articles, relevant studies and clinical
practice guidelines.
2. Letters seeking information about unpublished or incomplete
trials to investigators known to be involved in previous studies.
Data collection and analysis
Selection of studies
The search strategy described was used to obtain titles and
abstracts of studies that were potentially relevant to the review.
The titles and abstracts were screened independently by two
authors, who discarded studies that were not applicable. However,
studies and reviews that might include relevant data or information
on studies were retained initially. Two authors independently
assessed retrieved abstracts, and where necessary the full text, of
these studies to determine which satisfied the inclusion criteria.
Data extraction and management
Data extraction and assessment of the risk of bias were performed
independently by the same authors using standardised data
extraction forms. Studies reported in non-English language
journals were translated before assessment. Where more than one
publication of one study existed, the publication with the most
complete data was reviewed initially. Where relevant outcomes
were only published in earlier versions, these data were used.
Any discrepancy between published versions was highlighted.
Any further information required from the original author was
requested by written correspondence and any relevant information
obtained in this manner was included in the review. Disagreements
were resolved in consultation with a third author.
Assessment of risk of bias in included studies
The following items were assessed independently by two authors
using the risk of bias assessment tool (Higgins 2011) (see Appendix
2).
• Was there adequate sequence generation (selection bias)?
• Was allocation adequately concealed (selection bias)?• Was knowledge of the allocated interventions adequately
prevented during the study?* Participants and personnel (performance bias)* Outcome assessors (detection bias)• Were incomplete outcome data adequately addressed (attrition
bias)?• Are reports of the study free of suggestion of selective outcome
reporting (reporting bias)?• Was the study apparently free of other problems that could put
it at a risk of bias?
Measures of treatment e;ect
For dichotomous outcomes (number reaching target Hb, death)
results were expressed as RR with 95% confidence intervals (CI). RR
with 95% CI were calculated for adverse eKects. Where continuous
scales of measurement were used to assess the eKects of treatment
(Hb level, iron parameters) the mean diKerence (MD) was used,
or the standardised mean diKerence (SMD) if diKerent scales had
been used (end of study ESA dose). Either final levels or change
in levels were included in meta-analyses of continuous scales of
measurement. When both measures are provided in a study, final
levels were included.
Unit of analysis issues
Cross-over studies were thought likely to be inappropriate means
of examining IV and oral iron because of carry over eKects related to
achieved Hb levels and iron parameters. Therefore, only data from
the first period of cross-over studies were included where these
were reported separately, and included all or most patients who
completed the first period, rather than only those who completed
both treatment periods.
Dealing with missing data
Where necessary, we contacted triallists to request missing
patient data due to loss to follow-up and exclusion from study
analyses in an eKort to conduct intention-to-treat analyses. Eight
authors responded to our requests. Where missing dichotomous or
continuous data were few, and unlikely to aKect the overall results,
we analysed available data. Where possible we imputed missing
standard deviations and standard errors if data was presented
alternatively, using methods stated in the Cochrane handbook
(Higgins 2011a).
Assessment of heterogeneity
Heterogeneity was analysed using a Chi2 test on N-1 degrees of
freedom, with an alpha of 0.05 used for statistical significance and
with the I2 test (Higgins 2003). I2 values of 25%, 50% and 75%
correspond to low, medium and high levels of heterogeneity.
Assessment of reporting biases
Cochrane Kidney and Transplant's Specialised Register includes
studies obtained from searching major databases, conference
proceedings and prospective trial registers without language
restriction in an attempt to reduce publication bias related to
failure of authors to publish negative results or their inability to
publish negative results in journals indexed in major databases.
When suKicient studies were available, we created funnel plots and
calculated Eggers' test to assess publication bias. Where multiple
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publications of the same study were identified, data were included
from the most recent publication, and preferably, the definitive
publication. However, all publications were reviewed to identify
outcomes not reported in the index publication in an attempt to
reduce outcome reporting bias.
Data synthesis
Data were pooled using the random-eKects model for dichotomous
and continuous data.
Subgroup analysis and investigation of heterogeneity
To explore clinical diKerences among studies that could influence
the magnitude of the treatment eKect for the outcomes of
diKerences in ferritin, TSAT and Hb, subgroup analyses and
univariate meta-regression were performed using STATA soPware
(StataCorp LP, Texas, USA) using restricted maximum-likelihood
to estimate between study variance. The potential sources of
variability were defined a priori and were related to study
rationale (CKD stage, whether aiming to increase or maintain
Hb, concurrent use of erythropoietin co-intervention, timing of
initiation of erythropoietin co-intervention), dose delivered and
duration of IV and oral iron therapy, and study sponsorship. Where
subgroup analysis findings suggested that more than one factor
could influence the magnitude of observed diKerences, we planned
to conduct multivariate meta-regression.
Underlying cause of end-stage kidney disease (ESKD), baseline iron
status, and previous iron therapy were not examined in subgroup
analyses because most studies did not provide this information. All
studies, except two paediatric studies, included adults of similar
ages so diKerent age groups could not be examined in subgroup
analyses. Only one study (Li 2008 PD) included solely PD patients so
it was not possible to examine diKerent types of renal replacement
therapy in subgroup analyses.
Sensitivity analysis
Sensitivity analyses were performed to test decisions where
inclusion of a study, with a much higher MD in Hb, might have
altered meta-analysis results.
'Summary of findings' tables
We presented the main results of the review in 'Summary of
findings' tables. These tables present key information concerning
the quality of the evidence, the magnitude of the eKects of
the interventions examined, and the sum of the available data
for the main outcomes (Schünemann 2011a). The 'Summary of
findings' tables also include an overall grading of the evidence
related to each of the main outcomes using the GRADE (Grades
of Recommendation, Assessment, Development and Evaluation)
approach (GRADE 2008; GRADE 2011). The GRADE approach defines
the quality of a body of evidence as the extent to which one can be
confident that an estimate of eKect or association is close to the
true quantity of specific interest. The quality of a body of evidence
involves consideration of within-trial risk of bias (methodological
quality), directness of evidence, heterogeneity, precision of eKect
estimates and risk of publication bias (Schünemann 2011b). We
presented the following outcomes in the 'Summary of findings'
tables.
• Summary of findings for the main comparison* Death (all causes)* Cardiovascular death* Allergic reactions/hypotension* All gastrointestinal adverse eKects* Infection* Numbers of non-dialysis patients needing to commence
dialysis* Number requiring transfusion• Summary of findings 2* Number achieving target Hb or increase ≥1 g/dL* Hb: final or change* Ferritin: final or change* TSAT: final or change* HCT* End of treatment or change in ESA dose* eGFR end or change
R E S U L T S
Description of studies
Results of the search
The initial study resulted in a total of 522 study reports from the
Cochrane Kidney and Transplant Specialised Register to March
2010, CENTRAL (in The Cochrane Library Issue 1, 2010), MEDLINE (to
October week 5, 2008) and EMBASE (to week 45, 2008). From these
522 reports, 28 studies (46 reports) were included in the systematic
review while 28 studies were excluded; there were three ongoing
studies.
For the 2019 update of this review, a search of the Cochrane
Kidney and Transplant Specialised Register identified 49 new
reports. From these we identified 11 new included studies (31
reports) (Agarwal 2015 CKD; FIND-CKD 2014 CKD; Kalra 2016 CKD;
Lu 2010 CKD; Mudge 2009 TX; Nagaraju 2013 CKD; NCT01155375
HD,PD,CKD; Pisani 2014 CKD; Ragab 2007 HD; Tsuchida 2010
HD; Winney 1977 HD), three new excluded studies (4 reports)
and 14 additional reports of previously included studies.. The
additional reports included the full publication of Qunibi 2011
CKD. Of the 11 new included studies, four were publications of
trials identified as ongoing trials in the 2010 review (Agarwal 2015
CKD; Kalra 2016 CKD; Mudge 2009 TX; NCT01155375 HD,PD,CKD).
The paediatric study (NCT01155375 HD,PD,CKD) was terminated
because of challenges with enrolment with minimal data reported.
Search results are shown in Figure 1. One new report contained
further information on two already included studies (Li 2008 HD;
Li 2008 PD). Spinowitz 2008 CKD included all nine reports, which
included data for one new included study (Lu 2010 CKD). This 2019
update contains 44 studies (101 reports).
 
Parenteral versus oral iron therapy for adults and children with chronic kidney disease (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
10
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Figure 1.   Flow diagram of studies included in the systematic review
 
Included studies
The 11 new included studies (31 reports) provided an additional
1754 participants bringing the total to 3852 participants. Of the new
studies, seven included 1653 participants with CKD, three included
75 participants on HD and one included 102 transplant patients.
One study included both dialysis and non-dialysis patients but did
not specify how many patients were in each group.
Of the 39 included studies, 38 (3832 participants) were parallel
group studies, and one (20 patients) was a cross-over study
(Strickland 1977 HD). Only three studies involved paediatric
patients (NCT01155375 HD,PD,CKD; Ragab 2007 HD; Warady 2002
HD). Nineteen studies included only HD patients. Li 2008 PD
included only patients on PD while Macdougall 1999 HD,PD
included both HD and PD patients. Two studies (Ahsan 1997
TX; Mudge 2009 TX) evaluated patients who were in the early
phase of post-kidney transplantation. Results from these studies
were pooled with studies of dialysis patients. Thirteen studies
included non-dialysis patients (CKD stages 3 to 5) while two
studies (Macdougall 1996 HD,PD,CKD; NCT01155375 HD,PD,CKD)
included both dialysis and non-dialysis patients. Twelve studies
were available only as abstracts or from ClinicalTrials.Gov (Ahsan
1997 TX; Broumand 1998 HD; Erten 1998 HD; Leehey 2005 CKD;
Lu 2010 CKD; Lye 2000 HD; Macdougall 1999 HD,PD; Michael 2007
HD; NCT01155375 HD,PD,CKD; Souza 1997 HD; Wang 2003 HD;
Winney 1977 HD). Thirty-two studies were designed to increase Hb
levels and four studies were designed to maintain Hb stability in
iron replete patients and decrease ESA dose (Fishbane 1995 HD;
Kotaki 1997 HD; Michael 2007 HD; Warady 2002 HD). One study was
designed to examine changes in GFR during (Agarwal 2015 CKD)
while one study was designed to determine the time to the start of
additional anaemia management other than iron (FIND-CKD 2014
CKD).
The duration of follow-up ranged from 35 days to 26 months.
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Studies compared diKerent oral and IV iron preparations. The oral
iron agents investigated were ferrous sulphate (25 studies), ferrous
fumarate (7), ferrous succinate (2), iron gluconate (1), liposomal
iron (1), heme iron polypeptide (1) and unnamed agents in two
studies. The IV iron agents investigated were iron sucrose (15
studies), iron dextran (7), ferumoxytol (4), sodium ferric gluconate
complex (5), ferric carboxymaltose (2), iron isomaltoside (1), ferric
citrate (1), and ferric hydroxide polymaltose (3). The IV iron agent
was not reported in Kotaki 1997 HD. The calculated total dose
of elemental iron ranged from 2520 mg to 63,000 mg in the oral
iron groups and from 500 to 10,920 mg in the IV iron groups.
Three studies (Erten 1998 HD; FIND-CKD 2014 CKD; Kalra 2016 CKD)
included two IV iron treatment groups. For these studies, data from
patients who received the higher total dose of IV iron were included
in the meta-analyses.
In twenty-two studies all participants were treated with an ESA.
ESA therapy was started at study commencement in six studies
(Aggarwal 2003 CKD; Charytan 2005 CKD; Hussain 1998 HD; Lye
2000 HD; Macdougall 1996 HD,PD,CKD; Stoves 2001 CKD) and
before study commencement in 15 studies (Broumand 1998 HD;
Erten 1998 HD; Fishbane 1995 HD; Kotaki 1997 HD; Leehey 2005
CKD; Li 2008 HD; Li 2008 PD; Macdougall 1999 HD,PD; Michael
2007 HD; Mudge 2009 TX; Provenzano 2009 HD; Ragab 2007 HD;
Svara 1996 HD; Tsuchida 2010 HD; Warady 2002 HD). It was unclear
when ESA treatment was commenced in Wang 2003 HD. Seven
studies reported that no included patients received ESA treatment
(Agarwal 2006 CKD; Ahsan 1997 TX; Fudin 1998 HD; Kalra 2016 CKD;
McMahon 2009 CKD; Strickland 1977 HD; Winney 1977 HD), but nine
studies indicated that varying proportions of patients received an
ESA (Agarwal 2015 CKD; FIND-CKD 2014 CKD; Nagaraju 2013 CKD; Lu
2010 CKD; Pisani 2014 CKD; Qunibi 2011 CKD; Spinowitz 2008 CKD;
Souza 1997 HD; Van Wyck 2005 CKD).
The outcomes reported in 38 studies are presented in Figure 1.
One study was terminated and did not provide any outcomes
(NCT01155375 HD,PD,CKD). Final and/or change in Hb, serum
ferritin and TSAT levels were reported in 31, 33 and 27 studies
respectively. Four studies reported final HCT levels but not Hb levels
(Ahsan 1997 TX; Fishbane 1995 HD; Kotaki 1997 HD; Svara 1996
HD). Only 11 studies reported death (all causes) (Agarwal 2015
CKD; FIND-CKD 2014 CKD; Fishbane 1995 HD; Fudin 1998 HD; Kalra
2016 CKD; McMahon 2009 CKD; Lu 2010 CKD; Provenzano 2009 HD;
Qunibi 2011 CKD; Stoves 2001 CKD; Tsuchida 2010 HD) while three
studies reported on cardiovascular events including death (Agarwal
2015 CKD; Fudin 1998 HD; Stoves 2001 CKD). Five studies reported
on quality of life assessment (Agarwal 2006 CKD; Agarwal 2015 CKD;
FIND-CKD 2014 CKD; Kalra 2016 CKD; Van Wyck 2005 CKD). Eighteen
studies reported on adverse events (Agarwal 2006 CKD; Agarwal
2015 CKD; Charytan 2005 CKD; FIND-CKD 2014 CKD; Fishbane 1995
HD; Hussain 1998 HD; Kalra 2016 CKD; Li 2008 HD; Li 2008 PD;
Nagaraju 2013 CKD; Lu 2010 CKD; Pisani 2014 CKD; Provenzano
2009 HD; Qunibi 2011 CKD; Spinowitz 2008 CKD; Strickland 1977 HD;
Tsuchida 2010 HD; Van Wyck 2005 CKD).
Excluded studies
From the 2012 review, twenty-three reports were excluded based
on titles and abstracts; one study was not an RCT and the remainder
involved ineligible interventions. Five more studies (eight reports)
were excluded aPer full text review because participants were not
randomised or compared intramuscular with oral iron.
Three studies (four reports) identified in the search for the 2019
update were excluded. One study (Charytan 2013) involved an
ineligible comparator (standard medical care which could be oral
or IV iron), one study (HEMATOCRIT 2012) compared two oral
iron preparations and one study (Adhikary 2011) included non-
randomised patients.
Risk of bias in included studies
The assessment of risk of bias is shown in Figure 2 and Figure 3.
Figure 2 shows relative proportional rankings of studies for each
risk of bias indicator. Figure 3 shows the risk of bias items for
individual studies.
 
Figure 2.   Risk of bias graph: Review authors' judgements about each risk of bias item presented as percentages
across all included studies
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Figure 3.   Risk of bias summary: Review authors' judgements about each risk of bias item for each included study
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Figure 3.   (Continued)
 
Allocation
Random sequence generation was at low risk of bias in 20 studies
(Agarwal 2006 CKD; Agarwal 2015 CKD; FIND-CKD 2014 CKD; Fudin
1998 HD; Kalra 2016 CKD; Leehey 2005 CKD; Li 2008 HD; Li 2008
PD; Macdougall 1996 HD,PD,CKD; McMahon 2009 CKD; Mudge 2009
TX; Nagaraju 2013 CKD; Lu 2010 CKD; Pisani 2014 CKD; Qunibi 2011
CKD; Spinowitz 2008 CKD; Stoves 2001 CKD; Strickland 1977 HD; Van
Wyck 2005 CKD; Warady 2002 HD). Random sequence generation
was not reported in 18 studies.
Allocation concealment was at low risk of bias in 14 studies
(Agarwal 2006 CKD; Agarwal 2015 CKD; FIND-CKD 2014 CKD; Kalra
2016 CKD; Leehey 2005 CKD; Macdougall 1996 HD,PD,CKD; Mudge
2009 TX; Nagaraju 2013 CKD; Lu 2010 CKD; Pisani 2014 CKD;
Provenzano 2009 HD; Qunibi 2011 CKD; Spinowitz 2008 CKD; Van
Wyck 2005 CKD); at high risk of bias in two studies (Fudin 1998
HD; Lye 2000 HD), and for the remaining 23 studies allocation
concealment was unclear.
Blinding
No studies blinded either participants or personnel so were
considered to be at high risk of bias. As all studies used laboratory
data as primary outcomes, all studies were judged as having a low
risk of bias for outcome assessment.
Incomplete outcome data
Outcomes data reporting was considered to be complete with a low
risk of bias in 22 studies. Five studies (Charytan 2005 CKD; Fishbane
1995 HD; Fudin 1998 HD; Stoves 2001 CKD; Strickland 1977 HD)
reported that from 7% to 36% of patients were excluded from the
analyses, so were considered to be at high risk of bias. The risk
of bias was unclear in 12 studies because there was insuKicient
information provided to determine if data from all patients who
entered the study were included in the analysis.
Selective reporting
We identified 20 studies that were considered to have reported all
outcomes based on the detailed protocols described in the trial
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methods. Eight studies (Agarwal 2015 CKD; Aggarwal 2003 CKD;
Broumand 1998 HD; Charytan 2005 CKD; Leehey 2005 CKD; Ragab
2007 HD; Stoves 2001 CKD; Strickland 1977 HD) reported outcomes
incompletely so that either outcomes could not be included in
meta-analyses or included only with imputed standard deviations
or as incidence rates. It was unclear if outcomes were selectively
reported in 11 studies.
Other potential sources of bias
Sixteen studies reported receiving monetary support from
pharmaceutical companies; three studies reported funding from
non-pharmaceutical company sources and the remainder did
not report on how their study was funded. In funnel plots,
patient centred outcomes showed funnel plot symmetry (example
provided in Figure 4), suggesting a low likelihood of publication
and other biases. However, for biochemical outcomes, there was
some funnel plot asymmetry (example provided in Figure 5) which
suggests that the meta-analyses of these outcomes may be aKected
by some bias.
 
Figure 4.   Funnel plot of comparison: 1 Patient-centred outcomes.Outcome: 1.1 Death (all causes) Eggers test P =
0.25
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Figure 5.   Funnel plot of comparison: 2 Laboratory/pharmaceutical outcomes, outcome: 2.4 Transferrin saturation:
Final or change [%]. Eggers test P = 0.00
 
E;ects of interventions
See: Summary of findings for the main comparison Patient-
centred outcomes for oral versus IV iron in adults and children
with chronic kidney disease; Summary of findings 2 Laboratory
and pharmaceutical outcomes for adults and children with chronic
kidney disease
E;ects of IV iron compared with oral iron on patient-centred
outcomes• Death (all causes) was only reported in 11 studies. There was
insuKicient evidence to determine whether IV iron compared
with oral iron may makes any diKerence to death (low certainty
evidence) (Analysis 1.1 (11 studies, 1952 participants): RR 1.12,
95% CI 0.64 to 1.94; I2 = 0%). The absolute risk was 33 per 1000
with IV iron compared with 30 per 1000 with oral iron.• Cardiovascular death was reported in only three studies. It
is uncertain whether IV iron compared with oral iron reduces
cardiovascular death because the certainty of this evidence was
very low (Analysis 1.2 (3 studies, 206 participants): RR 1.71, 95%
CI 0.41 to 7.18; I2 = 0%).• Quality of life was only reported in five studies (Agarwal 2006
CKD; Agarwal 2015 CKD; FIND-CKD 2014 CKD; Kalra 2016 CKD;
Van Wyck 2005 CKD). Agarwal 2006 CKD reported that the SF12
physical composite score improved by 4.8% in patients treated
with IV iron, but there was no change in patients treated with
oral iron. Kidney disease quality of life score (KDQOL) items
- improvement in the ability to do moderate activities and
undertake work; and satisfaction with sex life - were reported to
be improved among patients treated with IV iron. Scores for a
number of factors, including feelings of imposing a burden on
family, were lower in patients who received IV iron. In contrast,
Van Wyck 2005 CKD found no diKerences between treatment
groups when health concept categories in the SF36 instrument
were applied. Agarwal 2015 CKD reported no diKerence between
groups or over time using the KDQOL. FIND-CKD 2014 CKD
reported no diKerence between groups using the SF-36 tool.
Using the Linear Analogue Scale Assessment score, Kalra 2016
CKD identified an improvement in quality of life from baseline
to eight weeks in both treatment groups with no diKerence
between groups (Analysis 1.3 (1 study, 312 participants): MD
1.45, 95% CI -5.89 to 8.79).• IV iron compared with oral iron may make little or no diKerence
to the number of participants needing to start dialysis (low
certainty evidence) (Analysis 1.4 (4 studies, 743 participants): RR
0.81, 95% CI 0.41 to 1.61; I2 = 0%). The absolute risk for starting
dialysis was 38 per 1000 with IV iron and 46 per 1000 with oral
iron.• IV iron compared with oral iron may make little or no diKerence
to the need for transfusion (low certainty evidence) (Analysis 1.5
(5 studies, 774 participants): RR 0.86, 95% CI 0.55 to 1.34; I2 = 0%).
The absolute risk for needing transfusion was 87 per 1000 with
IV iron and 101 with oral iron.
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• Although nine studies reported that patient adherence to
oral iron was assessed, only three provided numerical data
(Charytan 2005 CKD; Van Wyck 2005 CKD; Pisani 2014 CKD).
Mean adherence rates for IV iron therapy were 95%, 97% and
96% respectively, and adherence to oral iron therapy was 85%
and 88% and 95.8%.• The certainty of the evidence was downgraded because of
imprecision, heterogeneity between studies and publication
bias.
See Summary of findings for the main comparison.
E;ect of IV iron compared with oral iron on laboratory
outcomes• The numbers of patients reaching target Hb or increasing Hb
by at least 1 g/dL were reported in 13 studies. Target Hb
or an increase in Hb by 1 g/dL may be achieved by more
participants receiving IV iron compared with oral iron (low
certainty evidence) (Analysis 2.1 (13 studies, 2206 participants):
RR 1.71, 95% CI 1.43 to 2.04; I2 = 60%) in all patients (Summary of
findings 2) and in the subgroups of dialysis participants and CKD
participants (Table 1). There was low to moderate heterogeneity.
The absolute benefit for reaching the target Hb was 542 per 1000
for IV iron and 317 per 1000 for oral iron.
• End of study or change (g/dL) in Hb were reported in 31 studies.
IV iron compared with oral iron may increase Hb (low certainty
evidence) (Analysis 2.2 (31 studies, 3373 participants): MD 0.72
g/dL, 95% CI 0.39 to 1.05); I2 = 94%) in all participants and in
subgroups of dialysis and CKD participants (Table 1). There was a
high levels of heterogeneity, which persisted when a fixed-eKect
model was used for analyses. Excluding a study of 26 months
treatment and MD 4.92 g/dL (Fudin 1998 HD) did not significantly
reduce heterogeneity. Further analyses of heterogeneity are
addressed in later sections.• End of study or change (μg/L) in serum ferritin levels were
reported in 33 studies. IV iron compared with oral iron may
increase ferritin levels (low certainty evidence) in all participants
(Analysis 2.3 (33 studies, 3389 participants): MD 224.84 µg/
L, 95% CI 165.85 to 283.83, I2 = 99%) and in subgroups of
dialysis and CKD participants (Table 1). There was a high level of
heterogeneity in these analyses.• End of study or change (%) in TSAT levels were reported in
27 studies. IV iron compared with oral iron may increase TSAT
levels (low certainty evidence) in all participants (Analysis 2.4 (27
studies, 3089 participants): MD 7.69 %, 95% CI 5.10 to 10.28, I2
= 97%) and in subgroups of dialysis and CKD participants (Table
1). There was a high level of heterogeneity in these analyses.• Five studies reported results for HCT rather than Hb. It is
uncertain whether IV iron improves HCT because the certainty
of this evidence was very low (Analysis 2.5.1 (5 studies, 180
participants): MD 1.09%, 95% CI -2.19 to 4.37, I2 = 96%). There
was a high level of heterogeneity in this analysis.• Eleven studies reported end of study or change in ESA dose. IV
iron probably leads to a reduction in ESA dose compared with
oral iron (low certainty evidence) (Analysis 2.6 (11 studies, 522
participants): SMD -0.72, 95% CI -1.12 to -0.31) with a high level
of heterogeneity (I2 = 77%).• IV iron compared with oral iron may make little or no diKerence
to eGFR at the end of study (low certainty evidence) (Analysis 2.7
(8 studies,1052 participants): MD 0.83 mL/min, 95% CI -0.79 to
2.44). There was low to moderate heterogeneity (I2 = 38%).• The certainty of the evidence was downgraded because of high
risk of bias, inconsistency, imprecision and possible publication
bias.
See Summary of findings 2.
Adverse e;ects
18 studies provided some information on adverse eKects of
therapy.
• IV iron compared with oral iron may increase the numbers of
participants, who experience allergic reactions or hypotension
(low certainty evidence) (Analysis 1.6.1 (15 studies, 2607
participants): RR 3.56, 95% CI 1.88 to 6.74; I2 = 0%). The absolute
risk for allergic reactions/hypotension was 24 per 1000 with IV
iron and 7 per 1000 with oral iron.• Only four studies reported data on infection. The most
commonly reported infections were respiratory and urinary
tract infections. IV iron compared with oral iron may make little
or no diKerence to the risk of infection (low certainty evidence)
(Analysis 1.6.2 (4 studies, 954 participants): RR 1.32, 95% CI 0.90
to 1.95; I2 = 2%).• IV iron compared with oral iron may be associated with
fewer participants with all gastrointestinal adverse eKects
(low certainty evidence) (Analysis 1.6.3 (14 studies, 1986
participants): RR 0.47, 95% CI 0.33 to 0.66; I2 = 63%), fewer
participants with constipation (Analysis 1.6.4 (10 studies, 1618
participants): RR 0.32, 95% CI 0.18 to 0.57; I2 = 19%) and possibly
with diarrhoea (Analysis 1.6.5 (10 studies, 1625 participants):
RR 0.70, 95% CI 0.47 to 1.05; I2 = 0%). The absolute risk of all
gastrointestinal adverse eKects was 150 per 1000 with IV iron and
319 per 1000 with oral iron.• Only three studies reported data on iron overload. Each of these
studies defined iron overload as ferritin levels > 800 ng/mL. IV
iron compared with oral iron may make little or no diKerence to
the risk of iron overload (low certainty evidence) (Analysis 1.6.8
(3 studies, 158 participants): RR 6.58, 95% CI 0.81 to 53.51; I2 =
0%).
See Summary of findings for the main comparison.
Exploration of heterogeneity using subgroup analyses: e;ect
of di;erent doses of IV or oral iron on haemoglobin, ferritin
and TSAT
Subgroup analysis using testing for interaction was applied to
investigate the eKects of diKerent total doses of IV iron (≤ 1000 mg,
1000 to 2000 mg, > 2000 mg), diKerent doses/month of IV iron (≤
400 mg/month, > 400 to 700 mg/month, > 700 mg/month), diKerent
total doses of oral iron (< 12,000 mg, 12,000 to 30,000 mg, > 30,000
mg), and diKerent doses/month of oral iron (< 4000 mg/month,
4000 to <6000 mg/month, ≥ 6000 mg/month) on levels of Hb, ferritin
and TSAT. These values were chosen based on tertiles of doses
investigated in the included studies. Results for the outcomes of Hb,
ferritin and TSAT are shown as SMD in Table 2; Table 3 and Table 4
respectively.
There were no significant diKerences in total dose administered of
IV iron or of IV iron/month between subgroups for Hb or TSAT. There
was a significant diKerence found in the SMD for ferritin in the doses
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of IV iron per month, though the relationship did not appear to
be linear (P = 0.02); there was no diKerence in ferritin levels with
increasing total IV iron dose.
There were no significant diKerences in total oral iron dose or oral
iron/month dose for Hb between subgroups for Hb or TSAT. There
was a significant diKerence found in the SMD for ferritin in the dose
of oral iron per month but not with total oral iron dose.
In subgroup analyses no significant diKerences in results were
detected on testing for interaction among studies in which SDs were
imputed and other studies (Table 2; Table 3; Table 4).
Exploration of heterogeneity using subgroup analyses: e;ects
of erythrocyte-stimulating agents (ESAs) on the response to
iron therapy
Subgroup analysis was used to investigate the diKerential response
of Hb, ferritin and TSAT levels in patients who did or did not receive
an ESA during iron therapy, and in patients who began ESA therapy
at study commencement compared with those already on ESA. No
significant diKerences were found among subgroups (Table 2; Table
3; Table 4).
Other subgroup analyses
Subgroup analyses of study duration (≤ 2 months, ≥ 2 to 4
months, ≥ 4 months) showed no significant diKerence on testing for
interaction (Table 2; Table 3; Table 4) for final levels or changes in
levels in Hb, ferritin or TSAT. There was significant heterogeneity.
Pharmaceutical company sponsorship previously showed some
association with a lower mean reported Hb. With additional
data in this updated review, no significant association could be
demonstrated (Table 2). There were no significant diKerences for
ferritin or TSAT levels (Table 3; Table 4).
D I S C U S S I O N
Summary of main results
This review included 39 studies which compared IV iron with oral
iron therapy in patients with CKD. Eleven studies were added
to the original review; one paediatric study was terminated and
provided no outcome data. There was considerable variability
among studies in the total dose and duration of IV and oral iron
therapies prescribed. Durations of studies ranged from 35 days to
26 months with only 14 studies having durations greater than four
months. The doses/month of iron ranged from 200 mg to 1000 mg
for IV iron and 840 mg to 10,500 mg for oral iron. Use of ESAs also
varied. Eight studies reported that ESAs were not administered.
Of the studies that reported ESA use, some maintained ESA doses
unchanged and others altered the dose to maintain Hb within a
target range.
Patient-centred outcomes such as death (all causes) (11 studies),
cardiovascular death (three studies), and quality of life (five
studies) were rarely reported with studies concentrating on
surrogate laboratory outcomes. While no diKerences overall in
these outcomes were detected between treatment groups, the data
available were limited and of low quality (GRADE) so we have low
certainty evidence that IV iron compared with oral iron makes little
or no diKerence to these outcomes.
Compared with oral iron, IV iron increased levels of Hb (31 studies),
serum ferritin (33 studies) and TSAT (27 studies). The final weighted
mean increase with IV iron compared with oral iron was 0.72 g/
dL in Hb, 225 µg/L in ferritin and 8% in TSAT. The proportion of
patients who reached the targeted Hb or increased their Hb by 1
g/dL was 71% higher among those treated with IV iron compared
with oral iron. Increases in these outcomes were seen in dialysis
and non-dialysis participants (Table 1). The required ESA dose was
reduced in patients treated with IV iron compared with oral iron,
but was reported in only 11 studies involving 522 participants. eGFR
did not decline more rapidly with IV iron compared with oral iron.
However, the quality of the evidence (GRADE) was considered low
for all outcomes indicating that we have low certainty evidence to
support the findings above.
Adverse eKects were reported in 18 studies. Gastrointestinal
adverse eKects were more common with oral iron while allergic
reactions and/or hypotension were more common with IV iron.
However, the quality of the evidence (GRADE) was considered low
indicating that we have low certainty evidence to support these
findings.
There was considerable heterogeneity between studies so that
subgroup analyses using meta-regression was carried out to
investigate possible reasons for this heterogeneity. Subgroup
analyses investigated the eKect of diKerent monthly and total doses
of oral or IV iron, diKerent uses of ESA, CKD stage, and diKerent
durations of treatment on Hb, ferritin and transferrin levels. Other
than an increase in ferritin levels with increasing IV and oral iron per
month, no diKerences were found in these analyses. Comparing the
results of these subgroup analyses with those in the initial version
of this systematic review, no increase in Hb SMD with increased oral
iron dose/month could now be demonstrated. There was no longer
a significant increase in ferritin levels with total IV or oral iron dose.
The additional data from newly identified studies showed that
studies sponsored by pharmaceutical companies were no longer
associated with a significantly lower increase in MD in Hb compared
with studies that did not report sponsorship. Heterogeneity among
studies therefore remains largely unexplained, but was likely to be
related to the significant variation in the relative doses of IV and oral
iron used in each study.
Overall completeness and applicability of evidence
Most included studies reported on laboratory assessments of
response to IV and oral iron treatment in patients with CKD stages 3
to 5 including those receiving dialysis. Our meta-analyses identified
that there are probably small increases in laboratory parameters
of Hb, ferritin and transferrin in both dialysis and non-dialysis
patients though the certainty of the evidence was low. However, key
patient-centred outcomes were reported in only a few studies so
we were unable to make definitive conclusions about the influence
of IV iron compared with oral iron therapy on death (all causes),
cardiovascular death, morbidity, or on quality of life. This review
confirmed that gastrointestinal disorders are found to be more
common in patients taking oral iron while hypotension and allergic
reactions are more common in patients receiving IV iron. Although
ESA dose was probably lower in patients treated with IV iron, only 11
studies (522 participants) reported on ESA dosage at the end of the
study and all studies providing these data were in dialysis patients.
The observed Hb increase of 1.01 g/dL in dialysis patients, together
with a significant reduction in ESA dose, provides some support for
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the practice of administering IV iron to these patients, particularly
among those unable to tolerate oral iron. However, studies have
identified that high Hb levels achieved with IV iron and ESA are
associated with increased cardiovascular death and morbidity
(Phrommintikul 2007).
The Hb increase in non-dialysis patients was modest (0.41 g/
dL), but this was not significantly diKerent from the response in
dialysis patients. None of the included studies assessed if the
patient-centred benefits of achieving higher Hb levels outweighed
financial costs or disruption to patients not on dialysis as a result
of additional or prolonged hospital visits. While three further large
studies (Agarwal 2015 CKD; FIND-CKD 2014 CKD; Kalra 2016 CKD)
in CKD patients assessed quality of life, none identified improved
quality of life with the higher Hb associated with IV iron therapy
so that only one of five studies, which assessed quality of life,
identified some improvement in quality of life in non-dialysis
patients receiving IV iron (Agarwal 2006 CKD). A systematic review
of RCTs identified no significant benefit on quality of life of higher
Hb levels achieved with ESAs and iron supplements in CKD patients
(Collister 2016).There were no data relating to non-dialysis patients
to determine if ESA requirements were reduced. We were therefore
unable to derive a definitive conclusion on the relative benefits and
harms of IV iron for non-dialysis patients.
The applicability of the conclusions in children, PD patients and
kidney transplant patients may be limited since few studies were
identified for each of these patient groups. However, the magnitude
and direction of results in these studies did not diKer from the
overall results.
Quality of the evidence
Our review included 39 studies, which involved 3852 participants.
Twenty-one studies enrolled dialysis patients, two involved
transplant patients, two enrolled dialysis and non-dialysis patients
and the remainder enrolled CKD patients. There was considerable
variation among studies in dose and duration of IV and oral iron
administration.
Of the 39 included studies, 12 were available only as abstracts.
Twenty studies reported adequate random sequence generation
while only 14 studies demonstrated adequate allocation
concealment. Studies that lack adequate allocation concealment
are considered to be at increased risk of bias (Moyer 1998; Schultz
1995). Blinding of participants and personnel was not reported
in any study. No study reported blinding of outcome assessment,
but because primary outcomes were laboratory measurements
and unlikely to be influenced by lack of blinding, all studies were
considered to be at low risk of bias for blinding of outcome
assessment. Twenty-two studies reported complete outcome data
while 20 studies were at low risk of selective reporting. The
authors of 15 included studies indicated receiving some form of
sponsorship from pharmaceutical companies.
Although administration of IV iron consistently resulted in an
increase in Hb or HCT, ferritin and TSAT, there was considerable
heterogeneity among studies in the results of these laboratory
outcomes. This eKect could not be explained aPer examining for
interactions related to participants, interventions and risk of bias
items as reported.
The certainty of the evidence for patient centred outcomes was
considered low or very low because of small patient numbers
included in these analyses and high risk or unclear risk of bias for
allocation concealment in many studies (Summary of findings for
the main comparison). Similarly the certainty of the evidence for
laboratory and pharmaceutical outcomes was considered to be low
or very low because of considerable heterogeneity in study results
and the high or unclear risk for allocation concealment in many
studies (Summary of findings 2).
Potential biases in the review process
The literature search has been run several times (up to December
2018) since the publication of the original review in 2012 to reduce
the likelihood that additional studies eligible for inclusion were
missed. Although the Cochrane Kidney and Transplant Specialised
Register also includes references of reports of studies identified by
handsearching resources including conference proceedings, it is a
possibility that relevant studies may have been missed.
The relatively high proportion of included studies that were
available only as abstracts (12/39; 31%) is a potential source of bias
as abstracts may not contain complete results or provide detailed
information on risk of bias attributes. To address reporting gaps
in studies, we contacted authors to seek additional information.
Responses from nine study authors were received but information
received related principally to risk of bias attributes. In this update,
we only identified the full publication of one study (Qunibi 2011
CKD) previously included as an abstract. A large completed RCT
(Lu 2010 CKD) comparing IV ferumoxytol with oral iron enrolled
519 participants but has only been published in abstract form in
combination with other similar studies.
Some outcomes were reported in only a few studies which
increased the risk of selection bias. In particular, the final or change
in ESA dose was reported in only 11 studies (522 patients) so that
the observed significant decrease in ESA dose with IV iron therapy
compared with oral iron may not be generalisable to the dialysis
population. Similarly, adverse eKects were reported in only 18
(46%) of the included studies.
Agreements and disagreements with other studies or
reviews
A systematic review published in 2008 that included 13 studies
applied a comprehensive literature review strategy that included
searching some conference proceedings (American Society of
Nephrology, European Renal Association - European Dialysis and
Transplant Association) (Rozen-Zvi 2008). This systematic review
was updated to October 2015 and included 24 RCTs (Shepshelovich
2016). Our updated review includes 22 of the 24 studies included
by Shepshelovich 2016. We excluded one study included in the
2008 systematic review and one included in the 2015 review
because they included both randomised and non-randomised
data (Allegra 1991; Adhikary 2011). Shepshelovich 2016 identified
13 studies involving CKD participants and 11 studies involving
dialysis patients. Both reviews reported similar increases in mean
Hb, ferritin, TSAT and the proportion of participants achieving
an increase in Hb in patients treated with IV iron compared
with oral iron. In their initial systematic review, Rozen-Zvi 2008
demonstrated a significant correlation between Hb and IV iron
dose/month in dialysis patients but not non-dialysis patients. We
were unable to demonstrate an overall correlation or a correlation
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in dialysis patients alone in our 2012 review or in this update. Both
reviews reported considerable heterogeneity for the outcomes of
Hb, ferritin and TSAT concentrations which could not be explained.
A systematic review of 103 RCTs has evaluated the safety of IV
iron compared with oral iron, no iron, placebo or intramuscular
iron (Avni 2015). The review found no increase in overall serious
adverse eKects with IV iron. As in this review, the authors found that
serious infusion reactions were more common and gastrointestinal
adverse reactions were less common with IV iron, while there was
no increase in infections with IV iron. Another systematic review
(Susantitaphong 2014) included 34 single-arm and RCTs evaluating
IV iron in HD patients with relative or functional iron deficiency as
defined by ferritin levels > 200 ± TSAT < 30%; studies of patients with
absolute iron deficiency were excluded. Therefore only one study
(Provenzano 2009 HD) included in our review was also included
in that review. The review also concluded that IV iron resulted
in increases in Hb, ferritin and TSAT and reductions in ESA dose
though the changes were less evident in RCTs compared with single
arm studies.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
This systematic review identified evidence to indicate that
compared with oral iron therapy, IV iron therapy contributed
increased ferritin and TSAT levels, reduced ESA dose required, and
provided a  small but significant increase in Hb. Limited patient-
centred outcomes data (death, cardiovascular disease, quality of
life) were reported in the included studies. These data support the
current practice of administering IV iron to in-centre HD patients
to increase iron stores, and probably, reduce both the ESA dose
required, and its cost.
While this update identified a few more studies, which addressed
patient-centred outcomes, including adverse eKects, to determine
if benefits exceed harms for all patients with CKD, only 11 studies
reported on death (all causes), three reported on cardiovascular
death and five reported on quality of life. However, because of small
number of studies reporting these outcomes and low quality of
evidence, the relative eKects of diKerent iron regimens on these
patient-centred outcomes remain uncertain. More studies reported
on allergic reactions/hypotension (14 studies) and gastrointestinal
adverse eKects (13 studies), While gastrointestinal adverse eKects
with oral iron are common with oral iron, these eKects must be
balanced against the rare, but potentially life threatening adverse
eKects seen with IV iron.
There are now additional large studies examining IV and oral iron
in CKD participants with longer follow up periods. These confirm
that IV iron compared with oral iron in CKD participants increases
laboratory indices compared with oral iron, increases the number
achieving target Hb without changing the rate of decline in kidney
function. However, there are still no studies, which have assessed
whether these benefits outweigh the disadvantages of increased
numbers and durations of hospital visits for treatment.
Implications for research
Further large RCTs with longer durations of treatment and follow-
up periods are still required. These need to assess patient-centred
outcomes including death (all causes), cardiovascular death,
cardiac morbidity using cardiac function tests, hospitalisations,
quality of life and patient inconvenience created by hospital or
clinic visits for IV iron in non-dialysis or PD patients as well as
common haematological parameters. The costs of all aspects of IV
therapy must also be determined to assess overall value of IV iron,
especially in non-dialysis and PD patients. The doses of oral and IV
iron should be standardised across studies in an eKort to reduce the
heterogeneity seen in this systematic review.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Methods • Study design: parallel RCT• Study duration/time frame: not reported• Duration of follow-up: 70 days
Participants • Setting: 26 tertiary centres• Country: USA• Health status: GFR 10 to 59; Hb < 12 g/dL; ferritin <100 ng/mL; TSAT < 20%, no need for dialysis for ≥
16 weeks, negative stool occult blood, pregnancy test• Number: IV iron (80); 44 analysed for safety; 36 analysed for efficacy); oral iron (84; 45 analysed for
safety; 39 analysed for efficacy)• Mean age ± SD (years): IV iron (65.5 ± 12.9); oral iron (62.3 ± 15.2)• Sex (M/F): IV iron (20/16); oral iron (15/24)• Exclusion criteria: receiving ESA or IV iron within previous 4 weeks; ferritin > 300 ng/mL; TSAT > 30%,
albumin < 3 g/dL; allergy to SFGC; anaemia due to other causes than iron deficiency; systemic infec-
tion; uncontrolled hypertension; dialysis; kidney transplant; malignancy; clinical instability
Interventions IV iron
• Sodium ferric gluconate complex: 250 mg weekly for 4 weeks* Total dose of elemental iron: 1000 mg
Oral iron
• Ferrous sulphate: 325 mg, 3 times/day for 6 weeks* Total dose of elemental iron: 12,285 mg
Co-interventions
• Not reported
Outcomes • Change in Hb at day 43• Change in TSAT at day 43• Change in ferritin at day 43• Change in CHr at day 43• Change from baseline quality of life• Adverse effects
Notes • Funding source: Watson Laboratories Inc• Loss to follow-up: 7 in IV group (16%), 8 in oral group (18%)• 8 (18%) excluded from analysis in IV group due to lack of pre-study evaluation• 6 (13%) excluded from analysis in oral group due to missing results
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• Exclusions post-randomisation but pre-intervention: not reported• Stop or end point/s: not reported• Additional data requested from authors: further information on methods and more detailed results
were obtained from the sponsor, Watson Laboratories Inc
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer generated randomisation of blocks of 4
Allocation concealment
(selection bias)
Low risk Central randomisation
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding. Lack of blinding could influence management
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Laboratory outcomes unlikely to be affected by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Missing data balanced in both groups, reason for missing data unlikely to be
related to true outcome
Selective reporting (re-
porting bias)
Low risk Study protocol available in paper and all of the pre-specified outcomes report-
ed
Other bias High risk Funded by Watson Laboratories Inc
Agarwal 2006 CKD  (Continued)
 
 
Methods • Study design: Phase IV open-label RCT• Study duration: August 2008 to October 2014• Duration of follow-up: 2 years
Participants • Setting: "Single centre" 2 hospitals in Indianapolis, USA• Country: USA• Health status: >18 years, non-dialysis dependent, eGFR (MDRD) > 20 and ≤ 60 mL/min, Hb < 12 g/dL
and ferritin < 100 ng/mL or serum TSAT of < 25%• Number: IV iron (67); oral iron (69)• Mean age ± SD (years): IV iron (63.2 ± 10.7); oral iron (67.8 ± 11.5)• Sex (M/F): IV iron (50/17); oral iron (54/15)• Exclusion criteria: pregnant or breast feeding; known hypersensitivity to any IV iron, iothalamate meg-
lumine (Conray 60, Malinckrodt) or iodine; Hb < 8 g/dL or the potential need for imminent RBC trans-
fusion (e.g., active bleeding); serum ferritin > 800 ng/mL or TSAT > 50%; AKI; IV iron use within the
month prior to screening; anaemia not caused by iron deficiency (e.g., sickle cell anaemia); history of
surgery or systemic or urinary tract infection within the past month; organ (any) transplant recipients
or those who were currently being treated with immunosuppressive agents
Interventions IV iron
Agarwal 2015 CKD 
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• Iron sucrose: 200 mg/week for 5 weeks* Total dose of elemental iron 1000 mg
Oral iron
• Ferrous sulphate: 325 mg 3 times/day for 8 weeks* Total dose of elemental iron 10,920 mg
Co-interventions
• 11 patients (8.1%) received ESA at the beginning of the study
Outcomes • The difference between treatment groups in the slope of measured GFR from baseline to 2 years ad-
justed for the log of baseline urinary protein/creatinine ratio• Change in Hb• Change in ferritin• Change in TSAT• Quality of life• Adverse events
Notes • "The trial was stopped early on the unanimous recommendation of the data and safety monitoring
board based on an increase in the serious adverse event rate in participants assigned to IV iron treat-
ment compared with oral iron therapy and little difference in mGFR between treatment groups. Given
the persisting signal of safety, but little chance of finding the projected difference in measured GFR
between groups, they unanimously recommended termination of the trial."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomised in a 1:1 ratio using permuted blocks. The randomisation se-
quence was computer generated by a statistician
Allocation concealment
(selection bias)
Low risk Opaque and concealed envelopes
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Not blinded and lack of blinding could influence patient management
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Primary outcome is a laboratory outcome and unlikely to be influenced by lack
of blinding. Adverse events adjudicated by blinded personnel.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk At 3 months < 20% lost to follow-up (13/136). Trial stopped early
Selective reporting (re-
porting bias)
High risk All prespecified outcomes reported but no standard deviations reported
Other bias Low risk Supported in part by a grant from the National Institute of Diabetes and Diges-
tive and Kidney Diseases (U01-DK71633) and Indiana Institute for Medical Re-
search
Agarwal 2015 CKD  (Continued)
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Methods • Study design: parallel RCT• Study duration/time frame: not reported• Duration of follow-up: 3 months
Participants • Setting: single tertiary centre• Country: India• Health status: CKD on conservative treatment, Hb 5 to 8 g/dL, HCT 15% to 24%, negative stool occult
blood, negative direct Coombs test• Number: IV iron (20); oral iron (20)• Age range: 21 to 66 years• Sex (M/F): IV iron (13/7); oral iron (16/4)• Exclusion criteria: Age < 15 years; anaemia due to other causes; uncontrolled hypertension; CAD,
chronic infections/inflammation; pregnancy; receiving androgen therapy during the previous month
Interventions IV iron
• Iron dextran: 100 mg; twice/month for 3 months* Total dose of elemental iron: 600 mg
Oral iron
• Ferrous sulphate: 200 mg, 3 times/day for 3 months* Total of dose of elemental iron: 16,200 mg
Co-interventions
• EPO 2000 IU twice/week for 3 months, stable dose
Outcomes • Hb at end of study (3 months)• Ferritin at end of study (3 months)• TSAT at end of study (3 months)• PCV at end of study (3 months)• Reticulocyte % at end of study (3 months)• GFR at end of study (3 months)• Number with sensitivity reactions
Notes • Funding source: not reported• Follow-up period: 3 months• Loss to follow-up: not reported• Exclusions post-randomisation but pre-intervention: none reported• Stop or end point/s: none reported• Additional data requested from authors: method of randomisation and allocation concealment re-
quested. No additional information provided
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method of randomisation not reported
Allocation concealment
(selection bias)
Unclear risk Method of allocation not reported
Aggarwal 2003 CKD 
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Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding. Lack of blinding could influence management
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Laboratory outcomes unlikely to be affected by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk All reported patients included in follow up, but unclear whether any patients
included were initially excluded from analysis
Selective reporting (re-
porting bias)
High risk Some outcomes, such as symptoms of fatigue and shortness of breath, were
reported incompletely and could not be included in the meta-analysis
Other bias Unclear risk Funding source not reported
Aggarwal 2003 CKD  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration/time frame: not reported• Duration of follow-up: 8 weeks
Participants • Setting: single tertiary centre• Country: USA• Health status: adult kidney transplant recipients; HCT < 35 %; TSAT < 25 % at day 5 post-transplant• Number: IV iron (6); oral iron (6)• Mean age ± SD (years): IV iron (45.8 ± 4.7); oral iron (46.6 ± 8.1)• Sex (M/F): IV iron (5/1); oral iron (4/2)• Exclusion criteria: DGF requiring dialysis; received blood transfusion; acute rejection
Interventions IV iron
• Iron dextran: 1000 mg single dose* Total dose of elemental iron: 1000 mg
Oral iron
• Ferrous sulphate: 325 mg; 3 times/day for 3 months* Total dose of elemental iron: 26,325 mg
Co-interventions
• No reported
Outcomes • HCT at end of study• TSAT at end of study• Cr at end of study
Notes • Abstract-only publication• Funding source: not reported• Loss to follow-up: None• Exclusions post randomisation but pre-intervention: not reported• Stop or end points: not reported
Ahsan 1997 TX 
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• Additional data requested from authors: we requested data on method of randomisation and alloca-
tion concealment, excluded patients before randomisation, and side effects. No additional informa-
tion was obtained
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method of randomisation not reported
Allocation concealment
(selection bias)
Unclear risk Method of allocation not reported
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding. Lack of blinding could influence management
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Laboratory outcomes unlikely to be affected by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Scant data available from abstract
Selective reporting (re-
porting bias)
Unclear risk Limited information to judge
Other bias Unclear risk Funding source not reported
Ahsan 1997 TX  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration/time frame: not reported• Duration of follow-up: 6 months
Participants • Setting: multicentre• Country: Iran• Health status: patients on HD, EPO for 6 months• Number: IV iron (9); oral iron (8)• Mean age ± SD (years): not reported• Sex (M/F): not reported• Exclusion criteria: evidence of active and chronic infection
Interventions IV iron
• Iron sucrose: 100 mg twice/week for 6 months* Total dose of elemental iron: 4800 mg
Oral iron
• Ferrous formate: 350 mg for 6 months* Total oral elemental iron: 63,000 mg
Broumand 1998 HD 
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Co-intervention
• EPO 2000 IU three times/week 6 months prior to study, stable dose
Outcomes • Hb, HCT and ferritin at end of study (6 months)
Notes • Abstract-only publication• Funding source: not reported• Randomisation method: not reported• Loss to follow-up: not reported, started with 20 patients, 3 excluded before randomisation due to HCV
positivity, hypertension while on EPO• Exclusions post randomisation but pre-intervention: None reported• Stop or end points: None reported• Additional data requested from authors: We contacted authors seeking information on the method
of randomisation and allocation concealment, type of oral iron, number of patients in both groups,
whether SD or SE were reported, and data on ferritin. The authors provided data on type of oral iron,
ferritin data, and patient numbers
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method of randomisation not reported
Allocation concealment
(selection bias)
Unclear risk Method of allocation not reported
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding. Lack of blinding could influence management
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Laboratory outcomes unlikely to be affected by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patients were included in analysis
Selective reporting (re-
porting bias)
High risk Limited information on methods. SDs imputed
Other bias Unclear risk Funding source not reported
Broumand 1998 HD  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration/time frame: not reported• Duration of follow-up: 43 days
Participants • Setting: multicentre (16 sites)• Country: USA
Charytan 2005 CKD 
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• Health status: adults > 18 years; not on dialysis; CrCl < 40 mL/min; Hb < 10.5 g/dL; TSAT < 25 %; ferritin
< 300 ng/mL; absence of other causes of anaemia; absence of infection, surgery and cancer; expected
survival > 6 months• Number: IV iron (48; 39 analysed for efficacy and safety); oral iron (48; 44 analysed for efficacy and
safety)• Mean age ± SD (years): IV iron (62 ± 14.4); oral iron (60 ± 14.4)• Sex (M/F): IV iron (19/29); oral iron (14/34)• Exclusion criteria: IV iron or ESA within past month; blood transfusion within past month; gastroin-
testinal bleeding; albumin < 3 g/dL; pregnancy or lactation; HIV positivity; expected to commence
dialysis or kidney transplant
Interventions IV iron
• Iron sucrose: 200 mg weekly for 5 weeks* Total dose of elemental iron: 1000 mg
Oral iron
• Ferrous sulphate (elemental iron 195 mg/d): 325 mg 3 times/day for 29 days* Total dose of elemental iron: 5655 mg
Co-interventions
• EPO 2000 IU/week for 6 weeks, stable dose, started at day 1 of study
Outcomes • Final Hb and change in Hb at day 43• Change in TSAT at day 43• Change in ferritin at day 43• Number with adverse effects• Number reaching Hb > 11 g/dL
Notes • Funding source: American Regent Inc• Loss to follow-up: not reported. 39/48 in IV group completed. 44/48 in oral group completed• Exclusions post randomisation but pre-intervention: Unclear• Stop or end points: none reported• Additional data requested from authors: e contacted authors seeking information on method of ran-
domisation and allocation concealment, SD for continuous variables, denominator for dichotomous
outcomes as only percentages. No information was obtained
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method of randomisation not reported
Allocation concealment
(selection bias)
Unclear risk Method of allocation not reported
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding. Lack of blinding could influence management
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Laboratory outcomes unlikely to be affected by lack of blinding
Charytan 2005 CKD  (Continued)
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Incomplete outcome data
(attrition bias) 
All outcomes
High risk Reasons for patients not completing the trial were not provided, patients with
missing data were excluded from analysis (19% missing in IV, 8% missing in
oral group). Data were provided as percentages with unclear denominators
Selective reporting (re-
porting bias)
High risk Data were not provided with SD. SD imputed to enable entry in meta-analyses
Other bias High risk Funded by American Regent Inc
Charytan 2005 CKD  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration/time frame: not reported• Duration of follow-up: 6 months
Participants • Setting: single centre• Country: Turkey• Health status: Hb < 10 g/dL; HD; hypo-responsiveness to ESA for at least 3 months; no other causes
of ESA resistance• Number: IV iron group 1 (26), IV iron group 2 (21); oral iron (22)• Mean age ± SD (years): not reported• Sex (M/F): not reported• Exclusion criteria: not reported
Interventions IV iron group 1
• Iron sucrose: 100 mg/session for 10 sessions then 100 mg/week for 6 months* Total dose of elemental iron: 3400 mg• Data from this group used in meta-analyses
IV iron group 2
• Iron sucrose: 100 mg for 10 sessions for 6 months* Total dose of elemental iron: 1000 mg
Oral iron
• Ferrous sulphate: 200 mg/day for 6 months* Total dose of elemental iron: 10,800 mg
Co-interventions
• EPO 150 IU/kg 3 times/week for at least 3 months before study, dose varied during study
Outcomes • Hb at end of study (6 months)• Ferritin at end of study (6 months)• Change in EPO dose
Notes • Abstract-only publication• Funding source: not reported• Loss to follow-up: not reported, 1 patient excluded from IV group due to side effects• Exclusions post randomisation but pre-intervention: not reported• Stop or end points: not reported• Additional data requested from authors: we contacted authors seeking information concerning
method of randomisation and allocation concealment requested. No additional data were obtained
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method of randomisation not reported
Allocation concealment
(selection bias)
Unclear risk Method of allocation not reported
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding. Lack of blinding could influence management
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Laboratory outcomes not affected by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Only one patient excluded from analysis
Selective reporting (re-
porting bias)
Unclear risk Limited information on methods
Other bias Unclear risk Funding source not reported
Erten 1998 HD  (Continued)
 
 
Methods • Study design: parallel 3-arm RCT• Study duration: December 2009 to January 2012• Duration of follow-up: 56 weeks
Participants • Setting: multicentre (193 sites)• Country: 20 countries (Australia, Austria, Belgium, Czech Republic, Denmark, France, Germany,
Greece, Italy, the Netherlands, Norway, Poland, Portugal, Romania, Spain, Sweden, Switzerland,
Turkey, UK and the USA)• Health status: adults ≥18 years; non-dialysis-dependent CKD with at least one Hb level between 9 and
11 g/dL or any ferritin level < 100 or < 200 μg/L with TSAT (TSAT) < 20%, within 4 weeks of randomisa-
tion; eGFR ≤ 60 mL/min/1.73 m2 and no ESA had been administered within 4 months of randomisation.• Number: IV iron low-ferritin arm (154; 136 completed 56 weeks); IV iron high-ferritin arm (155; 133
completed 56 weeks); oral iron (317; 250 completed 56 weeks)• Mean age ± SD (years): IV iron low-ferritin arm (68.2 ± 13.3); IV iron high-ferritin arm (69.5 ±12.6); oral
iron (69.3 ± 13.4)• Sex (M/F): IV iron low-ferritin arm (54/98); IV iron high-ferritin arm (62/91); oral iron (116/192)• Exclusion criteria: anaemia due to reasons other than iron deficiency; documented history of discon-
tinuing oral iron products due to significant gastrointestinal distress; known active infection; CRP >
20 mg/L; overt bleeding; active malignancy; chronic liver disease and concomitant New York Heart
Association Class IV heart failure
Interventions IV iron low-ferritin arm
• Ferric carboxymaltose (FCM): maximum single IV doses of 200 mg of iron targeting a ferritin level of
100 to 200 µg/L, after an initial screening period of up to 4 weeks. During weeks 4 to 48, FCM was
FIND-CKD 2014 CKD 
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administered every 4 weeks at a dose of 200 mg iron if ferritin was < 100 μg/L. Dosing was withheld if
TSAT was > 40% or targeted ferritin level was 100 to 200 µg/L* Dose of elemental iron administered to reach target was 1040 ± 618 mg in the low ferritin group
IV iron high-ferritin arm
• Ferric carboxymaltose (FCM): maximum single IV doses of 1000 mg iron, after an initial screening pe-
riod of up to 4 weeks. During weeks 4 to 48, FCM was administered every 4 weeks at a dose of 500 mg
iron if ferritin was in the range 200 to < 400 μg/L, and at a dose of 1000 mg iron if ferritin was < 200 μg/
L. Dosing was withheld if TSAT was > 40%. targeted ferritin level was 400 - 600 mcg/L.* Dose of elemental iron administered to reach target was 2685 ± 978 mg in the high ferritin group
Oral iron
• Ferrous sulphate: 100 mg iron twice daily to Week 52* Calculated dose of elemental iron was 23,660 mg
Co-interventions
• During the first 8 weeks after randomisation, patients were not to receive ESA, blood transfusion or
any anaemia therapy other than study drug unless there was an absolute requirement (e.g. severe
or serious adverse reaction to study drug or otherwise unable to continue study drug, or rapid Hb
drop requiring an ESA or transfusion, at the investigator’s discretion). Subsequently, ESA and other
therapies were permitted according to local practice if the Hb was < 10 g/dL. Alternative iron therapy
in patients with Hb > 10 g/dL could be used but only when a patient was not able to comply with or
tolerate the randomised treatment
Outcomes • Time to initiation of other anaemia management, specified as ESA, blood transfusion, use of an alter-
native iron therapy (i.e. product, dosing schedule or total dose different from study drug)• Occurrence of an Hb trigger (two consecutive Hb values < 10 g/dL on or after week 8, without an in-
crease of .0.5 g/dL between the two measurements)• Percentage of patients requiring a blood transfusion• Percentage of patients with an increase of Hb ≥ 1 g/dL• Change in haematologic and iron indices from baseline to end of study• Change in eGFR (MDRD-4) from baseline to end of study• Percentage of patients requiring dialysis• Percentage of patients discontinuing study drug due to intolerance• Change in health related quality of life using the SF-36• Adverse events
Notes • Funding source: Vifor Pharma, Glattbrugg, Switzerland• Lost to follow-up: IV high-ferritin group (22 died or discontinued, 14%); IV low-ferritin group (18 died
or discontinued, 11.6%); oral group (67 died or discontinued, 21%)• Exclusions post randomisation: 2 in the IV high-ferritin group, 2 in the IV low-ferritin group and 9 in
the oral iron group• Stop or end points: none• Additional data requested from authors: we contacted authors to seek additional information and
data on missing patients. No response was received
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Via a central interactive voice-response system in a 1:1:2 ratio, with randomi-
sation blocks distributed by country
Allocation concealment
(selection bias)
Low risk Central interactive voice-response system
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Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding. Lack of blinding could influence management
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Laboratory outcomes unlikely to be influenced by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patients were accounted for
Selective reporting (re-
porting bias)
Low risk Review's prespecified primary outcomes reported in either full publication or
abstract
Other bias High risk Funding source bias: "This work was supported by Vifor Pharma"
FIND-CKD 2014 CKD  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration/ time frame: not reported• Duration of follow-up: 4 months
Participants • Setting: single centre• Country: USA• Health status: HD for at least 3 months; receiving ESA and oral iron for 3 months; no recent bleeding
or transfusion; no haematologic disease other than anaemia; not treated with IV iron for at least 6
months; ferritin > 100 ng/mL, TSAT > 15%• Number: IV group (20), oral group (32)• Mean age ± SD (years): IV iron (48.7 ± 8.7); oral iron (50.2 ± 9.9)• Sex (M/F): IV group (13/7); oral group (18/14)• Exclusions: not reported
Interventions IV iron
• Iron dextran: 100 mg twice/week for 4 months* Total dose of IV iron: 3200 mg
Oral iron
• Ferrous sulphate (21/32): 325 mg, 3 times/day for 4 months* Total dose of elemental iron: 35,100 mg• Iron polysaccharide (11/32): 150 mg twice/day for 4 months
Co-interventions
• ESA started at least 3 months before study, dose adjusted to maintain HCT 30% to 34%
Outcomes • HCT, Hb at end of study• TSAT at end of study• Ferritin at end of study• EPO dose at end of study• Number with reduction in ESA• Number with side effects
Fishbane 1995 HD 
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Notes • Funding source: not reported• Loss to follow-up: 5/25 discontinued treatment in IV group (one from diarrhoea, 2 from other illnesses,
2 from bleeding); 18/50 discontinued treatment in the oral group (4 failed treatment, others due to
illness, bleeding, death)• Exclusions post randomisation but pre-intervention: not reported• Stop or end points: not reported• Additional data requested from authors: we contacted authors to seek information concerning
method of randomisation and allocation concealment. No additional data were obtained
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method of randomisation not reported
Allocation concealment
(selection bias)
Unclear risk Method of allocation not reported
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding. Lack of blinding could influence patient management
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Laboratory outcomes unlikely to be affected by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Large number excluded from analysis, 20% in oral group, 36% in IV group
Selective reporting (re-
porting bias)
Low risk Study protocol available in paper and all of the pre-specified outcomes report-
ed
Other bias Unclear risk Funding source not reported
Fishbane 1995 HD  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration/time frame: not reported• Duration of follow-up: 26 months
Participants • Setting: single tertiary centre• Country: Israel• Health status: no blood transfusion or iron during previous year; commencing HD; no malignancy or
chronic inflammation; no severe hyperparathyroidism; no other causes of anaemia• Number: IV iron (24); oral iron (12)• Mean age ± SD (years): IV iron (56.6 ± 15.1); oral iron (42.6 ± 17.03)• Sex (M/F): IV iron (12/8); oral iron (5/5)• Exclusion criteria: not reported
Interventions IV iron
Fudin 1998 HD 
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• Iron sodium gluconate complex: 62.5 mg/week until TSAT 35%, then 62.5 mg or 125 mg/month to
maintain TSAT* Total dose of elemental iron could be calculated
Oral iron
• Ferrous sulphate: 150 mg equivalent to 50 mg/day of elemental iron* Total dose of elemental iron: 39,000 mg
Co-interventions
• Not reported
Outcomes • Hb at end of study (26 months)• Ferritin at end of study (26 months)• TSAT at end of study (26 months)
Notes • Funding source: not reported• Loss to follow-up: 4/24 (16%) in the IV group were excluded from analysis, 2/12 (16%) in the oral iron
were excluded from analysis• Exclusions post randomisation but pre-intervention: not reported• The authors included a third group of 9 patients who were not treated with iron supplements so not
included in the analysis• Stop of end points: not reported• Additional data requested from authors: we contacted authors to seek information concerning final
Hb and TSAT. Data were provided
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Table of 1000 random digits generated by multiplicative congruent method
Allocation concealment
(selection bias)
High risk Open random allocation schedule
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding. Lack of blinding could influence management
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Laboratory outcomes unlikely to be affected by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
High risk 16% in both groups did not complete and were excluded from the analysis
Selective reporting (re-
porting bias)
Unclear risk Limited information on methods
Other bias Unclear risk Funding source not reported
Fudin 1998 HD  (Continued)
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Methods • Study design: parallel RCT• Study duration/time frame: not reported• Duration of follow-up: 3 months
Participants • Setting: single tertiary centre• Country: Pakistan• Health status: Hb < 8.5 g/dL; ferritin 200 to 800 ng/mL; TSAT > 30%, on HD; normal vitamin B12, folate• Number: IV iron (10); oral iron (10)• Mean age: IV iron (58.4 years); oral iron (56 years)• Sex (M/F): IV iron (6/4); oral iron (5/5)• Exclusion criteria: uncontrolled hypertension; severe hyperparathyroidism; active peptic ulcer dis-
ease; hypersensitivity to IV iron
Interventions IV iron
• Iron sucrose: 100 mg twice/week for 3 months* Total dose of elemental iron: 2400 mg
Oral iron
• Ferrous sulphate: 200 mg 3 times/day for 3 months* Total dose of elemental iron: 16,200 mg
Co-interventions
• EPO 25 U/kg/week twice weekly, dose altered during study
Outcomes • Hb at end of study (3 months)• Ferritin at end of study (3 months)• TSAT at end of study (3 months)• Mean EPO dose/week at end of study (3 months)• Number with change in EPO dose
Notes • Funding source: not reported• Lost to follow-up: not reported• Exclusions post randomisation but pre-intervention: not reported• Stop or end points: not reported• Additional data requested from authors: we contacted authors to seek information concerning
method of randomisation and allocation concealment. No additional data were not obtained
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method of randomisation not mentioned
Allocation concealment
(selection bias)
Unclear risk Method of allocation not mentioned
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding. Lack of blinding could influence management
Blinding of outcome as-
sessment (detection bias) 
Low risk Laboratory outcomes unlikely to be affected by lack of blinding
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All outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Unclear whether results of all patients were included in the analysis
Selective reporting (re-
porting bias)
Unclear risk Limited information on methods
Other bias Unclear risk Funding source not reported
Hussain 1998 HD  (Continued)
 
 
Methods • Study design: phase III open-label RCT• Study duration/timeframe: June 2010 to April 2014• Duration of follow-up: 8 weeks
Participants • Setting: multicentre (67 sites)• Country: India, Germany, UK, Austria, Russia, Poland, Denmark, Romania, USA, Sweden, Ireland• Health status: eGFR between 15 and 59 mL/min/1.73 m2, · Hb < 11g/dL; either or both serum ferritin <
200 µg/L; TSAT < 20%; life expectancy > 12 months by PI's judgement• Number: IV iron (233); oral iron (118)• Mean age ± SD (years): IV iron (57.63 ± 15.54); oral iron (57.94 ± 16.34)• Sex (M/F): IV iron (92/141); oral iron (64/54)• Exclusion criteria: anaemia caused by factors other than renal impairment or iron deficiency (accord-
ing to PI’s judgment); iron overload or disturbances in utilization of iron (e.g. haemochromatosis and
haemosiderosis); s-Ferritin > 500 µg/L; drug hypersensitivity (i.e. previous hypersensitivity to iron dex-
tran or iron mono- or disaccharide complexes or iron sulphate or any excipients of the study drug);
history of multiple allergies; decompensated liver cirrhosis or active hepatitis; active acute or chron-
ic infections; active Rheumatoid arthritis; pregnancy or nursing; active bleeding necessitating blood
transfusion; planned elective surgery during the study; participation in any other clinical study with-
in 3 months prior to screening; untreated vitamin B12 or folate deficiency; IV or oral iron treatment
or blood transfusion within 4 weeks prior to screening visit; ESA treatment within 8 weeks prior to
screening visit; body weight < 30 kg
Interventions IV Iron
• Iron Isomaltoside 1000 administered to achieve cumulative dose mg from Ganzoni formula [BWkg x
(13 g/dL - actual Hb g/dL)] x 2.4 + depot iron (set at 500 mg)• Group A1: 116 patients received 1 dose of 1000 mg at week 0 and then 9 received second dose at
week 1• Group A2: 112 patients had 1 dose of 500 mg at week 0, 107 again at Week 1 and 16 patients again
at Week 2
Oral iron
• Iron sulphate (65 mg elemental iron): 200 mg daily for 8 weeks (3640 mg elemental iron total)
Co-interventions
• No patient received an ESA
Outcomes • Change in Hb from baseline to week 4• Change in Hb at week 2 and 8• Change in serum iron, ferritin, TSAT, TIBC at weeks 1, 2, 4 and 8• Energy
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• Activity• QOL
Notes • Funding source: Pharmacosmos A/S
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk An interactive web response system (IWRS) was used to randomise the pa-
tients
Allocation concealment
(selection bias)
Low risk Unique identifier number via IWRS
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Not blinded and lack of blinding could influence patient management
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Not blinded but primary outcome is laboratory measurement and unlikely to
be influenced by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 7 (2%) lost to follow-up
Selective reporting (re-
porting bias)
Low risk Prespecified outcomes reported
Other bias High risk Funded by Pharmacosmos A/S
Kalra 2016 CKD  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration/time frame: not reported• Duration of follow-up: 5 months
Participants • Setting: single centre• Country: USA• Health status: HD > 6 months; no IV iron for 6 months; no recent bleeding or blood transfusion; on ESA
> 3 months; HCT > 30%; ferritin > 100 ng/mL; TSAT > 20%• Number: IV iron (18, 15 analysed); oral iron (19, 16 analysed)• Mean age ± SD (years): not reported• Sex (M/F): not reported
Exclusion criteria
• Positive for HIV, other haematological disorders
Interventions IV iron
• Iron (preparation not reported): 100 mg/week for 5 months* Total dose of elemental iron: 2000 mg
Kotaki 1997 HD 
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Oral iron
• Ferrous sulphate: 325 mg, 3 times/day for 5 months* Total dose of elemental iron: 43,875 mg
Co-interventions
• ESA > 3 months before study, dose varied
Outcomes • Hb at end of study (5 months)• Ferritin at end of study (5 months)• TSAT at end of study (5 months)• Mean ESA dose at end of study (5 months)
Notes • Funding source: not reported• Lost to follow-up: 3/18 (17%) from IV group; 3/19 (16%) from oral group• Exclusion post randomisation but pre-intervention: not reported• Stop or end points: not reported• Additional data requested from authors: we contacted authors to seek additional information con-
cerning method of randomisation and allocation concealment. No additional data were obtained
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method of randomisation not mentioned
Allocation concealment
(selection bias)
Unclear risk Method of allocation not mentioned
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding. Lack of blinding could influence management
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Laboratory outcomes unlikely to be affected by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Missing data balanced across groups
Selective reporting (re-
porting bias)
Low risk Prespecified outcomes were reported
Other bias Unclear risk Funding source not reported
Kotaki 1997 HD  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration/time frame: not reported• Duration of follow-up: 10 weeks
Participants • Setting: multicentre
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• Country: USA• Health status: CKD stages 3 to 5 not on dialysis; Hb < 12 g/dL; ferritin < 100 ng/mL and/or TSAT < 20%;
stable ESA dose for > 4 weeks before enrolment• Number: IV iron (26 safety arm, 24 efficacy arm); oral iron (24 safety arm, 24 efficacy arm)• Mean age ± SD (years): not reported• Sex (M/F): not reported• Exclusion criteria: dialysis patients; positive FOBT result
Interventions IV iron
• Sodium ferric gluconate complex: 250 mg/week for 4 weeks* Total dose of elemental iron: 1000 mg
Oral iron
• Ferrous sulphate: 325 mg, 3 times/day for 6 weeks* Total dose of elemental iron: 12,285 mg
Co-interventions
• EPO: ≥ 4000 IU/week or ≥ 20 μg/week (darbepoetin), stable dose
Outcomes • Hb at end of study (10 weeks)• Ferritin at end of study (10 weeks)
Notes • Abstract-only publication• Funding source: Watson Laboratories Inc• Lost to follow-up: unclear• Exclusions post randomisation but pre-intervention: not reported• Stop or end points: not reported• Additional data requested from authors: we contacted authors to seek additional information con-
cerning SDs and numbers completing the study. The sponsor provided additional data on the study
design, but no data on results
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer generated randomisation schedule
Allocation concealment
(selection bias)
Low risk Central randomisation in blocks of 4 at a 1:1 ratio. Investigators had no prior
knowledge of allocation
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding. Lack of blinding could influence management
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Laboratory based outcome unlikely to be influenced by blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Abstract only
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Selective reporting (re-
porting bias)
High risk Abstract only. Reported change in Hb and ferritin. No SDs provided. SD imput-
ed for inclusion in meta-analyses
Other bias High risk Funded by Watson Laboratories Inc
Leehey 2005 CKD  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration/time frame: not reported• Duration of follow-up: 12 weeks
Participants • Setting: single centre• Country: China• Health status: stable on HD for 1 month, ferritin < 500 ng/mL, TSAT < 30%, Hb 60 to 90 g/dL, HCT 18
to 24%, all on oral iron and ESA pre-study• Number: IV iron (70); oral iron (66)• Mean age ± SE (years): IV iron (53.6 ± 13.8); oral iron (54.9 ± 12.6)• Sex (M/F): IV iron (31/39); oral iron (26/40)• Exclusion criteria: severe liver disease; hypersplenism; haemorrhage; blood transfusion in previous
month; malignancy, sensitive to iron; high CRP > 20 mg/L; severe infection or inflammation
Interventions IV iron
• Iron sucrose: 100 mg twice/week for 8 weeks, then once/week for 4 weeks* Total dose of elemental iron: 2000 mg
Oral iron
• Ferrous succinate: 200 mg 3 times/day for 12 weeks* Total dose of elemental iron: 16,800 mg
Co-interventions
• EPO 100 to 150 IU/kg/week started before study, dose varied; folic acid; vitamin B12
Outcomes • Final or change in Hb (12 weeks)• Final ferritin (12 weeks)• Final TSAT (12 weeks)• Mean ESA dose at end of study (12 weeks)• Number with adverse effects• Number with a specific rise in Hb
Notes • Funding source: not reported• Lost to follow-up: none• Exclusions post randomisation but pre-intervention: not reported• Stop or end points: not reported• Additional data requested from authors: we contacted authors to seek additional information con-
cerning method of randomisation and allocation concealment, and whether data were expressed as
SD or SE. No additional data were obtained
Risk of bias
Bias Authors' judgement Support for judgement
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Random sequence genera-
tion (selection bias)
Low risk Computerised random number list
Allocation concealment
(selection bias)
Unclear risk Method of allocation not reported
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding. Lack of blinding could influence management
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Laboratory outcomes unlikely to be affected by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk No missing data. All participants completed the study and were included in the
analysis
Selective reporting (re-
porting bias)
Low risk All prespecified outcomes were reported
Other bias Unclear risk Funding source not reported
Li 2008 HD  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration/time frame: not reported• Duration of follow-up: 8 weeks
Participants • Setting: single centre• Country: China• Health status: stable on PD for 1 month; ferritin < 500 ng/mL; TSAT < 30%; Hb 60 to 90 g/L; HCT 18%
to 27%• Number: IV iron (26); oral iron (20)• Mean age ± SE (years): IV iron (56.9 ± 14.8); oral iron (57.6 ± 15.6)• Sex (M/F): IV iron (12/14); oral iron (9/110)• Exclusion criteria: severe liver disease; hypersplenism; haemorrhage; active gastrointestinal ulcer;
blood transfusion in previous month; malignancy; sensitive to iron; high CRP > 20 mg/L; severe infec-
tion or inflammation; malnourished
Interventions IV iron
• Iron sucrose: 200 mg/week for 4 weeks, then every second week for 8 weeks* Total dose of elemental iron: 1200 mg
Oral iron
• Ferrous succinate: 200 mg, 3 times/day for 8 weeks* Total dose of elemental iron: 11,200 mg
Co-interventions
• ESA 100 to 150 U/kg/week before study, dose varied during study
Outcomes • Final or change in Hb (8 weeks)
Li 2008 PD 
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• Final or change in ferritin (8 weeks)• Final or change in TSAT (8 weeks)• Mean ESA dose at end of study (8 weeks)• Cr at end of study• Number with adverse effects• Number with specific rise in Hb
Notes • Funding source: not reported• Lost to follow-up: not reported• Exclusions post randomisation but pre-intervention: not reported• Stop or end points: not reported• Additional data requested from authors: we contacted authors to seek additional information con-
cerning Method of randomisation and allocation concealment, and whether data were expressed as
SE or SD. No additional data were obtained
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer random number list
Allocation concealment
(selection bias)
Unclear risk Method of allocation not mentioned
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding. Lack of blinding could influence management
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Laboratory outcomes unlikely to be affected by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk No missing data
Selective reporting (re-
porting bias)
Low risk All prespecified outcomes were reported
Other bias Unclear risk Funding source not reported
Li 2008 PD  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration/time frame: June 2004 to November 2006• Duration of follow-up: 35 days
Participants • Setting: multicentre (31 sites)• Country: USA• Health status: adults > 18 years with CKD stages 1 to 5 (not on dialysis); Hb ≤ 11 g/dL; TSAT ≤ 30%;
ferritin ≤ 600 ng/mL; no change in ESA while in study; no parenteral or oral iron within 10 days of study
start
Lu 2010 CKD 
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• Number: IV iron (227 (1 lost to follow up on entry; ITT population 226; 220 commenced medication;
215 completed; 7 withdrawn); oral iron (77; 74 commenced medication; 67 completed; 5 withdrawn)• Mean age ± SD (years): IV iron (65.7 ± 14.1); oral iron (67.6 ± 12.9)• Sex (M/F): IV iron (95/131); oral iron (29/48)• Exclusion criteria: pregnancy or breastfeeding; other causes of anaemia; recent iron therapy; cancer;
PTH > 1500 pg/mL; bleeding; surgery; recent blood transfusion; active infection; allergy to IV iron; dial-
ysis treatment; malignancy; uncontrolled hyperparathyroidism
Interventions IV iron
• Ferumoxytol: 510 mg, 2 doses* Total dose of elemental iron: 1020 mg
Oral iron
• Ferrous fumarate: 100 mg elemental iron twice/day for 21 days* Total dose of elemental iron: 4200 mg
Co-interventions
• ESA stable dose at < 35,000 IU/week or < 120 μg darbepoetin every 2 weeks or not started. 30% to 40%
received ESA in stable dose. 95/226 in IV group received ESA, 34/77 in oral group received ESA
Outcomes • Final or change in Hb (35 days)• Final or change in ferritin (35 days)• Number with adverse events: only provided as combined data with Spinowitz 2008 CKD• Number with rise in Hb > 1 g/dL
Notes • Funding source: AMAG Pharmaceuticals• Lost to follow-up: IV group (1 lost to FU and 6 patients did not complete study); oral group (6 patients
did not complete study)• Exclusion post randomisation but pre-intervention: IV group (5); oral group (3)• Additional information on this unpublished study obtained from AMAG Pharmaceuticals• Stop or end points: none stated• Additional data requested from authors: information provided by AMAG Pharmaceuticals about the
study data on 4-3-2015 as no primary study reporting this study was identified
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk 3:1 automated pre-programmed interactive voice response system
Allocation concealment
(selection bias)
Low risk Telephone based
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open label. Lack of blinding could have influenced management
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Open label but outcomes were laboratory based and unlikely to be affected by
lack of blinding
Incomplete outcome data
(attrition bias) 
Low risk Missing data of primary endpoint balanced between groups,5.3% IV,12% oral
Lu 2010 CKD  (Continued)
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All outcomes
Selective reporting (re-
porting bias)
Low risk Study protocol not available but identical to Spinowitz 2008. Information on
outcomes provided by AMAG Pharmaceuticals
Other bias High risk Funded by AMAG Pharmaceuticals whose employees identified study sites,
monitored the study and performed data analyses according to a predefined
statistical analysis plan
Lu 2010 CKD  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration/time frame: not reported• Duration of follow-up: 24 weeks
Participants • Setting: single centre• Country: Singapore• Health status: stable on HD ≥ 3 months; ferritin ≥ 100 ng/mL; TSAT ≥ 20%; no ESA for ≥ 1 month; ade-
quate B12 and folate levels; no sepsis; no chronic inflammation; no active bleeding• Number: IV iron (30); oral iron (30)• Mean age ± SD (years): not reported• Sex (M/F): not reported• Exclusion criteria: bleeding, severe infection or inflammation
Interventions IV iron
• Ferric hydroxide polymaltose complex (Ferrum): 200 mg/month for 24 weeks* Total dose of elemental iron: 1200 mg
Oral iron
• Ferrous fumarate: 200 mg 3 times/day for 24 weeks* Total dose of elemental iron: 33,600 mg
Co-interventions
• EPO 4000 U/week started at study commencement. Dose stable through study
Outcomes • Hb at end of study (24 weeks)• Ferritin at end of study (24 weeks)
Notes • Abstract-only publication• Funding source: not reported• Lost to follow-up: unclear• Exclusions at post randomisation: not reported• Stop or end points: not reported• Additional data requested from authors: the author provided information on numbers in each group
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Abstract only. No information provided
Lye 2000 HD 
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Allocation concealment
(selection bias)
High risk Inadequate allocation. Author reported that patients were allocated alternate-
ly to each group
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Abstract only. No blinding. Lack of blinding could influence management
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Abstract only. Outcome was laboratory based and unlikely to be influenced by
blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Abstract only. No information provided
Selective reporting (re-
porting bias)
Unclear risk Abstract only. Reported end of study Hb and ferritin levels. Patient numbers
provided by the author
Other bias Unclear risk Abstract only
Lye 2000 HD  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration/time frame: not reported• Duration of follow-up: 16 weeks
Participants • Setting: single tertiary centre• Country: UK• Health status: stable on HD or CAPD > 3 months; CKD stage 5; Hb ≤ 8.5 g/dL on 3 occasions; normal
folate and vitamin B12 levels; ferritin 100 to 800 μg/L; no other cause of anaemia; no malignancy; nor-
mal CRP; no infection; no surgery in last 3 months; no hyperparathyroidism• Number: IV iron (13, 1 discontinued due to anaphylactic reaction; 12 were analysed); oral iron (13)• Mean age ± SD (years): IV iron (47 ± 15); oral iron (58 ± 16)• Sex (M/F): IV iron (6/6); oral iron (8/5)• Exclusion criteria: severe hyperparathyroidism (PTH > 100 pmol/L); uncontrolled hypertension; alu-
minium toxicity
Interventions IV iron
• Iron dextran: 250 mg every 2 weeks for 16 weeks* Total dose of elemental iron: 2000 mg
Oral iron
• Ferrous sulphate: 200 mg 3 times/day for 16 weeks* Total dose of elemental iron: 21,600 mg
Outcomes • Hb at end of study (16 weeks)• Ferritin at end of study (16 weeks)• TSAT at end of study (16 weeks)• Mean ESA dose at end of study (16 weeks)• Number with a change in ESA dose
Notes • Funding source: not reported
Macdougall 1996 HD,PD,CKD 
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• Lost to follow-up: none• Exclusions post randomisation and pre-intervention: not reported• Stop or end points: not reported• Additional data requested from authors: further details concerning method of randomisation and al-
location concealment were requested. Data were provided by the authors
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Sealed envelopes containing random numbers
Allocation concealment
(selection bias)
Low risk Central, by pharmacy
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding. Lack of blinding could influence management
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Laboratory outcomes unlikely to be affected by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patients were accounted for
Selective reporting (re-
porting bias)
Low risk Primary outcomes reported in either full publication or abstract
Other bias Unclear risk Funding source not reported
Macdougall 1996 HD,PD,CKD  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration/time frame: not reported• Duration of follow-up: 24 weeks
Participants • Country: UK• Setting: Multicentre• Health status: stable on dialysis; receiving ESA; Hb 9 to 12 g/dL; ferritin 100 to 600 ng/mL• Number: IV iron (41); oral iron (35)• Mean age ± SD (years): not reported• Sex (M/F): not reported• Exclusion criteria: not reported
Interventions IV iron
• Iron sucrose: 20 mg/dialysis session in HD patients and 200 mg/month in PD patients for 24 weeks* Total dose of elemental iron 1200 mg in PD and 1440 mg in HD (assuming dialysis 3 times/week)
Oral iron
Macdougall 1999 HD,PD 
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• No information provided
Co-interventions
• Dose of ESA varied during study according to requirements
Outcomes • Hb at end of study (24 weeks)• Ferritin at end of study (24 weeks)• ESA dose at end of study (24 weeks)• Per cent with rise in Hb > 1 g/dL (24 weeks)
Notes • Abstract-only publication• Funding source: not reported• Lost to follow-up: unclear• Exclusions post randomisation but pre-intervention: not reported• Stop or end points: not reported• Additional data requested from authors: none
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Abstract only; not reported
Allocation concealment
(selection bias)
Unclear risk Abstract only; not reported
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Abstract only. No blinding. Lack of blinding could influence management
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Abstract only. Outcome was laboratory based and unlikely to be influenced by
blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Abstract only. Unclear if all patients completed study
Selective reporting (re-
porting bias)
Unclear risk Abstract only. Reported end of study Hb, ferritin and per cent of participants
who had a rise in Hb
Other bias Unclear risk Abstract only
Macdougall 1999 HD,PD  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration/time frame: not reported• Duration of follow-up: 6 to 12 months
Participants • Setting: multicentre (6 sites)• Country: Australia
McMahon 2009 CKD 
Parenteral versus oral iron therapy for adults and children with chronic kidney disease (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
55
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
• Health status: CKD stages 3 to 5 (GFR ≤ 35 in non-diabetic participants, ≤ 50 in diabetic participants),
non-dialysis; Hb > 11 g/dL; 36% diabetic; ESA naive; aged 18 to 80 years, clinically significant fall in Hb
and/or Cr in past 18 months• Number: IV iron (52, 43 completed at least 6 months, 39 completed 12 months); oral iron (48, 42 com-
pleted at least 6 months, 38 completed 12 months)• Median age, IQR: IV iron (70 years, 58 to 75); oral iron (68 years, 59 to 74)• Sex (M/F): IV iron (40/12); oral iron (33/15)• Exclusion criteria: receiving ESA; iron overload (ferritin > 300 μg/L, TSAT > 25%); severe iron deficiency
(ferritin < 30, TSAT < 15); active malignancy, bleeding or haemolysis; chronic sepsis or inflammation
(CRP > 25 mg/L); severe IHD or CHF; adult PCKD
Interventions IV iron
• Iron sucrose: 100 to 200 mg every second month for 12 months to maintain ferritin 300 at 500 and/or
TSAT 25% to 50%; 34 participants required monthly IV iron on one or more occasions* Dose of elemental iron could not be calculated
Oral iron
• Ferrous sulphate: 325 mg (105 mg elemental iron) to maintain ferritin at 100 to 150 and/or TSAT 20%
to 25%; 6 participants required no iron, 25 needed iron intermittently, 5 intolerant to iron and needed
IV iron intermittently.* Dose of elemental iron could not be calculated
Co-interventions
• ACEi administered to 51/52 IV group participants and 45/48 oral group participants
Outcomes • Hb at end of study (at least 6 months) and 12 months• Ferritin at end of study (at least 6 months) and 12 months• TSAT at end of study (at least 6 months) and 12 months• eGFR at end of study
Notes • Funding source: Vifor• Lost to follow-up: IV group (9 died or discontinued, 14%); oral group (6 died or discontinued, 12.5%)• Exclusions post randomisation: not reported• Stop or end points: none• Additional data requested from authors: we contacted authors to seek additional information con-
cerning allocation concealment and data on missing patients. No data were obtained
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Simple block randomisation from block randomisation lists generated with
Graphpad Statmate
Allocation concealment
(selection bias)
Unclear risk Method of allocation not mentioned
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open label. Lack of blinding could influence management
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Open label study but outcomes based on laboratory results unlikely to be in-
fluenced by lack of blinding
McMahon 2009 CKD  (Continued)
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Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patients were accounted for. Patients not completing 6 months were ex-
cluded a priori
Selective reporting (re-
porting bias)
Low risk Primary outcomes (end Hb, ferritin, TSAT) reported in either full publication or
abstract
Other bias High risk Grant/research support from Vifor (NCT 000202345)
McMahon 2009 CKD  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration/time frame: not reported• Duration of follow-up: 22 weeks
Participants • Setting: tertiary centre• Country: USA• Health status: adult HD patients; iron replete; stable ESA dose for 8 weeks; TSAT 20% to 50%; ferritin
100 to 800 ng/mL• Number: IV iron (33); oral iron (27)• Mean age ± SD (years): not reported• Sex (M/F): not reported• Exclusion criteria: not reported
Interventions IV iron
• Sodium ferric gluconate complex: 62.5 mg/week for 20 weeks* Total dose of elemental iron: 1250 mg
Oral iron
• Ferrous sulphate: 325 mg, 3 times/day for 20 weeks* Total dose of elemental iron: 40,950 mg
Co-interventions
• ESA started before the study. Dose varied during study
Outcomes • Change in Hb• Change in ferritin• Change in TSAT• Change in ESA dose
Notes • Abstract-only publication• Funding source: Watson Laboratories• Lost to follow-up: none• Exclusions post randomisation but pre-intervention: not reported• Stop or end points: not reported• Additional data requested from authors: we sought method of randomisation and allocation conceal-
ment from authors. No data were obtained
Risk of bias
Bias Authors' judgement Support for judgement
Michael 2007 HD 
Parenteral versus oral iron therapy for adults and children with chronic kidney disease (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
57
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Random sequence genera-
tion (selection bias)
Unclear risk Method of randomisation not mentioned
Allocation concealment
(selection bias)
Unclear risk Method of allocation not mentioned
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open label. Lack of blinding could influence management
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Laboratory outcomes unlikely to be affected by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Unclear if all patients completed study
Selective reporting (re-
porting bias)
Unclear risk No clear protocol
Other bias High risk Grant/Research support: Watson Laboratories
Michael 2007 HD  (Continued)
 
 
Methods • Study design: open-label RCT• Study duration: December 2007 to March 2009• Duration of follow-up: 90 days
Participants • Setting: tertiary centre• Country: Australia• Health status: adult patients; undergoing living-donor or deceased donor kidney transplant surgery;• Number: IV iron (51); oral iron (51)• Mean age: 46 years• Sex (M/F): 74/28• Exclusion criteria: iron overload (TSAT > 50% or ferritin > 800 g/L); women lactating, pregnant, or of
child-bearing potential not using a reliable contraceptive method; patients with a history of psycho-
logical illness or condition thought to interfere with their ability to understand or comply with the re-
quirements of the study; previous intolerance of IV or PO iron supplements
Interventions IV iron
• Iron polymaltose: single dose of 500 mg given on the fourth postoperative day* Total dose of elemental iron: 500 mg
Oral iron
• Ferrous sulphate: 2 slow release tablets daily on the fiPh postoperative day, and treatment was con-
tinued until the primary endpoint (Hb ≥ 11 g/dL) was reached* Total dose of elemental iron: 210 mg elemental iron daily for median duration of 21 days (4410 mg)
Co-interventions
• ESA started before the study. Dose varied during study
Mudge 2009 TX 
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Outcomes • Time to normalisation of Hb post transplant (≥ 11 g/dL)• post-transplant Hb concentration• Gastrointestinal adverse effects defined as the onset of nausea, vomiting, abdominal cramping or di-
arrhoea• Infusion related reactions described as self-limiting flushing, sweating, chills, myalgias, arthralgias,
bronchospasm and chest pain occurring at the time of the infusion• All infectious episodes
Notes • Protocol published in BMC Nephrology• Funding source: P.A. Hospital Research Foundation funding the trial• Follow-up period: unclear; times to resolution of anaemia• Exclusions post randomisation but pre-intervention: 2 patients• Stop or end points: 2 patients discontinued the PO iron intervention• Additional data requested from authors: none
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated sequence with blocks of 10
Allocation concealment
(selection bias)
Low risk Was performed by the use of sequentially numbered, sealed, opaque en-
velopes with stratification for calcineurin inhibitor type (cyclosporine or
tacrolimus), in a one-to-one ratio
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open label. Lack of blinding could influence management
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Laboratory outcomes unlikely to be affected by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patients completed the study
Selective reporting (re-
porting bias)
Low risk All prespecified outcomes were reported
Other bias Low risk Funded by Princess Alexandra Hospital Research Foundation
Mudge 2009 TX  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration/time frame: May 2007 to February 2011• Duration of follow-up: 6 months
Participants • Setting: single centre• Country: Canada• Health status: CKD stages 3 to 5 (GFR ≤ 60), non-dialysis; Hb 9 to 12 g/dL (females) and 9 to 13.5 g/dL
(males); iron indices < 100 µg/L for ferritin or TSAT < 20%; aged > 18 years
Nagaraju 2013 CKD 
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• Number: IV iron (22, 19 completed 6 months); oral iron (18, 14 completed 6 months)• Median age, IQR (years): IV iron (66, 58 to 76); oral iron (76, 66 to 83)• Sex (M/F): IV iron (12/10); oral iron (13/5)• Exclusion criteria: receiving iron parenteral therapy or blood transfusion within the last 3 months;
pregnant; major surgery; infection; active malignancy; bleeding or GI bleed or if serum folate or vita-
min B12 levels below the normal limits (< 15 nmol/L, < 133 pmol/L)
Interventions IV iron
• Iron sucrose: 200 mg monthly for 12 months to maintain ferritin 100 - 500 µg/L and/or TSAT 20% to
50%;* Dose of elemental iron: 1200 mg
Oral iron
• Heme Iron Polypeptide (HIP): 11 mg 3 times/day (33 mg/day) to maintain ferritin at 100 to 500 µg/L
and/or TSAT 20% to 50%, 3 intolerant to iron due to new or worsening abdominal cramps* Dose of elemental iron: 6006 mg
Co-interventions
• ESA administered to 6/22 IV group participants and 7/18 oral group participants at baseline. One in IV
group ceased ESA and one in oral group commenced ESA. Dose altered according to Hb
Outcomes • Hb at end of study (6 months) and changes from baseline• Ferritin at end of study (6 months) and changes from baseline• TSAT at end of study (6 months) and changes from baseline• Adverse events
Notes • Funding source: Ottawa Hospital Research Institute• Lost to follow-up: IV group (3 died or discontinued, 13%); oral group (4 died or discontinued, 22.2%)• Exclusions post randomisation: not reported• Stop or end points: none• Additional data requested from authors: none
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer generated sequence
Allocation concealment
(selection bias)
Low risk Group allocation was stored in sealed opaque sequentially numbered en-
velopes
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Single blind (investigator) was blinded but no blinding of care givers or pa-
tients. Lack of blinding could have influenced management
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcomes were laboratory based and unlikely to be influenced by lack of
blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 7/40 (17.5%) dropped out but were included in analyses (last result carried for-
ward). All randomised patients were followed until the end of the study, rea-
sons for dropout provided
Nagaraju 2013 CKD  (Continued)
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Selective reporting (re-
porting bias)
Low risk Outcomes were reported as median and IQR and could not be entered in meta-
analyses; we have changed this to low risk as we have used the median as the
mean and imputed standard deviations
Other bias Low risk Baseline age imbalance between the two groups but group ages were not sig-
nificantly different. Funded by Ottawa Hospital Research Institute
Nagaraju 2013 CKD  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration/time frame: enrolment July 2010 to November 2017• Duration of study: 35 days
Participants • Setting: multicentre (number not reported)• Country: USA• Health status: 14 dialysis (stable on HD or PD) and non-dialysis paediatric CKD patients; 6 months to
< 18 years; CKD or stable on PD or HD; known to have iron deficiency anaemia defined as a) Hb ≤ 12.0
g/dL and b) with either TSAT level ≤ 40% or ferritin level < 100 ng/mL.• Number: IV iron (8); oral iron (6)• Mean age ± SD (years): IV iron (15.2 ± 1.65); oral iron (13.8 ± 4.52)• Sex (M/F): IV iron (3/5); oral iron (5/1)• Exclusion criteria: history of allergy to either oral or IV iron; Hb ≤ 7.0 g/dL; serum ferritin > 600 ng/mL;
female participants who were pregnant or intended to become pregnant, or were breastfeeding, were
within 3 months postpartum, or had a positive serum pregnancy
Interventions IV ferumoxytol
• Four IV injections of ferumoxytol 3.5 mg Fe/kg (maximum of 255 mg/dose) administered on non-con-
secutive days within a 14-day period as follows* Day 1 (dose 1), Days 3* to 10 (dose 2), Days 5 to 12 (dose 3), and Days 7 to 14 (dose 4)* *Participants participating in PK sampling received the second dose on Day 4 after the 72-hour PK
sample was collected• Two IV injections of ferumoxytol 7.0 mg Fe/kg (maximum of 510 mg/dose), the first administered on
Day 1 and the second on Days 3 through 9
Oral ferrous fumarate
• 2.5 mg Fe/kg twice daily (maximum of 100 mg/dose) on Days 1 through 35
Outcomes • Mean change in Hb from baseline to week 5• No outcomes provided when study terminated
Notes • Study terminated because of significant challenges to recruitment. One adverse effect was recorded
with ferumoxytol but type of reaction not recorded. No other results were reported.• Study AMAG-FER-CKD-251 (NCT01155375) was a study evaluating the efficacy and safety of IV feru-
moxytol in paediatric participants with dialysis-dependent CKD.• Study AMAG-FER-CKD-252 (NCT01155388) was a study evaluating the efficacy and safety of IV feru-
moxytol in paediatric participants with non-dialysis-dependent CKD• Study AMAG-FER-CKD-252 was combined with Study AMAG-FER-CKD-251 and enrolment continued
under Study AMAG-FER-CKD-251. The enrolment number (n = 14) includes the number of participants
for both AMAG-FER-CKD-251 and AMAG-FER-CKD-252 studies, combined
Risk of bias
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label study
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Primary outcome laboratory based
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Insufficient information to permit judgement
Selective reporting (re-
porting bias)
Unclear risk Insufficient information to permit judgement
Other bias High risk Study set up by AMAG Pharmaceuticals, Inc.
NCT01155375 HD,PD,CKD  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration/time frame: October 2011 to September 2013• Duration of follow-up: 3 months
Participants • Setting: single centre• Country: Italy• Health status: aged > 18 years; eGFR (MDRD) ≤ 60 mL/min/1.73 m2, Hb ≤ 12 g/dL, ferritin ≤ 100 ng/mL,
TSAT≤ 25%, PTH between 30 and 300 pg/mL, and calcium and phosphate plasma levels within their
normal values• Number: IV iron (37 started, 4 lost to FU, 33 analysed); oral iron (69 started, 3 lost to FU, 66 analysed)• Mean age ± SD (years): IV iron (47.6 ± 16); oral iron (53.1 ± 15)• Sex (M/F): IV iron (30%/70%); oral iron (27%/73%)• Exclusion criteria: CRP levels ≥ 5 mg/L; presence of inflammatory, infectious disease or surgical inter-
ventions in the last 3 months; haematological disorders, bleeding or blood transfusions in the last
6 months; malignancies or treatment with immunosuppressive drugs; severe malnutrition, concomi-
tant severe liver or CV disease, chronic alcohol or drug abuse within the past 6 months; known hepati-
tis B or C infection; pregnant or lactating women
Interventions IV iron
• Iron gluconate: 125mg, weekly for 3 months* Elemental iron: 1000 mg
Oral Iron
• Sideral® Forte, PharmanutraSpa (30 mg of pyrophosphate liposomal iron and 70 mg of ascorbic acid):
Pisani 2014 CKD 
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• One capsule daily for 3 months* Elemental iron: 2520 mg
Co-interventions
• ESA: 9/99 patients received ESA
Outcomes • Change in Hb values from baseline to end of treatment• Difference in the per cent of patients achieving an increase in Hb of ≥ 0.6 g/dL at any study point• Change in TSAT and ferritin from baseline to end of treatment• Treatment was suspended if ferritin exceeded 800 ng/mL or TSAT% exceeded 50%
Notes • 93% completed study & were analysed• Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation list generated by computer
Allocation concealment
(selection bias)
Low risk numbered, sealed envelopes opened in sequence by staK personnel not in-
volved in patient care
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Not blinded and lack of blinding could influence management
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk outcomes were laboratory based and unlikely to be affected by lack of blind-
ing
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 99/109 patients analysed, only 6 lost to follow-up
Selective reporting (re-
porting bias)
Low risk Prespecified outcomes were all reported
Other bias Unclear risk Funding not stated
Pisani 2014 CKD  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration/time frame: October 2005 to April 2007• Duration of follow-up: 35 days
Participants • Setting: multicentre (5 sites)• Country: USA• Health status: aged > 18 years; on HD for ≥ 90 days; Hb < 11.5 g/dL; TSAT < 30%; ferritin < 600 ng/mL;
stable ESA (dose ± 25%) for ≥ 10 days before study commencement• Number: IV iron (114; 110 started, 102 completed); oral iron (116; 114 started, 99 completed)• Mean age ± SD: IV iron (59.5 ± 14.3); oral iron (60.8 ± 13)
Provenzano 2009 HD 
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• Sex (M/F): IV iron (57/57); oral iron (73/43)• Exclusion criteria: pregnancy or breastfeeding; other causes of anaemia; use of investigational drug
within 30 days; iron treatment within 10 days; recent blood transfusion; active infection; allergy to
iron or drug classes
Interventions IV iron
• Ferumoxytol: 510 mg for 2 doses* Total dose of elemental iron: 1020 mg
Oral iron
• Ferrous fumarate: 200 mg/day for 21 days* Total dose of elemental iron: 4200 mg
Co-intervention
• ESA maintained stable
Outcomes • Final Hb and change in Hb (35 days)• Final ferritin and change in ferritin (35 days)• Final TSAT and change in TSAT (35 days)• Change TIBC, CHr at end (35 days)• Number with adverse events• Per cent who had a specific rise in Hb > 1 g/dL
Notes • Funding source: AMAG Pharmaceuticals• Lost to follow-up: 8 withdrew from IV group, 4 due to adverse effects (7%), 15 withdrew from oral
group, 9 due to adverse effects (13%)• Exclusions post randomisation but pre-intervention: IV group (4); oral group (2)• Stop or end points: not reported• Additional data requested from authors: we sought additional information about method of randomi-
sation and allocation concealment from authors. some data were obtained
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method of randomisation not reported
Allocation concealment
(selection bias)
Low risk Telephone-based system
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open label. Lack of blinding could influence management
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Laboratory outcomes unlikely to be affected by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patients who were randomised were included in the analysis
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Selective reporting (re-
porting bias)
Low risk All outcomes defined in study registration reported
Other bias High risk Funded by AMAG Pharmaceuticals whose employees identified study sites,
monitored the study and performed data analyses according to a predefined
statistical analysis plan
Provenzano 2009 HD  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration/time frame: May 2005 to February 2007• Duration of follow-up: 56 days
Participants • Setting: multicentre (47 centres)• Country: USA, Australia, Hong Kong• Health status: non-dialysis patients ≥ 12 years; GFR ≤ 45 mL/min; Hb ≤ 11g/dL; TSAT ≤ 25%; ferritin ≤
300 ng/mL. Those on ESA had a fixed dose of ESA ≥ 8 weeks• Number: IV iron (152/147 received at least one dose); oral iron (103)• Mean age ± SD (years): IV iron (65.4 ± 12.6); oral iron (66.8 ± 13.5)• Sex (M/F): IV iron (53/94); oral iron (30/73)• Exclusion criteria: history of intolerance to oral iron; IV iron in previous 12 weeks; active infection;
severe liver/heart disease; severe psychiatric disorders; drug abuse: pregnancy/lactation; hepatitis B/
C; HIV: anticipated dialysis/transplant in 3 months
Interventions IV iron
• Ferric carboxymaltose: 1000 mg with up to 2 additional doses of 500 mg* Total dose of elemental iron could not be calculated
Oral iron
• Ferrous sulphate: 325 mg 3 times/day for 56 days* Total dose of elemental iron: 10,920 mg
Co-interventions
• ESA in some patients, stable ESA dose before and during study
Outcomes • Mean change in Hb, ferritin, TSAT• Number having increase in Hb ≥ 1g/dL• Number with adverse reactions
Notes • Funding source: American Reagent/Luipold Pharmaceuticals• Loss to follow-up: none• Exclusions post randomisation but pre-intervention: not reported• Stop or end points: not reported• Additional data requested from authors: we sought information regarding method of randomisation
and allocation concealment, number analysed, SD of change in Hb. No data were obtained but addi-
tional information became available with full publication of study in 2011
Risk of bias
Bias Authors' judgement Support for judgement
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Random sequence genera-
tion (selection bias)
Low risk Centralised interactive voice-response system. Stratified by severity of CKD
Allocation concealment
(selection bias)
Low risk Centralised interactive voice-response system
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open label study. Lack of blinding could influence management
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Laboratory outcomes unlikely to be affected by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 10/255 (4%) not included in analyses
Selective reporting (re-
porting bias)
Low risk Data provided on expected outcomes including adverse effects
Other bias High risk Funding support from American Reagent/Luipold Pharmaceuticals
Qunibi 2011 CKD  (Continued)
 
 
Methods • Study design: quasi-RCT• Study duration/timeframe: December 2004 to March 2005• Duration of follow-up: 3 months
Participants • Setting: single centre• Country: Egypt• Health status: dialysis patients < 18 years; HD 3 times/week for ≥ 3.5 hours, Kt/V > 1.2, TSAT ≥ 20%,
ferritin ≥ 100ng/mL, Hb < 11g/dL and/or HCT < 33%; no iron or transfusions; all on oral iron pre study• Number: IV iron (12); oral iron (12)• Median age: IV iron (12 years); oral iron (10 years)• Sex (M/F): IV iron (5/7); oral iron (8/4)• Exclusion criteria: TSAT ≤ 20% or ≥ 50% or ferritin ≤ 100g/dL or ≥ 800ng/dL; positive CRP
Interventions IV Iron
• Iron sucrose: 2 mg/kg, every 2 weeks, max 100 mg/dose, for 3 months* Total dose could not be calculated.
Oral Iron
• Iron gluconate: 3 mg/kg daily for 3 months* Total dose could not be calculated.
Co-interventions
• ESA: All participants received epoetin alpha
Outcomes • Median serum iron at 3 months• Median TIBC at 3 months• Median TSAT at 3 months
Ragab 2007 HD 
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• Median Ferritin at 3 months• Median Hb at 3 months• Median HCT at 3 months
Notes • Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Patients were "randomly subdivided"
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Not blinded, lack of blinding could influence management
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Laboratory based outcome, unlikely to be affected by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk No patients lost to follow-up
Selective reporting (re-
porting bias)
High risk No prespecified outcomes and only medians reported with no IQR
Other bias Unclear risk Funding not reported
Ragab 2007 HD  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration/time frame: not reported• Duration of follow-up: not reported
Participants • Setting: single tertiary centre• Country: Brazil• Health status: HD patients considered iron deficient based on Hb and ferritin levels• Number: IV iron (12); oral iron (12)• Mean age ± SD (years): not reported• Sex (M/F): not reported• Exclusion criteria: not reported
Interventions IV iron
• Iron sucrose: dose calculated based on iron status and body weight* Total dose of elemental iron could not be calculated
Oral iron
Souza 1997 HD 
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• Ferrous sulphate: dose calculated based on iron status* Total dose of elemental iron could not be calculated
Co-intervention
• Some patients received ESA
Outcomes • Change in Hb• Change in ferritin• Change in iron status
Notes • Abstract-only publication• Funding source: not reported• Lost to follow-up: IV group: 4 (33%) did not complete; oral group: 1 (8%) did not complete• Exclusion post randomisation but pre-intervention: not reported• Stop or end point: not reported• Additional data requested from authors: we sought information regarding method of randomisation
and allocation concealment, number of patients in each group, dose of oral iron, number of patients
who were on ESA, variation in the dose of ESA during study, change in Hb for those who were on ESA.
No data were obtained
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method of randomisation not reported
Allocation concealment
(selection bias)
Unclear risk Method of allocation not reported
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding. Lack of blinding could influence management
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Laboratory outcomes unlikely to be affected by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Unclear if all patients completed study
Selective reporting (re-
porting bias)
Unclear risk No clear protocol
Other bias Unclear risk Funding source not reported
Souza 1997 HD  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration/time frame: May 2004 to August 2006• Duration of follow-up: 35 days
Spinowitz 2008 CKD 
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Participants • Setting: multicentre (number of sites not reported)• Country: USA• Health status: Adults with CKD stages 1 to 5; Hb < 11 g/dL; TSAT < 30%; ferritin < 600 ng/mL; no change
in ESA while in study; no parenteral or oral iron within 10 days of study start• Number: IV iron (228; 217 started, 207 completed); oral iron (76; 75 started, 63 completed)• Mean age ± SD: IV iron (65.1 ± 14.3); oral iron (63.7 ± 11.6)• Sex (M/F): IV iron (93/135); oral iron (24/52)• Exclusion criteria: pregnancy or breastfeeding; other causes of anaemia; recent iron therapy; cancer;
PTH > 1500 pg/mL; bleeding; surgery; recent blood transfusion; active infection; allergy to IV iron
Interventions IV iron
• Ferumoxytol: 510 mg, 2 doses* Total dose of elemental iron: 1020 mg
Oral iron
• Ferrous fumarate: 100 mg elemental iron twice/day for 21 days* Total dose of elemental iron: 4200 mg
Co-interventions
• ESA stable dose at < 35,000 IU/week or < 120 μg darbepoetin every 2 weeks or not started. 83/228 in
IV group received ESA, 33/76 in oral group received ESA
Outcomes • Final or change in Hb (35 days)• Final or change in ferritin (35 days)• Final or change in TSAT (35 days)• Number with adverse events• Per cent with rise in Hb > 1 g/dL
Notes • Funding source: AMAG Pharmaceuticals• Lost to follow-up: IV group (10 patients did not complete study); oral group (12 patients did not com-
plete study)• Exclusion post randomisation but pre-intervention: IV group (11); oral group (1)• Stop or end points: none stated• Additional data requested from authors: we sought information regarding method of randomisation
and allocation concealment. Data were obtained from authors
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk 3:1 automated pre-programmed interactive voice response system
Allocation concealment
(selection bias)
Low risk Telephone based
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open label. Lack of blinding could influence management
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Laboratory outcomes unlikely to be affected by lack of blinding
Spinowitz 2008 CKD  (Continued)
Parenteral versus oral iron therapy for adults and children with chronic kidney disease (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
69
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Missing data of primary endpoint balanced between groups,10% IV,13% oral
Selective reporting (re-
porting bias)
Low risk Study protocol available in paper and all of the prespecified outcomes report-
ed
Other bias High risk Funded by AMAG Pharmaceuticals whose employees identified study sites,
monitored the study and performed data analyses according to a predefined
statistical analysis plan
Spinowitz 2008 CKD  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration/time frame: not reported• Follow up: 6 months
Participants • Setting: single tertiary centre• Country: UK• Health status: progressive deterioration in kidney function; Cr > 250 μmol/L; not on dialysis; worsening
anaemia; Hb < 11 g/dL; not on ESA• Number: IV iron (22, 15 completed); oral iron (23, 17 completed)• Mean age ± SD (years): IV iron (57.3 ±14); oral iron (59.9 ± 13.4)• Sex (M/F): IV iron (10/12); oral iron (15/8)• Exclusion criteria: treatment with IV iron for previous 6 months; malignancy; intolerance to oral iron;
poor compliance; dialysis, on ESA; gastrointestinal bleeding
Interventions IV iron
• Iron sucrose: 300 mg monthly according to ferritin levels* Total dose of elemental iron: 1638 mg
Oral iron
• Ferrous sulphate: 200 mg 3 times/day for 6 months* Total dose of elemental iron: 32,400 mg
Co-interventions
• EPO: 2000 IU twice weekly started at start of study, dose varied• ACEi: 23% IV group, 52% oral group
Outcomes • Hb at end of study• Ferritin at end of study• ESA dose at end of study• Number with adverse events• Number reaching target Hb• Number with change in ESA dose
Notes • Funding source: Janssen Cilag and Syner-Med• Lost to follow-up: IV group: 7 (32%) discontinued; oral group 6 (26%) discontinued• Exclusion post randomisation but pre-intervention: not reported• Stop or end points: not reported• Additional data requested from authors: we sought information regarding method of allocation con-
cealment, Hb mean change and SD. No information was obtained
Stoves 2001 CKD 
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• Email from Dr Richardson (8 Jan 2011) stated that the RCT registered in Current Clinical Trials is the
report published by Stoves et al. No further information available as to why the RCT was published in
2001 but the trial registered in 2004
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-based
Allocation concealment
(selection bias)
Unclear risk Method of allocation not mentioned
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding. Lack of blinding could influence management
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Laboratory outcomes unlikely to be affected by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
High risk 29% did not complete the study; this large number could induce bias the re-
sults
Selective reporting (re-
porting bias)
High risk Outcomes reported as median and IQR and could not be entered in meta-
analyses
Other bias High risk Imbalance between ACEi treatment in each group
Sponsored by Janssen Cilag and Syner-Med
Stoves 2001 CKD  (Continued)
 
 
Methods • Study design: cross-over RCT• Study duration/time frame: not reported• Duration of follow-up: 52 weeks
Participants • Setting: University teaching hospital• Country: UK• Health status: HD for 3 months; no previous iron supplements• Number: IV iron 20 (19 completed 26 weeks and crossed over, 15 completed 52 weeks, 5 discontinued);
oral iron (20)• Mean age ± SD (years): not reported• Sex (M/F): not reported• Exclusion criteria: blood transfusion in the previous 3 months; low vitamin B12; folate; kidney trans-
plant with rejection
Interventions IV iron
• Iron dextran: 100 mg every 2 weeks* Total dose of elemental iron: 1300 mg
Oral iron
Strickland 1977 HD 
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• Ferrous sulphate: 100 mg daily for 26 weeks* Total dose of elemental iron: 18,200 mg
Co-interventions
• Not reported
Outcomes • Hb change reported for all who received IV and oral iron• Number with adverse reactions
Notes • Funding source: Abbott Laboratories Ltd and Fisons Pharmaceuticals Ltd• Loss to follow-up: none• Exclusions post randomisation but pre-intervention: not reported• Stop or end points: not reported• Additional data requested from authors: because of the date of the study (1977), authors were not
contacted
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Balanced allocation within strata using a method similar to the minimisation
procedure
Allocation concealment
(selection bias)
Unclear risk Method of allocation not mentioned
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding. Lack of blinding could influence management
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Laboratory outcomes unlikely to be affected by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
High risk 25% of participants were excluded from analysis
Selective reporting (re-
porting bias)
High risk Data combined in crossover study and could not be incorporated in meta-
analyses
Other bias High risk Funding support from Abbott Laboratories Ltd and Fisons Pharmaceuticals Ltd
Strickland 1977 HD  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration/time frame: not reported• Duration of follow-up: 6 weeks
Participants • Setting: single centre• Country: Czech Republic• Health status: HD patients; ferritin < 300 ng/mL; TSAT < 20 %; EPO 60 U/kg/week in both groups and
were on a stable dose
Svara 1996 HD 
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• Number: IV iron (30, 29 analysed); oral iron (32, 28 analysed)• Mean age ± SD (years): IV iron (61 years); oral iron (61 years)• Sex (M/F): not reported• Exclusion criteria: non-dialysis patients
Interventions IV iron
• Iron sucrose: 100 mg/week for 6 weeks* Total dose of elemental iron: 600 mg
Oral iron
• Ferrous sulphate: 34.5 mg, 3 times/day (total dose 724.5 mg/week)* Total dose of elemental iron: 4347 mg
Co-interventions
• EPO 60 IU/kg/week in both groups and were on a stable dose
Outcomes • Hb at end of study (6 weeks)• Ferritin at end of study (6 weeks)• TSAT at end of study (6 weeks)
Notes • Funding source: not reported• Randomisation method: not reported• Loss to follow-up: none; 4 patients excluded from analysis• Exclusion post randomisation but pre-intervention: IV iron: 1 excluded (chronic inflammatory
process); oral iron: 3 excluded (gastrointestinal intolerance)• Stop or end points: not reported• Additional data requested from authors: none requested
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method of randomisation not reported
Allocation concealment
(selection bias)
Unclear risk Method of allocation not reported
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding. Lack of blinding could influence management
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Laboratory outcomes unlikely to be affected by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Three patients were excluded from oral, one from IV group
Selective reporting (re-
porting bias)
Low risk All outcomes specified in methods were reported
Other bias Unclear risk Funding source not reported
Svara 1996 HD  (Continued)
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Methods • Study design: parallel RCT• Study duration/time frame: March to September 2007• duration of follow-up: 6 months
Participants • Setting: single tertiary centre• Country: Japan• Health status: HD patients (> 6 months) using ultrapure dialysate; anaemia; tested negative for occult
blood in stool• Number: IV iron (12, 12 completed); oral iron (11, 11 completed)• Mean age ± SD (years): IV iron (61 ±13.3); oral iron (59.5 ± 10.7)• Sex (M/F): IV iron (6/6); oral iron (5/6)• Exclusion criteria: uncontrolled hypertension; history of coronary artery disease; patients who
changed treatment options from oral to IV or vice-versa; awaiting kidney transplantation; pregnant or
lactating women; received a blood transfusion within 1 month prior to the study
Interventions IV iron
• Cideferron: 50 mg iron in 2 mL during HD once a week for 6 months* Total dose of elemental iron: 1300 mg
Oral iron
• Ferrous fumarate: 305 mg once a day for 6 months* Total dose of elemental iron: 18200 mg
Co-interventions
• rHuEPO: dose adjusted to maintain a target HCT of 33% to 38%.
Outcomes • Hb and HCT at end of study• Ferritin at end of study• TSAT at end of study• ESA dose at end of study• Number with adverse events (gastrointestinal symptoms and gastrointestinal haemorrhage)• Changes in dry weight• Changes in cardiothoracic ratio• Changes in ESA dose
Notes • Funding source: not reported• Lost to follow-up: IV group: 0 (0%) discontinued; oral group 0 (0%) discontinued• Exclusion post randomisation but pre-intervention: not reported• Stop or end points: not reported• Additional data requested from authors: We sought information regarding method of allocation con-
cealment, Hb mean change and SD. No information was obtained
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
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Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding. Lack of blinding could influence management
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Laboratory outcomes unlikely to be influenced by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk No flow chart provided, only data about included patients is provided
Selective reporting (re-
porting bias)
Low risk Expected outcomes of haematological outcomes and adverse effects reported
Other bias Unclear risk Funding source not reported
Tsuchida 2010 HD  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration/time frame: not reported• Duration of follow-up: 56 days
Participants • Setting: multicentre (35 sites)• Country: USA• Health status: non-dialysis patients; CKD stages 3 to 5; Hb < 11 g/dL; TSAT < 25%; ferritin < 300 ng/mL;
no ESA or no change in ESA for 8 weeks; no IV iron for 6 months• Number: IV iron (95, 91 started treatment); oral iron (93, 91 started treatment)• Mean age: IV iron (62.3 years); oral iron (63.9 years)• Sex (M/F): IV iron (26/53); oral iron (26/56)• Exclusion criteria: treatment with IV iron for previous 6 months; malignancy; allergy to oral or IV iron;
infection; major surgery in the prior month; blood transfusion within 2 months; bleeding within 3
months; severe liver disease; pregnancy; lactation; asthma; haemochromatosis
Interventions IV iron
• Iron sucrose: 1000 mg, divided doses over 14 days* Total dose of elemental iron: 1000 mg
Oral iron
• Ferrous sulphate: 325 mg, 3 times/day for 56 days* Total dose of elemental iron: 10,920 mg
Co-interventions
• ESA use in some of patients, dose stable
Outcomes • Change in Hb at end of study (56 days)• Change in ferritin at end of study (56 days)• Change in TSAT at end of the study (56 days)• Change in ESA dose• Number reaching target Hb or a specific rise• Number with adverse events
Van Wyck 2005 CKD 
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Notes • Funding source: American Regent, Inc• Lost to follow-up: IV iron: 12 (13%) participants excluded from the analysis (discontinued treatment);
oral iron: 9 (10%) excluded (discontinued treatment) due to unstable ESA dose prior to randomisation
or lack of baseline data and 2 lost to follow-up• Exclusions post randomisation but pre-intervention: IV iron (4); oral iron (2)• Stop or end points: not reported• Additional data requested from authors: we contacted author to seek method of allocation conceal-
ment and randomisation, numerical values for the change in Hb, TSAT, ferritin as mean and SD. Data
were provided by authors
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Sequential random numbers
Allocation concealment
(selection bias)
Low risk Central randomisation
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding. Lack of blinding could influence management
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Laboratory outcomes unlikely to be affected by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Missing data balanced between groups
Selective reporting (re-
porting bias)
Low risk All of outcomes have been reported
Other bias High risk Supported by American Regent, Inc
Van Wyck 2005 CKD  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration/time frame: not reported• Duration of follow-up: 5 weeks
Participants • Setting: single tertiary centre• Country: China• Health status: stable adult HD patients on ESA therapy• Number: IV iron (21); oral iron (22)• Mean age ± SD (years): not reported• Sex (M/F): not reported• Exclusion criteria: not reported
Interventions IV iron
Wang 2003 HD 
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• Ferric citrate: 50 mg twice/week for 5 weeks* Total dose of elemental iron: 500 mg
Oral iron
• Ferrous sulphate: 600 mg/day for 5 weeks* Total dose of elemental iron: 6300 mg
Co-interventions
• EPO 6000 U/week. Unclear when started. Stable dose
Outcomes • Hb at end of study (5 weeks)• Ferritin at end of study (5 weeks)
Notes • Abstract-only publication• Funding source: not reported• Follow-up period: 5 weeks• Lost to follow-up: unclear. Reported to have enrolled 45 patients, but 21 included in IV arm and 22 in
oral arm• Exclusions post randomisation but pre-intervention: not reported• Stop or end points: not reported• Additional data requested from authors: none requested
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding. Lack of blinding could influence management
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcome is laboratory based and unlike to be altered by blinding.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Insufficient information to permit judgement
Selective reporting (re-
porting bias)
Unclear risk Reported end Hb and ferritin
Other bias Unclear risk Insufficient information to permit judgement
Wang 2003 HD  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration/time frame: not reported
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• Duration of follow-up: 16 weeks
Participants • Setting: multicentre (5 sites)• Country: USA• Health status: aged > 1 year to < 20 years; HD > 2 months; TSAT > 20%; stable ESA > 4 weeks prior to
study; URR > 60%• Number: IV iron (17); oral iron (18)• Mean age ± SD (months): IV iron (181.4 ± 54.8); oral iron (175.9 ± 41.9)• Sex (M/F): IV iron (7/10); oral iron (9/9)• Exclusion criteria: non-renal cause of anaemia; malignancy; serious reaction to IV iron; active infection
or inflammation; HIV, iron overload (ferritin > 800 ng/mL); hyperparathyroidism (PTH > 1000 pg/mL);
uncontrolled HTN
Interventions IV iron
• Iron dextran: 12 doses weekly. Dose differed according to body weight* Total dose of elemental iron could not be calculated
Oral iron
• Ferrous fumarate: 5 mg/kg/day for 16 weeks* Total dose of oral iron: 560 mg/kg
Co-interventions
• ESA use, dose variable
Outcomes • Final or change in Hb (16 weeks)• Final or change in ferritin (16 weeks)• Final or change in TSAT (16 weeks)• Final or change in mean ESA dose (16 weeks)• Final or change in CHr (16 weeks)• Number with change in ESA dose
Notes • Funding source: Watson Laboratories• Lost to follow-up: None• Exclusions post randomisation but pre-intervention: not reported• Stop or end points: not reported• Additional data requested from authors: We contacted authors to seek method of allocation conceal-
ment, and to investigate if all patients were included in the analysis. Some data were obtained from
authors
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Random number table
Allocation concealment
(selection bias)
Unclear risk Method of allocation not mentioned
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding. Lack of blinding could influence management
Warady 2002 HD  (Continued)
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Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Laboratory outcomes unlikely to be affected by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patients were included in the analysis (information from authors)
Selective reporting (re-
porting bias)
Low risk All of outcomes have been reported
Other bias High risk Supported by a grant from Watson Laboratories
Warady 2002 HD  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration/time frame: not reported• Follow up: 12 months
Participants • Setting: single centre• Country: UK• Health status: patients established on HD twice weekly• Number: 28 patients; umbers receiving IV iron or oral iron unclear• Mean age ± SD: not reported• Sex (M/F): not reported• Exclusion criteria: not reported
Interventions IV iron
• Iron dextran: 50 mg IV weekly* Total dose of elemental iron: 2600 mg
Oral iron
• Slow Fe: 320 mg daily for 12 months* Total dose of oral iron: 36,400 mg
Co-interventions
• Not reported
Outcomes • End Hb and HVT
Notes • Abstract-only publication• Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk "randomly allocated"
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Winney 1977 HD 
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Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding and lack of blinding could influence results
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Laboratory outcomes unlikely to be affected by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Insufficient information to permit judgement
Selective reporting (re-
porting bias)
Unclear risk Abstract only. Only information provided is for Hb/HCT
Other bias Unclear risk No information provided on funding
Winney 1977 HD  (Continued)
ACE - angiotensin-converting enzyme; ACEi - angiotensin-converting enzyme inhibitor; AKI - acute kidney injury; CAD - coronary artery
disease; CAPD - continuous ambulatory peritoneal dialysis; CHF - congestive heart failure; CHr - reticulocyte haemoglobin content; CKD -
chronic kidney disease; Cr - creatinine; CrCl - creatinine clearance; CRP - C-reactive protein; DGF - delayed graP function; eGFR - estimated
glomerular filtration rate; (rHu)EPO - (recombinant human) erythropoietin; ESA - erythrocyte-stimulating agent/s; FOBT - faecal occult
blood test; GFR - glomerular filtration rate; Hb - haemoglobin; HCT - haematocrit; HCV - hepatitis C virus; HD - haemodialysis; HIV - human
immunosuppressive virus; HTN - hypertension; IHD - ischaemic heart disease; IQR - interquartile range; IV - intravenous; Kt/V - dialyser
urea clearance adequacy; M/F - male/female; MDRD - Modified Diet in Renal Disease; PCKD - polycystic kidney disease; PCV - packed cell
volume; PD - peritoneal dialysis; PTH - parathyroid hormone; RBC - red blood cell/s; SD - standard deviation; SE - standard error; SFGC -
sodium ferric gluconate complex; TIBC - total iron binding capacity; TSAT - transferrin saturation; URR - urea reduction ratio
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Adhikary 2011 Said to be RCT but included some non-randomised participants
Allegra 1991 Said to be RCT but results included some non-randomised patients
Charytan 2013 Wrong comparator: IV iron is compared to standard medical therapy, which could be oral or IV iron.
No separate data available for patients receiving oral iron
HEMATOCRIT 2012 Wrong intervention: Compares two oral iron preparations
Lye 1997 Wrong intervention: compares intramuscular and oral routes
RCT - randomised controlled trial
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Comparison 1.   Patient centred outcomes
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Death (all causes) 11 1952 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.64, 1.94]
2 Cardiovascular death 3 206 Risk Ratio (M-H, Random, 95% CI) 1.71 [0.41, 7.18]
3 Quality of life 1   Mean Difference (IV, Random,
95% CI)
Totals not selected
4 Number of non-dialysis patients need-
ing to commence dialysis
4 743 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.41, 1.61]
5 Number requiring transfusion 5 774 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.55, 1.34]
6 Type of adverse event 21   Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 Allergic reactions/hypotension 15 2607 Risk Ratio (M-H, Random, 95% CI) 3.56 [1.88, 6.74]
6.2 Infection 4 954 Risk Ratio (M-H, Random, 95% CI) 1.32 [0.90, 1.95]
6.3 All gastrointestinal adverse effects 14 1986 Risk Ratio (M-H, Random, 95% CI) 0.47 [0.33, 0.66]
6.4 Constipation 10 1618 Risk Ratio (M-H, Random, 95% CI) 0.32 [0.18, 0.57]
6.5 Diarrhoea 10 1625 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.47, 1.05]
6.6 Nausea and vomiting 9 1573 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.45, 1.29]
6.7 Taste disturbances 4 851 Risk Ratio (M-H, Random, 95% CI) 3.78 [0.84, 16.97]
6.8 Iron overload 3 158 Risk Ratio (M-H, Random, 95% CI) 6.58 [0.81, 53.51]
 
 
Analysis 1.1.   Comparison 1 Patient centred outcomes, Outcome 1 Death (all causes).
Study or subgroup IV iron Oral iron Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Tsuchida 2010 HD 0/12 0/11   Not estimable
Stoves 2001 CKD 1/18 0/20 3.1% 3.32[0.14,76.6]
Qunibi 2011 CKD 2/147 0/103 3.34% 3.51[0.17,72.43]
Kalra 2016 CKD 3/228 0/117 3.5% 3.61[0.19,69.25]
Fishbane 1995 HD 0/20 3/32 3.6% 0.22[0.01,4.13]
Fudin 1998 HD 2/20 1/12 5.82% 1.2[0.12,11.87]
Provenzano 2009 HD 1/114 3/116 6.04% 0.34[0.04,3.21]
McMahon 2009 CKD 5/41 1/42 6.9% 5.12[0.63,41.97]
Lu 2010 CKD 4/225 3/77 14.05% 0.46[0.1,1.99]
Agarwal 2015 CKD 6/67 4/69 20.54% 1.54[0.46,5.23]
FIND-CKD 2014 CKD 6/153 12/308 33.11% 1.01[0.39,2.63]
   
Total (95% CI) 1045 907 100% 1.12[0.64,1.94]
Less with IV iron 1000.01 100.1 1 Less with oral iron
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Study or subgroup IV iron Oral iron Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 30 (IV iron), 27 (Oral iron)  
Heterogeneity: Tau2=0; Chi2=7.64, df=9(P=0.57); I2=0%  
Test for overall effect: Z=0.39(P=0.7)  
Less with IV iron 1000.01 100.1 1 Less with oral iron
 
 
Analysis 1.2.   Comparison 1 Patient centred outcomes, Outcome 2 Cardiovascular death.
Study or subgroup IV iron Oral iron Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Stoves 2001 CKD 1/18 0/20 20.96% 3.32[0.14,76.6]
Fudin 1998 HD 2/20 0/12 23.63% 3.1[0.16,59.52]
Agarwal 2015 CKD 2/67 2/69 55.41% 1.03[0.15,7.1]
   
Total (95% CI) 105 101 100% 1.71[0.41,7.18]
Total events: 5 (IV iron), 2 (Oral iron)  
Heterogeneity: Tau2=0; Chi2=0.6, df=2(P=0.74); I2=0%  
Test for overall effect: Z=0.73(P=0.47)  
Less with IV iron 1000.01 100.1 1 Less with oral iron
 
 
Analysis 1.3.   Comparison 1 Patient centred outcomes, Outcome 3 Quality of life.
Study or subgroup IV iron Oral iron Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Kalra 2016 CKD 204 7.6 (44.3) 108 6.1 (21.8) 1.45[-5.89,8.79]
Better with oral iron 105-10 -5 0 Better with IV iron
 
 
Analysis 1.4.   Comparison 1 Patient centred outcomes, Outcome
4 Number of non-dialysis patients needing to commence dialysis.
Study or subgroup IV iron Oral iron Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
McMahon 2009 CKD 1/41 3/42 9.58% 0.34[0.04,3.15]
Van Wyck 2005 CKD 3/79 3/82 19.19% 1.04[0.22,4.99]
Stoves 2001 CKD 3/18 5/20 28.79% 0.67[0.19,2.4]
FIND-CKD 2014 CKD 5/153 10/308 42.44% 1.01[0.35,2.89]
   
Total (95% CI) 291 452 100% 0.81[0.41,1.61]
Total events: 12 (IV iron), 21 (Oral iron)  
Heterogeneity: Tau2=0; Chi2=0.93, df=3(P=0.82); I2=0%  
Test for overall effect: Z=0.6(P=0.55)  
Less with IV iron 1000.01 100.1 1 Less with oral iron
 
 
Parenteral versus oral iron therapy for adults and children with chronic kidney disease (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
82
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Analysis 1.5.   Comparison 1 Patient centred outcomes, Outcome 5 Number requiring transfusion.
Study or subgroup IV iron Oral iron Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Warady 2002 HD 0/17 0/18   Not estimable
Nagaraju 2013 CKD 1/22 0/18 1.97% 2.48[0.11,57.4]
Mudge 2009 TX 5/51 9/51 18.66% 0.56[0.2,1.54]
Agarwal 2015 CKD 12/67 12/69 36.96% 1.03[0.5,2.13]
FIND-CKD 2014 CKD 11/153 26/308 42.41% 0.85[0.43,1.68]
   
Total (95% CI) 310 464 100% 0.86[0.55,1.34]
Total events: 29 (IV iron), 47 (Oral iron)  
Heterogeneity: Tau2=0; Chi2=1.38, df=3(P=0.71); I2=0%  
Test for overall effect: Z=0.66(P=0.51)  
Less with IV iron 1000.01 100.1 1 Less with 0ral iron
 
 
Analysis 1.6.   Comparison 1 Patient centred outcomes, Outcome 6 Type of adverse event.
Study or subgroup IV iron Oral iron Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.6.1 Allergic reactions/hypotension  
Charytan 2005 CKD 0/39 0/44   Not estimable
Qunibi 2011 CKD 0/147 0/103   Not estimable
Warady 2002 HD 1/17 0/18 4.13% 3.17[0.14,72.8]
Kalra 2016 CKD 2/228 0/117 4.43% 2.58[0.12,53.23]
Provenzano 2009 HD 2/110 0/113 4.44% 5.14[0.25,105.76]
Van Wyck 2005 CKD 2/91 0/91 4.45% 5[0.24,102.72]
Lu 2010 CKD 3/220 0/74 4.66% 2.38[0.12,45.46]
Agarwal 2006 CKD 3/44 0/45 4.72% 7.16[0.38,134.62]
Spinowitz 2008 CKD 4/217 0/75 4.8% 3.14[0.17,57.6]
Stoves 2001 CKD 3/22 0/23 4.8% 7.3[0.4,133.75]
Pisani 2014 CKD 4/37 0/66 4.85% 15.87[0.88,286.81]
Ragab 2007 HD 4/12 0/12 5.11% 9[0.54,150.81]
Nagaraju 2013 CKD 4/22 1/18 9.2% 3.27[0.4,26.75]
Agarwal 2015 CKD 2/67 2/69 10.89% 1.03[0.15,7.1]
FIND-CKD 2014 CKD 8/154 5/312 33.53% 3.24[1.08,9.74]
Subtotal (95% CI) 1427 1180 100% 3.56[1.88,6.74]
Total events: 42 (IV iron), 8 (Oral iron)  
Heterogeneity: Tau2=0; Chi2=3.82, df=12(P=0.99); I2=0%  
Test for overall effect: Z=3.91(P<0.0001)  
   
1.6.2 Infection  
FIND-CKD 2014 CKD 6/154 12/312 16.01% 1.01[0.39,2.65]
Qunibi 2011 CKD 20/147 8/103 24.15% 1.75[0.8,3.82]
Mudge 2009 TX 10/51 12/51 26.51% 0.83[0.4,1.75]
Agarwal 2015 CKD 19/67 11/69 33.34% 1.78[0.92,3.45]
Subtotal (95% CI) 419 535 100% 1.32[0.9,1.95]
Total events: 55 (IV iron), 43 (Oral iron)  
Heterogeneity: Tau2=0; Chi2=3.05, df=3(P=0.38); I2=1.54%  
Test for overall effect: Z=1.43(P=0.15)  
   
1.6.3 All gastrointestinal adverse effects  
Less with IV iron 5000.002 100.1 1 Less with oral iron
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Study or subgroup IV iron Oral iron Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Fishbane 1995 HD 1/20 0/32 1.11% 4.71[0.2,110.4]
Stoves 2001 CKD 0/22 1/23 1.11% 0.35[0.01,8.11]
Li 2008 PD 0/26 8/20 1.39% 0.05[0,0.75]
Li 2008 HD 0/70 22/66 1.4% 0.02[0,0.34]
Tsuchida 2010 HD 1/12 3/11 2.29% 0.31[0.04,2.52]
Mudge 2009 TX 3/51 6/51 4.74% 0.5[0.13,1.89]
Agarwal 2006 CKD 7/44 11/45 8.15% 0.65[0.28,1.53]
Van Wyck 2005 CKD 8/91 16/91 8.68% 0.5[0.23,1.11]
Spinowitz 2008 CKD 10/217 15/75 9.11% 0.23[0.11,0.49]
Lu 2010 CKD 19/220 13/74 10.24% 0.49[0.26,0.95]
Charytan 2005 CKD 10/39 28/44 11.13% 0.4[0.23,0.72]
Agarwal 2015 CKD 14/67 28/69 11.53% 0.51[0.3,0.89]
FIND-CKD 2014 CKD 32/154 128/312 14.07% 0.51[0.36,0.71]
Nagaraju 2013 CKD 17/22 18/18 15.04% 0.78[0.61,0.99]
Subtotal (95% CI) 1055 931 100% 0.47[0.33,0.66]
Total events: 122 (IV iron), 297 (Oral iron)  
Heterogeneity: Tau2=0.19; Chi2=35.42, df=13(P=0); I2=63.29%  
Test for overall effect: Z=4.34(P<0.0001)  
   
1.6.4 Constipation  
Agarwal 2006 CKD 0/44 0/45   Not estimable
Stoves 2001 CKD 0/22 1/23 3.24% 0.35[0.01,8.11]
Pisani 2014 CKD 1/37 3/66 6.15% 0.59[0.06,5.51]
Ragab 2007 HD 1/12 3/12 6.73% 0.33[0.04,2.77]
Spinowitz 2008 CKD 1/217 6/75 6.82% 0.06[0.01,0.47]
Van Wyck 2005 CKD 1/91 8/91 7.07% 0.13[0.02,0.98]
FIND-CKD 2014 CKD 2/154 37/312 13.28% 0.11[0.03,0.45]
Lu 2010 CKD 7/220 3/74 14.58% 0.78[0.21,2.96]
Nagaraju 2013 CKD 4/22 5/18 17.77% 0.65[0.21,2.08]
Charytan 2005 CKD 5/39 16/44 24.36% 0.35[0.14,0.87]
Subtotal (95% CI) 858 760 100% 0.32[0.18,0.57]
Total events: 22 (IV iron), 82 (Oral iron)  
Heterogeneity: Tau2=0.15; Chi2=9.9, df=8(P=0.27); I2=19.23%  
Test for overall effect: Z=3.83(P=0)  
   
1.6.5 Diarrhoea  
Fishbane 1995 HD 1/20 0/32 1.64% 4.71[0.2,110.4]
Van Wyck 2005 CKD 0/91 3/91 1.87% 0.14[0.01,2.73]
Charytan 2005 CKD 0/39 3/44 1.89% 0.16[0.01,3.02]
Agarwal 2006 CKD 2/44 2/45 4.43% 1.02[0.15,6.94]
Nagaraju 2013 CKD 3/22 2/18 5.78% 1.23[0.23,6.57]
Pisani 2014 CKD 3/37 3/66 6.78% 1.78[0.38,8.39]
Spinowitz 2008 CKD 3/217 4/75 7.49% 0.26[0.06,1.13]
Lu 2010 CKD 5/220 3/74 8.21% 0.56[0.14,2.29]
Ragab 2007 HD 3/12 3/12 8.47% 1[0.25,4]
FIND-CKD 2014 CKD 15/154 45/312 53.45% 0.68[0.39,1.17]
Subtotal (95% CI) 856 769 100% 0.7[0.47,1.05]
Total events: 35 (IV iron), 68 (Oral iron)  
Heterogeneity: Tau2=0; Chi2=7.61, df=9(P=0.57); I2=0%  
Test for overall effect: Z=1.71(P=0.09)  
   
1.6.6 Nausea and vomiting  
Less with IV iron 5000.002 100.1 1 Less with oral iron
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Study or subgroup IV iron Oral iron Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Pisani 2014 CKD 2/37 2/66 6.83% 1.78[0.26,12.15]
Nagaraju 2013 CKD 2/22 2/18 7.23% 0.82[0.13,5.25]
Ragab 2007 HD 2/12 2/12 7.74% 1[0.17,5.98]
Lu 2010 CKD 4/220 2/74 8.67% 0.67[0.13,3.6]
Van Wyck 2005 CKD 2/91 5/91 9.26% 0.4[0.08,2.01]
Agarwal 2006 CKD 5/44 2/45 9.54% 2.56[0.52,12.49]
Charytan 2005 CKD 2/39 9/44 10.86% 0.25[0.06,1.09]
Spinowitz 2008 CKD 4/217 5/75 13.48% 0.28[0.08,1]
FIND-CKD 2014 CKD 9/154 15/312 26.38% 1.22[0.54,2.71]
Subtotal (95% CI) 836 737 100% 0.76[0.45,1.29]
Total events: 32 (IV iron), 44 (Oral iron)  
Heterogeneity: Tau2=0.11; Chi2=9.59, df=8(P=0.3); I2=16.58%  
Test for overall effect: Z=1.03(P=0.31)  
   
1.6.7 Taste disturbances  
Lu 2010 CKD 1/220 0/74 22.12% 1.02[0.04,24.72]
Spinowitz 2008 CKD 2/217 0/75 24.59% 1.74[0.08,35.9]
Charytan 2005 CKD 3/39 0/44 26.17% 7.88[0.42,147.84]
Van Wyck 2005 CKD 5/91 0/91 27.12% 11[0.62,196.07]
Subtotal (95% CI) 567 284 100% 3.78[0.84,16.97]
Total events: 11 (IV iron), 0 (Oral iron)  
Heterogeneity: Tau2=0; Chi2=1.73, df=3(P=0.63); I2=0%  
Test for overall effect: Z=1.74(P=0.08)  
   
1.6.8 Iron overload  
Warady 2002 HD 0/17 0/18   Not estimable
Pisani 2014 CKD 2/37 0/66 48.46% 8.82[0.43,178.88]
Hussain 1998 HD 2/10 0/10 51.54% 5[0.27,92.62]
Subtotal (95% CI) 64 94 100% 6.58[0.81,53.51]
Total events: 4 (IV iron), 0 (Oral iron)  
Heterogeneity: Tau2=0; Chi2=0.07, df=1(P=0.79); I2=0%  
Test for overall effect: Z=1.76(P=0.08)  
Less with IV iron 5000.002 100.1 1 Less with oral iron
 
 
Comparison 2.   Laboratory/pharmaceutical outcomes
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Number achieving target
haemoglobin or increase ≥ 1 g/
dL
13 2206 Risk Ratio (M-H, Random, 95% CI) 1.71 [1.43, 2.04]
2 Haemoglobin: final or change
(all patients)
31 3373 Mean Difference (IV, Random, 95% CI) 0.72 [0.39, 1.05]
3 Ferritin: final or change (all pa-
tients)
33 3389 Mean Difference (IV, Random, 95% CI) 224.84 [165.85, 283.83]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
4 Transferrin saturation: final or
change
27 3089 Mean Difference (IV, Random, 95% CI) 7.69 [5.10, 10.28]
5 Haematocrit 4 152 Mean Difference (IV, Random, 95% CI) 1.18 [-2.17, 4.52]
6 End of treatment or change in
ESA dose
11 522 Std. Mean Difference (IV, Random, 95% CI) -0.72 [-1.12, -0.31]
7 eGFR end or change 8 1052 Mean Difference (IV, Random, 95% CI) 0.83 [-0.79, 2.44]
 
 
Analysis 2.1.   Comparison 2 Laboratory/pharmaceutical outcomes,
Outcome 1 Number achieving target haemoglobin or increase ≥ 1 g/dL.
Study or subgroup IV iron Oral iron Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Macdougall 1999 HD,PD 19/41 2/35 1.46% 8.11[2.03,32.41]
Hussain 1998 HD 9/10 5/10 4.84% 1.8[0.94,3.46]
Charytan 2005 CKD 21/39 14/44 6.37% 1.69[1.01,2.85]
Spinowitz 2008 CKD 89/228 14/76 6.66% 2.12[1.29,3.49]
Lu 2010 CKD 117/225 15/77 7.09% 2.67[1.67,4.28]
Li 2008 PD 23/26 11/20 7.9% 1.61[1.06,2.45]
Li 2008 HD 45/70 19/66 7.94% 2.23[1.47,3.39]
Pisani 2014 CKD 18/33 29/66 8% 1.24[0.82,1.88]
Provenzano 2009 HD 56/114 29/116 8.84% 1.96[1.36,2.83]
Stoves 2001 CKD 13/18 16/20 8.95% 0.9[0.63,1.29]
Van Wyck 2005 CKD 47/79 35/82 9.91% 1.39[1.02,1.9]
Qunibi 2011 CKD 89/147 36/103 10.22% 1.73[1.29,2.32]
FIND-CKD 2014 CKD 87/153 99/308 11.81% 1.77[1.43,2.19]
   
Total (95% CI) 1183 1023 100% 1.71[1.43,2.04]
Total events: 633 (IV iron), 324 (Oral iron)  
Heterogeneity: Tau2=0.06; Chi2=29.67, df=12(P=0); I2=59.55%  
Test for overall effect: Z=5.96(P<0.0001)  
More with oral iron 500.02 100.1 1 More with IV iron
 
 
Analysis 2.2.   Comparison 2 Laboratory/pharmaceutical
outcomes, Outcome 2 Haemoglobin: final or change (all patients).
Study or subgroup IV iron Oral iron Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Winney 1977 HD 14 7.5 (9.4) 14 8.4 (8.6) 0.23% -0.9[-7.56,5.76]
Nagaraju 2013 CKD 22 11.3 (1.3) 18 11.8 (1.8) 2.8% -0.46[-1.45,0.53]
Tsuchida 2010 HD 12 10.7 (1.1) 11 11.1 (0.6) 3.19% -0.36[-1.07,0.35]
Lye 2000 HD 30 9.1 (1.4) 30 9.4 (1.5) 3.16% -0.3[-1.03,0.43]
Warady 2002 HD 17 11.2 (1.3) 18 11.4 (0.8) 3.15% -0.24[-0.98,0.5]
Higher with oral iron 105-10 -5 0 Higher with IV iron
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Study or subgroup IV iron Oral iron Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
McMahon 2009 CKD 39 11.8 (1) 38 11.9 (1.2) 3.45% -0.1[-0.59,0.39]
Michael 2007 HD 33 -0.2 (1.1) 27 -0.2 (1.1) 3.38% 0[-0.55,0.55]
Agarwal 2015 CKD 153 0.7 (1.2) 58 0.6 (1.2) 3.58% 0.08[-0.28,0.44]
Agarwal 2006 CKD 36 0.4 (0.8) 39 0.2 (0.9) 3.56% 0.2[-0.18,0.58]
Pisani 2014 CKD 33 11.7 (1) 66 11.4 (0.8) 3.55% 0.3[-0.09,0.69]
Qunibi 2011 CKD 147 1 (0.8) 103 0.7 (0.9) 3.68% 0.3[0.08,0.52]
Charytan 2005 CKD 39 11.1 (1.1) 44 10.7 (1) 3.49% 0.4[-0.05,0.85]
Kalra 2016 CKD 210 0.9 (1.1) 112 0.5 (1.1) 3.66% 0.45[0.21,0.69]
Provenzano 2009 HD 114 11.7 (1.2) 116 11.2 (1.2) 3.61% 0.5[0.19,0.81]
FIND-CKD 2014 CKD 153 12 (1.2) 308 11.5 (1.8) 3.64% 0.5[0.22,0.78]
Macdougall 1999 HD,PD 41 10.8 (1.4) 35 10.3 (1.1) 3.37% 0.5[-0.06,1.06]
Van Wyck 2005 CKD 72 10.9 (1) 71 10.4 (1.1) 3.58% 0.5[0.15,0.85]
Lu 2010 CKD 226 11.2 (1.3) 77 10.6 (1.1) 3.62% 0.6[0.29,0.91]
Ragab 2007 HD 12 9.5 (1.1) 12 8.8 (1.1) 3% 0.7[-0.15,1.55]
Leehey 2005 CKD 24 1.5 (0.9) 24 0.8 (0.9) 3.43% 0.7[0.19,1.21]
Spinowitz 2008 CKD 228 10.9 (1.3) 76 10.2 (1) 3.64% 0.73[0.45,1.01]
Souza 1997 HD 8 1 (0.9) 11 0.2 (0.8) 3.12% 0.8[0.04,1.56]
Broumand 1998 HD 9 9.8 (1.1) 8 9 (1) 2.79% 0.8[-0.19,1.79]
Hussain 1998 HD 10 11.6 (0.6) 10 10.5 (1.1) 3.05% 1.1[0.29,1.91]
Macdougall 1996 HD,PD,CKD 9 11.7 (1.3) 11 10.6 (1.4) 2.53% 1.1[-0.09,2.29]
Aggarwal 2003 CKD 20 10.1 (0.9) 20 8.9 (1.2) 3.27% 1.11[0.46,1.76]
Wang 2003 HD 21 9.3 (1.8) 22 7.9 (1.4) 2.82% 1.4[0.43,2.37]
Li 2008 PD 26 12.2 (1.1) 20 10.6 (1) 3.32% 1.58[0.97,2.19]
Erten 1998 HD 26 11.8 (1.3) 22 9.9 (0.9) 3.3% 1.9[1.27,2.53]
Li 2008 HD 70 12 (1.3) 66 10 (1.1) 3.55% 1.99[1.6,2.38]
Fudin 1998 HD 20 11 (0.9) 12 6.1 (0.4) 3.49% 4.92[4.47,5.37]
   
Total *** 1874   1499   100% 0.72[0.39,1.05]
Heterogeneity: Tau2=0.76; Chi2=488.04, df=30(P<0.0001); I2=93.85%  
Test for overall effect: Z=4.27(P<0.0001)  
Higher with oral iron 105-10 -5 0 Higher with IV iron
 
 
Analysis 2.3.   Comparison 2 Laboratory/pharmaceutical outcomes, Outcome 3 Ferritin: final or change (all patients).
Study or subgroup IV iron Oral iron Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Agarwal 2015 CKD 61 0.8 (0.6) 57 -0.2 (0.6) 3.27% 1.04[0.82,1.26]
Svara 1996 HD 29 166 (123) 28 109 (114) 3.16% 57[-4.54,118.54]
Tsuchida 2010 HD 12 183.5 (47.5) 11 115.4 (28.2) 3.24% 68.14[36.51,99.77]
Li 2008 HD 70 495.7
(315.2)
66 400.3
(264.1)
3% 95.4[-2.13,192.93]
Michael 2007 HD 33 80 (147) 27 -31 (130) 3.13% 111[40.86,181.14]
Leehey 2005 CKD 24 132 (162) 24 19 (162) 3.03% 113[21.34,204.66]
Nagaraju 2013 CKD 22 213 (227.2) 18 79.4 (60.1) 3% 133.6[34.71,232.49]
Warady 2002 HD 17 259.1
(163.1)
18 122 (118.8) 3.02% 137.1[42.11,232.09]
Pisani 2014 CKD 33 238.5 (49.7) 66 85.5 (31.3) 3.26% 153[134.44,171.56]
Ragab 2007 HD 12 238.5 (49.7) 12 85.5 (31.3) 3.24% 153[119.77,186.23]
Kalra 2016 CKD 209 222 (220) 112 66 (220) 3.2% 156[105.51,206.49]
Aggarwal 2003 CKD 20 267 (59) 20 104 (25) 3.25% 163[134.92,191.08]
Higher with oral iron 1000500-1000 -500 0 Higher with IV iron
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Study or subgroup IV iron Oral iron Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Fudin 1998 HD 20 393.5
(249.3)
10 229.7
(113.6)
2.82% 163.8[33.82,293.78]
Li 2008 PD 26 466.7 (85.3) 20 299.4 (83.2) 3.2% 167.3[118.26,216.34]
Agarwal 2006 CKD 36 232 (160.8) 39 55.9 (236.2) 3.04% 176.1[85.25,266.95]
Van Wyck 2005 CKD 72 323 (178.5) 72 132 (90.3) 3.21% 191[144.79,237.21]
Lye 2000 HD 30 432 (288) 30 231 (204) 2.85% 201[74.71,327.29]
Wang 2003 HD 21 496 (306) 22 279 (206) 2.66% 217[60.35,373.65]
Broumand 1998 HD 9 779 (205) 8 546.5 (139) 2.61% 232.5[67.53,397.47]
Souza 1997 HD 8 245 (133) 11 2.3 (77.2) 2.98% 242.7[139.86,345.54]
McMahon 2009 CKD 39 412 (206) 38 153 (88) 3.13% 259[188.55,329.45]
Macdougall 1999 HD,PD 41 432 (202) 35 140 (91) 3.13% 292[223.21,360.79]
Lu 2010 CKD 225 443.8
(282.4)
77 150.8
(140.5)
3.2% 293[244.56,341.44]
Charytan 2005 CKD 39 288 (150) 44 -5.1 (151) 3.15% 293.1[228.24,357.96]
Hussain 1998 HD 10 671 (388) 10 367 (238) 1.87% 304[21.88,586.12]
Provenzano 2009 HD 114 601.8 (283) 116 289.3
(165.8)
3.16% 312.49[252.43,372.55]
FIND-CKD 2014 CKD 153 503 (136.1) 308 184 (140.4) 3.25% 319[292.34,345.66]
Macdougall 1996 HD,PD,CKD 9 490 (276) 11 165 (95) 2.45% 325[136.15,513.85]
Erten 1998 HD 26 573 (246.7) 22 247.4
(187.7)
2.86% 325.6[202.54,448.66]
Qunibi 2011 CKD 147 358.8
(178.4)
103 25.8 (49.4) 3.24% 333[302.62,363.38]
Spinowitz 2008 CKD 228 555.7 (320) 76 160.8 (161) 3.18% 394.9[339.8,450]
Kotaki 1997 HD 15 750 (147) 16 255 (64) 3.08% 495[414.27,575.73]
Fishbane 1995 HD 20 753.9 (135) 32 157.3 (87) 3.14% 596.6[530.2,663]
   
Total *** 1830   1559   100% 224.84[165.85,283.83]
Heterogeneity: Tau2=27687.38; Chi2=2866.96, df=32(P<0.0001); I2=98.88%  
Test for overall effect: Z=7.47(P<0.0001)  
Higher with oral iron 1000500-1000 -500 0 Higher with IV iron
 
 
Analysis 2.4.   Comparison 2 Laboratory/pharmaceutical
outcomes, Outcome 4 Transferrin saturation: final or change.
Study or subgroup IV iron Oral iron Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Macdougall 1996 HD,PD,CKD 12 23 (4) 13 31 (4) 4.05% -8[-11.14,-4.86]
Nagaraju 2013 CKD 22 21.8 (10) 18 22.3 (12) 3.29% -0.53[-7.47,6.41]
Agarwal 2015 CKD 60 0.1 (0.1) 57 0 (0.1) 4.31% 0.02[-0.01,0.05]
Michael 2007 HD 33 -0.6 (9.1) 27 -1.1 (8.4) 3.83% 0.5[-3.94,4.94]
Van Wyck 2005 CKD 72 25 (8.9) 72 22.2 (9.4) 4.07% 2.8[-0.2,5.8]
Kalra 2016 CKD 209 6.7 (9.3) 112 3.5 (9.3) 4.19% 3.19[1.05,5.33]
Pisani 2014 CKD 33 21.5 (5.2) 66 18.3 (4.3) 4.2% 3.2[1.14,5.26]
Ragab 2007 HD 12 21.5 (5.2) 12 18.3 (4.3) 3.94% 3.2[-0.62,7.02]
Charytan 2005 CKD 39 4.5 (8.3) 44 0.5 (8.5) 3.98% 4[0.38,7.62]
Tsuchida 2010 HD 12 33.8 (8.6) 11 29.7 (7.2) 3.39% 4.02[-2.48,10.52]
Svara 1996 HD 29 26.8 (11.1) 28 22.2 (9.6) 3.63% 4.6[-0.78,9.98]
Qunibi 2011 CKD 144 12.1 (8.8) 101 7 (10.3) 4.15% 5.1[2.63,7.57]
Kotaki 1997 HD 15 35.7 (5.1) 16 30.6 (1.9) 4.11% 5.1[2.36,7.84]
Agarwal 2006 CKD 36 8.3 (7.5) 39 2.9 (8.8) 3.96% 5.4[1.71,9.09]
Higher with oral iron 10050-100 -50 0 Higher with IV iron
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Study or subgroup IV iron Oral iron Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Provenzano 2009 HD 114 22.3 (13.3) 116 16.5 (9.7) 4.07% 5.85[2.83,8.87]
McMahon 2009 CKD 39 30 (9) 38 24 (11) 3.81% 6[1.5,10.5]
FIND-CKD 2014 CKD 153 35.3 (17.3) 308 28.6 (17.6) 4.02% 6.7[3.33,10.07]
Lu 2010 CKD 225 19.1 (10.4) 77 10.4 (5.2) 4.22% 8.7[6.91,10.49]
Spinowitz 2008 CKD 228 21 (10.1) 76 11.8 (6.7) 4.2% 9.2[7.2,11.2]
Li 2008 HD 70 39.6 (16.7) 66 28.6 (18.4) 3.52% 11[5.08,16.92]
Li 2008 PD 26 37.8 (16.1) 20 25.7 (17.5) 2.65% 12.1[2.25,21.95]
Warady 2002 HD 17 44.1 (14.1) 18 31.3 (15) 2.7% 12.73[3.11,22.35]
Fudin 1998 HD 20 33.2 (3.5) 10 19.9 (5.4) 3.96% 13.31[9.63,16.99]
Hussain 1998 HD 10 44.6 (19.8) 10 29 (11) 1.9% 15.61[1.57,29.65]
Ahsan 1997 TX 6 38 (8.2) 6 22 (3.4) 3.25% 16[8.9,23.1]
Aggarwal 2003 CKD 20 64.9 (11) 20 45.7 (14.1) 3.09% 19.23[11.39,27.07]
Fishbane 1995 HD 20 74.8 (13) 32 19.8 (5.7) 3.49% 55[48.98,61.02]
   
Total *** 1676   1413   100% 7.69[5.1,10.28]
Heterogeneity: Tau2=40.48; Chi2=745.19, df=26(P<0.0001); I2=96.51%  
Test for overall effect: Z=5.82(P<0.0001)  
Higher with oral iron 10050-100 -50 0 Higher with IV iron
 
 
Analysis 2.5.   Comparison 2 Laboratory/pharmaceutical outcomes, Outcome 5 Haematocrit.
Study or subgroup IV iron Oral iron Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Ahsan 1997 TX 6 37.7 (1.7) 6 33.4 (1.9) 24.04% 4.3[2.26,6.34]
Svara 1996 HD 29 27.8 (3.4) 28 27.2 (2.9) 24.83% 0.6[-1.04,2.24]
Fishbane 1995 HD 20 34.4 (3.1) 32 31.8 (2.3) 24.93% 2.6[1.02,4.18]
Kotaki 1997 HD 15 33.2 (0.9) 16 35.7 (0.7) 26.2% -2.5[-3.07,-1.93]
   
Total *** 70   82   100% 1.18[-2.17,4.52]
Heterogeneity: Tau2=11.03; Chi2=74.54, df=3(P<0.0001); I2=95.98%  
Test for overall effect: Z=0.69(P=0.49)  
Higher with oral iron 105-10 -5 0 Higher with IV iron
 
 
Analysis 2.6.   Comparison 2 Laboratory/pharmaceutical
outcomes, Outcome 6 End of treatment or change in ESA dose.
Study or subgroup IV iron Oral iron Std. Mean Difference Weight Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Nagaraju 2013 CKD 5 50 (28.3) 7 60 (28.3) 6.15% -0.33[-1.48,0.83]
Hussain 1998 HD 10 3400 (1356) 10 4600 (1356) 7.54% -0.85[-1.77,0.08]
Tsuchida 2010 HD 12 4375
(2473.7)
11 5590.9
(1513.6)
8.11% -0.57[-1.4,0.27]
Macdougall 1996 HD,PD,CKD 12 1202 (229) 13 1294 (314) 8.43% -0.32[-1.11,0.47]
Kotaki 1997 HD 15 3760 (1762) 16 4025 (2168) 9.03% -0.13[-0.84,0.58]
Warady 2002 HD 17 -76.3
(104.7)
18 -30.9 (77.7) 9.25% -0.48[-1.16,0.19]
Fishbane 1995 HD 20 4050 (2455) 32 7563 (2138) 9.51% -1.53[-2.17,-0.89]
Less with IV iron 42-4 -2 0 Less with oral iron
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Study or subgroup IV iron Oral iron Std. Mean Difference Weight Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Li 2008 PD 26 6100 (1043) 26 7635 (1024) 9.65% -1.46[-2.08,-0.85]
Michael 2007 HD 33 -28.4
(103.6)
27 -12.6 (79.7) 10.39% -0.17[-0.68,0.34]
Macdougall 1999 HD,PD 41 74 (36) 35 84 (53) 10.77% -0.22[-0.67,0.23]
Li 2008 HD 70 4500 (1049) 66 6140 (1014) 11.18% -1.58[-1.97,-1.19]
   
Total *** 261   261   100% -0.72[-1.12,-0.31]
Heterogeneity: Tau2=0.34; Chi2=43.98, df=10(P<0.0001); I2=77.26%  
Test for overall effect: Z=3.48(P=0)  
Less with IV iron 42-4 -2 0 Less with oral iron
 
 
Analysis 2.7.   Comparison 2 Laboratory/pharmaceutical outcomes, Outcome 7 eGFR end or change.
Study or subgroup IV iron Oral iron Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Ragab 2007 HD 12 22.9 (7.8) 12 25.1 (12.7) 3.35% -2.2[-10.63,6.23]
Aggarwal 2003 CKD 20 10.9 (5.3) 20 17.1 (18.3) 3.42% -6.22[-14.55,2.11]
Mudge 2009 TX 51 46.9 (17.5) 51 51.7 (17) 5.04% -4.8[-11.5,1.9]
Pisani 2014 CKD 33 27.9 (7.8) 66 25.1 (12.7) 11.16% 2.8[-1.26,6.86]
McMahon 2009 CKD 43 23 (8) 42 22 (10) 11.98% 1[-2.86,4.86]
Agarwal 2015 CKD 38 -4 (5.9) 42 -3.6 (5.9) 19.16% -0.4[-2.99,2.19]
Van Wyck 2005 CKD 79 -1.4 (5.6) 82 -4.4 (8.8) 21.62% 2.95[0.68,5.22]
FIND-CKD 2014 CKD 153 0.4 (9.9) 308 -1.1 (10.5) 24.25% 1.5[-0.46,3.46]
   
Total *** 429   623   100% 0.83[-0.79,2.44]
Heterogeneity: Tau2=1.8; Chi2=11.2, df=7(P=0.13); I2=37.52%  
Test for overall effect: Z=1.01(P=0.31)  
Higher with oral iron 2010-20 -10 0 Higher with IV iron
 
 
A D D I T I O N A L   T A B L E S
 
Outcome Population Studies Participants MD RR 95% CI
All studies 31 3373 0.72 - 0.39 to 1.05
Dialysis 17 917 1.01 - 0.26 to 1.77
Hb (g/dL)
CKD 14 2456 0.41 - 0.28 to 0.55
All studies 33 3389 224.8 - 165.8 to 283.8
Dialysis 19 1027 233.7 - 163.4 to 303.9
Ferritin (µg/
L)
CKD 14 2362 213.1 - 123.7 to 302.6
TSAT (%) All studies 27 3089 7.69 - 5.10 to 10.28
Table 1.   Laboratory outcomes in dialysis and chronic kidney disease participants 
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Dialysis 14 781 10.55 - 3.89 to 17.22
CKD 13 2308 5.32 - 2.67 to 7.97
All studies 13 2206 - 1.71 1.43 to 2.04
Dialysis 5 508 - 2.01 1.52 to 2.66
Achieving
target Hb
CKD 8 1698 - 1.59 1.27 to 1.97
Table 1.   Laboratory outcomes in dialysis and chronic kidney disease participants  (Continued)
CKD - chronic kidney disease; Hb - haemoglobin; TSAT - transferrin saturation
 
 
  Total
studies
(N)
Studies SMD (95% CI) P
Dose IV iron/study month 
≥ 400 mg/month 12 8 0.17 (-0.18 to 0.52) 0.12
> 400 to 700 mg/month 7 6 0.76 (0.29 to 1.24) -
> 700 mg/month 9 8 0.74 (0.41 to 1.06) -
Dose IV iron (mg total dose)
≤ 1000 mg 11 8 0.46 (0.25 to 0.66) 0.21
1000 to 1999 mg 12 10 0.48 (0.11 to 0.84) - 
> 2000 mg 5 4 0.89 (0.04 to 1.73) - 
Oral dose iron/study month
< 4000 mg/month 12 10 0.87 (0.37 to 1.38) 0.15
≥ 4000 and < 6000 mg/month 12 11 0.46 (0.28 to 0.64) -
≥ 6000 mg/month 7 5 0.37 (0.16 to 0.59) -
Dose oral iron (mg total dose)
≥ 12,000 mg 13 12 0.60 (0.38 to 0.82) 0.86
1200 to 30,000 mg 10 8 0.66 (0.29 to 1.03) -
> 30,000 mg 18 11 0.45 (-0.05 to 0.94) -
Any ESA use 
No EPO 8 6 0.57 (0.05 to 1.08) 0.34
EPO 27 22 0.55 (0.32 to 0.78) -
Table 2.   Subgroup analysis and meta-regression to examine heterogeneity in haemoglobin meta-analyses 
Parenteral versus oral iron therapy for adults and children with chronic kidney disease (Review)
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ESA timing of use 
Start of study 8 7 0.40 (0.08 to 0.72) 0.90
Before study 19 15 0.57 (0.28 to 0.85) -
CKD stage 
1 to 5 15 14 0.37 (0.26 to 0.50) 0.10
Dialysis (5D) 22 16 0.80 (0.37 to 1.24) -
Study duration 
≥ 2 months 14 12 0.55 (0.35 to 0.75) 0.81
> 2 to ≤ 4 months 9 7 0.74 (0.28 to 1.19) -
> 4 months 14 11 0.46 (0.002 to 0.91) -
Intervention aim 
Increase Hb 24 20 1.00 (0.51 to 1.50) 0.18
Maintain Hb 4 2 -0.09 (-0.53 to 0.36)  -
Pharmaceutical company sponsorship
Unclear 23 18 0.81 (0.40 to 1.23) 0.08
Sponsored 15 13 0.38 (0.28 to 0.48) -
Imputed SD
Not imputed  - 5 0.42 (0.02 to 0.81) 0.52
Imputed  - 26 0.55 (0.35 to 0.76) -
Table 2.   Subgroup analysis and meta-regression to examine heterogeneity in haemoglobin meta-analyses  (Continued)
CKD: chronic kidney disease; EPO - erythropoietin; ESA: erythropoiesis-stimulating agent; Hb: haemoglobin; SD: standard deviation
 
 
  Total
studies
(N)
Studies SMD (95% CI) P
Dose IV iron/study month
≥ 400 mg/month 12 8 1.59 (0.73 to 2.44) 0.02
> 400 to 700 mg/month 7 6 1.62 (1.41 to 1.83) -
>700 mg/month 9 9 1.32 (0.85 to 1.78) -
Dose IV iron (mg total dose) 
Table 3.   Subgroup analysis and meta-regression to examine heterogeneity in ferritin meta-analyses    
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≥ 1000 mg 11 9 1.67 (1.03 to 2.30) 0.08
1000 to 1999 mg 12 10 1.12 (0.83 to 1.42) -
> 2000 mg 5 4 2.27 (0.55 to 3.99) -
Oral dose iron/study month
<4000 mg/month 12 10 1.44 (0.77 to 2.11) 0.04
≥ 4000 to < 6000 mg/month 12 11 1.43 (1.16 to 1.69) -
≥ 6000 mg/month 7 7 2.16 (1.18 to 3.14) -
Dose oral iron (mg total dose) 
≥ 12,000 mg 13 13 1.44 (1.05 to 1.83) 0.40
12000 to 30,000 mg 10 8 1.69 (1.05 to 2.34) -
> 30,000 mg 18 12 1.79 (1.15 to 2.43) -
Any ESA use 
No EPO 8 5 1.27 (0.46 to 2.08) 0.91
EPO 27 25 1.62 (1.28 to 1.96) -
ESA timing of use 
Start of study 8 6 1.75 (0.88 to 2.62) 0.70
Before study 19 18 1.64 (1.22 to 2.06) -
CKD stage
1 to 5 15 14 1.70 (1.29 to 2.11) 0.66
Dialysis (5D) 22 18 1.50 (1.07 to 1.92) -
Study duration
≥ 2 months 10 13 1.18 (0.86 to 1.49) 0.54
> 2 to ≤ 4 months 7 8 2.64 (1.45 to 3.82) -
> 4 months 9 11 1.54 (1.05 to 2.04) -
Intervention aim
Increase Hb 24 20 336 (84 to 588) 0.12
Maintain Hb 4 4 282 (177 to 261) - 
Pharmaceutical company sponsorship 
Table 3.   Subgroup analysis and meta-regression to examine heterogeneity in ferritin meta-analyses     (Continued)
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Unclear 23 20 1.84 (1.31 to 2.37) 0.63
Sponsored 15 13 1.36 (1.02 to 1.71) -
Imputed SD
Not imputed  - 5 1.18 (0.51 to 1.86) 0.62
Imputed -  26 1.63 (1.31 to 1.94) -
Table 3.   Subgroup analysis and meta-regression to examine heterogeneity in ferritin meta-analyses     (Continued)
CKD: chronic kidney disease; EPO - erythropoietin; ESA: erythropoiesis-stimulating agent; Hb: haemoglobin; SD: standard deviation
 
 
  Total
studies
(N)
Studies SMD (95% CI) P
Dose IV iron/study month
≥ 400 mg/month 12 7 0.69 (0.39 to 1.00) 0.20
> 400 to 700 mg/month 7 5 0.46 (0.14 to 0.78) -
> 700 mg/month 9 7 2.00 (0.55 to 3.45) -
Dose IV iron (mg total dose)
≥ 1000 mg 11 8 0.62 (0.34 to 0.90) 0.06
1000 to 1999 mg 12 9 0.41 (0.07 to 0.74) -
> 2000 mg 5 2 3.5 (-1.46 to 8.39) -
Oral dose iron/study month
< 4000 mg/month 12 9 0.56 (0.25 to 0.86) 0.21
≥ 4000 to < 6000 mg/month 12 9 0.54 (0.20 to 0.87) -
≥ 6000 mg/month 7 6 1.64 (0.69 to 2.59) -
Dose oral iron (mg total dose)
≥ 12,000 mg 13 11 0.56 (0.41 to 0.72) 0.15
1200 to 30,000 mg 10 8 0.56 (0.00 to 1.13) -
> 30,000 mg 18 8 1.59 (0.55 to 2.63) -
Any ESA use
No EPO 8 6 0.83 (0.36 to 1.31) 0.83
EPO 27 19 0.73 (0.42 to 1.03) -
Table 4.   Subgroup analysis and meta-regression to examine heterogeneity in transferrin saturation meta-analyses 
Parenteral versus oral iron therapy for adults and children with chronic kidney disease (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
94
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
ESA timing of use 
Start of study 8 5 0.29 (-0.42 to 1.00) 0.57
Before study 19 14 0.85 (0.51 to 1.20) -
CKD stage
1 to 5 15 13 0.55 (0.35, 0.74) 0.08
Dialysis (5D) 22 13 1.27 (0.75 to 1.80) -
Study duration
≥ 2 months 14 11 0.56 (0.41, 0.72) 0.93
> 2 to ≤ 4 months 9 9 1.34 (0.32 to 2.35) -
> 4 months 14 7 0.67 (0.16 to 1.18) -
Intervention aim
Increase Hb 24 14 7.59 (4.07 to 17.11) 0.18
Maintain Hb 4 4 18.28 (-3.73 to 40.30) - 
Pharmaceutical company sponsorship
Unclear 23 15 1.07 (0.52 to 1.62) 0.26
Sponsored 15 12 0.52 (0.34 to 0.71) -
Imputed SD
Not imputed - 3 0.26 (-0.24 to 0.77) 0.45
Imputed - 21 0.72 (0.47 to 0.97) -
Table 4.   Subgroup analysis and meta-regression to examine heterogeneity in transferrin saturation meta-
analyses  (Continued)
CKD: chronic kidney disease; EPO - erythropoietin; ESA: erythropoiesis-stimulating agent; Hb: haemoglobin; SD: standard deviation
 
 
A P P E N D I C E S
Appendix 1. Electronic search strategies
 
Database Search terms
CENTRAL 1. MeSH descriptor Ferric Compounds explode all trees
2. MeSH descriptor Ferrous Compounds explode all trees
3. MeSH descriptor Hematinics, this term only
4. MeSH descriptor Iron-Dextran Complex, this term only
5. MeSH descriptor Iron, this term only
6. MeSH descriptor Ferrosoferric Oxide, this term only
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7. (iron and (gluconate* or fumarate* or dextran* or sucrose* or saccharate*)) in Clinical Trials
8. (iron and (supplement* or therap* or replacement)) in Clinical Trials
9. (ferric or ferrous) and gluconate* in Clinical Trials
10.(ferumoxytol or magnetite or "ferriferous oxide") in Clinical Trials
11.(1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10)
12.MeSH descriptor Renal Replacement Therapy explode all trees
13.MeSH descriptor Renal Insufficiency, this term only
14.MeSH descriptor Kidney Failure, this term only
15.MeSH descriptor Renal Insufficiency, Chronic explode all trees
16.MeSH descriptor Kidney Diseases, this term only
17.MeSH descriptor Uremia, this term only
18.(hemodialysis or haemodialysis) in Clinical Trials
19.(hemofiltration or haemofiltration) in Clinical Trials
20.(hemodiafiltration or haemodiafiltration) in Clinical Trials
21.(dialysis) in Clinical Trials
22.(PD or CAPD or CCPD or APD) in Clinical Trials
23.(end-stage renal or end-stage kidney or endstage renal or endstage kidney) in Clinical Trials
24.(ESRF or ESKF or ESRD or ESKD) in Clinical Trials
25.(chronic kidney or chronic renal) in Clinical Trials
26.(CKF or CKD or CRF or CRD) in Clinical Trials
27.(ur?emi*.) in Clinical Trials
28.(ur?emi*) in Clinical Trials
29.(12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 18 OR 19 OR 20 OR 21 OR 22 OR 23 OR 24 OR 25 OR 26
OR 27 OR 28)
30.(11 AND 29)
MEDLINE 1. exp Ferric Compounds/ or exp Ferrous Compounds/
2. Hematinics/
3. Iron-Dextran Complex/
4. Iron/
5. Ferrosoferric Oxide/
6. (iron and (gluconate$ or fumarate$ or dextran$ or sucrose$ or saccharate$)).tw.
7. (iron and (supplement$ or therap$ or replacement)).tw.
8. ((ferric or ferrous) and gluconate$).tw.
9. (ferumoxytol or magnetite or "ferriferous oxide").tw.
10.or/1-9
11.exp administration, intravenous/ or exp administration, oral/
12.(iv or intravenous or oral).tw.
13.or/11-12
14.Kidney Diseases/
15.exp Renal Replacement Therapy/
16.Renal Insufficiency/
17.exp Renal Insufficiency, Chronic/
18.dialysis.tw.
19.(hemodialysis or haemodialysis).tw.
20.(hemofiltration or haemofiltration).tw.
21.(hemodiafiltration or haemodiafiltration).tw.
22.(end-stage renal or end-stage kidney or endstage renal or endstage kidney).tw.
23.(ESRF or ESKF or ESRD or ESKD).tw.
24.(chronic kidney or chronic renal).tw.
25.(CKF or CKD or CRF or CRD).tw.
26.(CAPD or CCPD or APD).tw.
  (Continued)
Parenteral versus oral iron therapy for adults and children with chronic kidney disease (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
96
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
27.(predialysis or pre-dialysis).tw.
28.or/14-27
29.10 and 13 and 28
EMBASE 1. Iron therapy/
2. antianemic agent/ or ferric citrate/ or ferric gluconate/ or ferric hydroxide sucrose/ or ferric mal-
tol/ or ferric pyrophosphate/ or ferrous ascorbate/ or ferrous aspartate/ or ferrous chloride/ or
ferrous fumarate/ or ferrous gluconate/ or ferrous succinate/ or ferrous sulfate/ or ferrous sulfate
plus folic acid/ or ferumoxytol/ or iron dextran/ or iron polymaltose/ or "iron poly(sorbitol glucon-
ic acid) complex"/ or iron protein succinylate/ or iron saccharate/ or iron salt/ or iron sorbitex/
3. Ferumoxytol/
4. (iron and (gluconate$ or fumarate$ or dextran$ or sucrose$ or saccharate$)).tw.
5. (iron and (supplement$ or therap$ or replacement)).tw.
6. ((ferric or ferrous) and gluconate$).tw.
7. (ferumoxytol or magnetite or "ferriferous oxide").tw.
8. or/1-7
9. exp renal replacement therapy/
10.kidney disease/
11.chronic kidney disease/
12.kidney failure/
13.kidney transplantation/
14.chronic kidney failure/
15.(hemodialysis or haemodialysis).tw.
16.(hemofiltration or haemofiltration).tw.
17.(hemodiafiltration or haemodiafiltration).tw.
18.dialysis.tw.
19.(CAPD or CCPD or APD).tw.
20.(chronic kidney or chronic renal).tw.
21.(CKF or CKD or CRF or CRD).tw.
22.(end-stage renal or end-stage kidney or endstage renal or endstage kidney).tw.
23.(ESRF or ESKF or ESRD or ESKD).tw.
24.(predialysis or pre-dialysis).tw.
25.or/9-24
26.exp Injections, Intravenous/
27.exp Administration, Oral/
28.or/26-27
29.and/8,25,28
  (Continued)
 
Appendix 2. Risk of bias assessment tool
 
Potential source of bias Assessment criteria
Low risk of bias: Random number table; computer random number generator; coin tossing; shuf-
fling cards or envelopes; throwing dice; drawing of lots; minimization (minimization may be imple-
mented without a random element, and this is considered to be equivalent to being random).
Random sequence genera-
tion
Selection bias (biased alloca-
tion to interventions) due to
inadequate generation of a
randomised sequence
High risk of bias: Sequence generated by odd or even date of birth; date (or day) of admission; se-
quence generated by hospital or clinic record number; allocation by judgement of the clinician; by
preference of the participant; based on the results of a laboratory test or a series of tests; by avail-
ability of the intervention.
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Unclear: Insufficient information about the sequence generation process to permit judgement.
Low risk of bias: Randomisation method described that would not allow investigator/participant to
know or influence intervention group before eligible participant entered in the study (e.g. central
allocation, including telephone, web-based, and pharmacy-controlled, randomisation; sequential-
ly numbered drug containers of identical appearance; sequentially numbered, opaque, sealed en-
velopes).
High risk of bias: Using an open random allocation schedule (e.g. a list of random numbers); as-
signment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or
non-opaque or not sequentially numbered); alternation or rotation; date of birth; case record num-
ber; any other explicitly unconcealed procedure.
Allocation concealment
Selection bias (biased alloca-
tion to interventions) due to
inadequate concealment of al-
locations prior to assignment
Unclear: Randomisation stated but no information on method used is available.
Low risk of bias: No blinding or incomplete blinding, but the review authors judge that the outcome
is not likely to be influenced by lack of blinding; blinding of participants and key study personnel
ensured, and unlikely that the blinding could have been broken.
High risk of bias: No blinding or incomplete blinding, and the outcome is likely to be influenced by
lack of blinding; blinding of key study participants and personnel attempted, but likely that the
blinding could have been broken, and the outcome is likely to be influenced by lack of blinding.
Blinding of participants and
personnel
Performance bias due to
knowledge of the allocated
interventions by participants
and personnel during the
study
Unclear: Insufficient information to permit judgement
Low risk of bias: No blinding of outcome assessment, but the review authors judge that the out-
come measurement is not likely to be influenced by lack of blinding; blinding of outcome assess-
ment ensured, and unlikely that the blinding could have been broken.
High risk of bias: No blinding of outcome assessment, and the outcome measurement is likely to be
influenced by lack of blinding; blinding of outcome assessment, but likely that the blinding could
have been broken, and the outcome measurement is likely to be influenced by lack of blinding.
Blinding of outcome assess-
ment
Detection bias due to knowl-
edge of the allocated interven-
tions by outcome assessors.
Unclear: Insufficient information to permit judgement
Low risk of bias: No missing outcome data; reasons for missing outcome data unlikely to be relat-
ed to true outcome (for survival data, censoring unlikely to be introducing bias); missing outcome
data balanced in numbers across intervention groups, with similar reasons for missing data across
groups; for dichotomous outcome data, the proportion of missing outcomes compared with ob-
served event risk not enough to have a clinically relevant impact on the intervention effect esti-
mate; for continuous outcome data, plausible effect size (difference in means or standardized dif-
ference in means) among missing outcomes not enough to have a clinically relevant impact on ob-
served effect size; missing data have been imputed using appropriate methods.
High risk of bias: Reason for missing outcome data likely to be related to true outcome, with either
imbalance in numbers or reasons for missing data across intervention groups; for dichotomous
outcome data, the proportion of missing outcomes compared with observed event risk enough to
induce clinically relevant bias in intervention effect estimate; for continuous outcome data, plausi-
ble effect size (difference in means or standardized difference in means) among missing outcomes
enough to induce clinically relevant bias in observed effect size; ‘as-treated’ analysis done with
substantial departure of the intervention received from that assigned at randomisation; potentially
inappropriate application of simple imputation.
Incomplete outcome data
Attrition bias due to amount,
nature or handling of incom-
plete outcome data.
Unclear: Insufficient information to permit judgement
Selective reporting
Reporting bias due to selective
outcome reporting
Low risk of bias: The study protocol is available and all of the study’s pre-specified (primary and
secondary) outcomes that are of interest in the review have been reported in the pre-specified way;
  (Continued)
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the study protocol is not available but it is clear that the published reports include all expected out-
comes, including those that were pre-specified (convincing text of this nature may be uncommon).
High risk of bias: Not all of the study’s pre-specified primary outcomes have been reported; one or
more primary outcomes is reported using measurements, analysis methods or subsets of the data
(e.g. subscales) that were not pre-specified; one or more reported primary outcomes were not pre-
specified (unless clear justification for their reporting is provided, such as an unexpected adverse
effect); one or more outcomes of interest in the review are reported incompletely so that they can-
not be entered in a meta-analysis; the study report fails to include results for a key outcome that
would be expected to have been reported for such a study.
Unclear: Insufficient information to permit judgement
Low risk of bias: The study appears to be free of other sources of bias.
High risk of bias: Had a potential source of bias related to the specific study design used; stopped
early due to some data-dependent process (including a formal-stopping rule); had extreme base-
line imbalance; has been claimed to have been fraudulent; had some other problem.
Other bias
Bias due to problems not cov-
ered elsewhere in the table
Unclear: Insufficient information to assess whether an important risk of bias exists; insufficient ra-
tionale or evidence that an identified problem will introduce bias.
  (Continued)
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Date Event Description
20 February 2019 New search has been performed New studies added (11)
20 February 2019 New citation required and conclusions
have changed
GRADE used to assess the evidence
 
H I S T O R Y
Protocol first published: Issue 3, 2009
Review first published: Issue 1, 2012
 
Date Event Description
12 March 2014 Amended Search strategies updated
 
C O N T R I B U T I O N S   O F   A U T H O R S
1. DraP the protocol: JA, EH, JC
2. Study selection: JA, EH, EO'L
3. Extract data from studies: JA, EH, EO'L
4. Enter data into RevMan: JA, EH, EO'L
5. Carry out the analysis: JA, EH, AW, EO'L
6. Interpret the analysis: JA, EH, AW, JC, EO'L
7. DraP the final review: JA, EH, AW, JC, EO'L
8. Disagreement resolution: AW, JC
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D E C L A R A T I O N S   O F   I N T E R E S T
• Emma L O'Lone: none known• Elisabeth M Hodson: none known• Ionut Nistor: none known• Davide Bolignano: none known• Angela C Webster: none known• Jonathan C Craig: none known
I N D E X   T E R M S
Medical Subject Headings (MeSH)
Administration, Oral;  Anemia, Iron-Deficiency  [blood]  [*therapy];  Blood Transfusion  [statistics & numerical data];  Cause of Death; 
Ferritins  [blood];  Hemoglobin A  [metabolism];  Injections, Intravenous;  Iron Compounds  [*administration & dosage]  [adverse eKects]; 
Kidney Failure, Chronic  [blood]  [*complications];  Randomized Controlled Trials as Topic;  Transferrin  [metabolism]
MeSH check words
Adult; Child; Humans
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